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A B S T R A C T
Background
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary
iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.
Both deferoxamine and deferiprone are effective; however, a review of the effectiveness and safety of the newer oral chelator deferasirox
in people with thalassaemia is needed.
Objectives
To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload.
Search methods
We searched the Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register: 12 August 2016.
We also searchedMEDLINE, Embase, the Cochrane Library, Biosis Previews, Web of Science Core Collection and three trial registries:
ClinicalTrials.gov; the WHO International Clinical Trials Registry Platform; and the Internet Portal of the German Clinical Trials
Register: 06 and 07 August 2015.
Selection criteria
Randomised controlled studies comparing deferasirox with no therapy or placebo or with another iron-chelating treatment.
Data collection and analysis
Two authors independently assessed risk of bias and extracted data. We contacted study authors for additional information.
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Main results
Sixteen studies involving 1807 randomised participants (range 23 to 586 participants) were included. Twelve two-arm studies compared
deferasirox to placebo (two studies) or deferoxamine (seven studies) or deferiprone (one study) or the combination of deferasirox and
deferoxamine to deferoxamine alone (one study). One study compared the combination of deferasirox and deferiprone to deferiprone
in combination with deferoxamine. Three three-arm studies compared deferasirox to deferoxamine and deferiprone (two studies) or
the combination of deferasirox and deferiprone to deferiprone and deferasirox monotherapy respectively (one study). One four-arm
study compared two different doses of deferasirox to matching placebo groups.
The two studies (a pharmacokinetic and a dose-escalation study) comparing deferasirox to placebo (n = 47) in people with transfusion-
dependent thalassaemia showed that deferasirox leads to net iron excretion. In these studies, safety was acceptable and further investi-
gation in phase II and phase III studies was warranted.
Nine studies (1251 participants) provided data for deferasirox versus standard treatment with deferoxamine. Data suggest that a similar
efficacy can be achieved depending on the ratio of doses of deferoxamine and deferasirox being compared. In the phase III study, similar
or superior efficacy for the intermediate markers ferritin and liver iron concentration (LIC) could only be achieved in the highly iron-
overloaded subgroup at a mean ratio of 1 mg of deferasirox to 1.8 mg of deferoxamine corresponding to a mean dose of 28.2 mg per
day and 51.6 mg per day respectively. The pooled effects across the different dosing ratios are: serum ferritin, mean difference (MD)
454.42 ng/mL (95% confidence interval (CI) 337.13 to 571.71) (moderate quality evidence); LIC evaluated by biopsy or SQUID,MD
2.37 mg Fe/g dry weight (95% CI 1.68 to 3.07) (moderate quality evidence) and responder analysis, LIC 1 to < 7 mg Fe/g dry weight,
risk ratio (RR) 0.80 (95% CI 0.69 to 0.92) (moderate quality evidence). The substantial heterogeneity observed could be explained
by the different dosing ratios. Data on mortality (low quality evidence) and on safety at the presumably required doses for effective
chelation therapy are limited. Patient satisfaction was better with deferasirox among those who had previously received deferoxamine
treatment, RR 2.20 (95% CI 1.89 to 2.57) (moderate quality evidence). The rate of discontinuations was similar for both drugs (low
quality evidence).
For the remaining comparisons in people with transfusion-dependent thalassaemia, the quality of the evidence for outcomes assessed was
low to very low, mainly due to the very small number of participants included. Four studies (205 participants) compared deferasirox to
deferiprone; one of which (41 participants) revealed a higher number of participants experiencing arthralgia in the deferiprone group, but
due to the large number of different types of adverse events reported and compared this result is uncertain. One study (96 participants)
compared deferasirox combined with deferiprone to deferiprone with deferoxamine. Participants treated with the combination of
the oral iron chelators had a higher adherence compared to those treated with deferiprone and deferoxamine, but no participants
discontinued the study. In the comparisons of deferasirox versus combined deferasirox and deferiprone and that of deferiprone versus
combined deferasirox and deferiprone (one study, 40 participants), and deferasirox and deferoxamine versus deferoxamine alone (one
study, 94 participants), only a few patient-relevant outcomes were reported and no significant differences were observed.
One study (166 participants) included people with non-transfusion dependent thalassaemia and compared two different doses of
deferasirox to placebo. Deferasirox treatment reduced serum ferritin, MD -306.74 ng/mL (95% CI -398.23 to -215.24) (moderate
quality evidence) and LIC, MD -3.27 mg Fe/g dry weight (95% CI -4.44 to -2.09) (moderate quality evidence), while the number of
participants experiencing adverse events and rate of discontinuations (low quality evidence) was similar in both groups. No participant
died, but data on mortality were limited due to a follow-up period of only one year (moderate quality evidence).
Authors’ conclusions
Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available
data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of
deferoxamine.However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared todeferoxamine.
Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine,
needs to be confirmed. Data from randomised controlled trials on rare toxicities and long-term safety are still limited. However, after
a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first-line option to individuals who show a
strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to
deferoxamine.
P L A I N L A N G U A G E S U M M A R Y
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Background
Thalassaemia is a hereditary anaemia due to a defect in the production of haemoglobin. Regular red blood cell transfusions are needed,
particularly for the severe form of the disease, thalassaemia major. This results in iron overload. Since the human body has no means
of actively getting rid of excessive iron, drug treatment (iron-chelating drugs) is needed. Several years ago, a newer oral iron chelator,
deferasirox, was introduced.
Review question
Does deferasirox offer advantages compared to placebo or to the other iron chelators deferoxamine or deferiprone in people with
thalassaemia with regard to effectiveness and safety?
Study characteristics
The evidence is current to 12 August 2016. This updated review includes 16 randomised controlled studies (1807 participants)
containing 20 comparisons of deferasirox versus another treatment.
In people with transfusion-dependent thalassaemia, two studies compared deferasirox with placebo and nine studies (1251 participants)
compared deferasirox with standard treatment of deferoxamine. Four studies (205 participants) compared deferasirox to deferiprone.
One study each compared deferasirox and deferiprone respectively to deferasirox and deferiprone combination therapy (40 participants),
deferasirox anddeferoxamine combination therapy todeferoxamine alone (94 participants) and deferasirox anddeferiprone combination
therapy to deferiprone and deferoxamine combination therapy (96 participants).
In people with non-transfusion dependent thalassemia (individuals not requiring regular blood transfusions), one study (166 partici-
pants) compared deferasirox to placebo. The duration of the included studies ranged from 12 days to two years.
Key results
Two studies comparing deferasiroxwith placebo in people with transfusion-dependent thalassaemia showed that deferasiroxwas effective
at removing iron.Nine other studies compared deferasiroxwith standard treatment of deferoxamine. Similar effectiveness seems possible,
depending of the doses of the two drugs compared. It needs to be confirmed whether this leads to similar improvements in patient-
important outcomes in the long run. The safety of deferasirox was acceptable; however, rarer adverse events or long-term side effects
could not be adequately investigated due to the limited number of participants and the relatively short duration of the studies. Patient
satisfaction was significantly better with deferasirox among those who had previously been treated with deferoxamine. The rate of
discontinuations was similar for both drugs. Deferasirox may be an alternative for those individuals who do not tolerate, or have poor
adherence with, deferoxamine. In people with a strong preference to deferasirox, potential benefits and risks should be discussed.
One study (41 participants) reported that more individuals with transfusion-dependent thalassaemia experienced joint pain when
treated with deferiprone than with deferasirox, but due to the large number of different types of adverse events reported and compared,
this result may be due to chance. One study revealed that adherence to treatment was higher when both oral iron chelators, deferasirox
and deferiprone are used than the combination of deferiprone and deferoxamine, but no participant discontinued the study. We found
no evidence for any differences comparing deferasirox or deferiprone alone to combined deferasirox and deferiprone treatment or
deferasirox and deferoxamine combination to deferoxamine alone, but the numbers of people in the studies were small and available
data were very limited.
One study in people with non-transfusion-dependent thalassaemia found deferasirox was better at reducing serum ferritin and liver
iron concentration compared to placebo. However, there is no evidence on the impact on patient-important outcomes or long-term
safety data in this population.
Quality of the evidence
The quality of included studies comparing deferasirox to deferoxamine in people with transfusion-dependent thalassaemia was moderate
to low, mainly due fact that the investigators and participants knew which interventions had been assigned to which participants, the
small number of participants included in the studies and the use of a surrogate markers (measures used in place of a hard clinical end
point) instead of patient-important outcomes. For the comparison of deferasirox to placebo in people with non-transfusion-dependent
thalassaemia, the quality of the evidence was moderate to very low based on only one small study. For the other comparisons, the quality
of the evidence was low to very low, mainly due to the inclusion of even fewer participants. Ideally, further randomised studies looking
at patient-important, long-term outcomes and rarer adverse events, should be conducted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Deferasirox compared to deferoxamine in people with transfusion-dependent thalassemia
Patient or population: people with transfusion-dependent thalassemia
Setting: outpat ient care
Intervention: deferasirox
Comparison: deferoxamine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferoxam-
ine
Risk with deferasirox
Mortality at any t ime
point
Study populat ion RR 0.48
(0.09 to 2.63)
1170
(8 RCTs)
⊕⊕©©
LOW 12
7 per 1.000 3 per 1.000
(1 to 18)
Responder analysis II
(responder: LIC 1 to
less than 7 mg Fe/ g dw)
Study populat ion RR 0.80
(0.69 to 0.92)
553
(1 RCT)
⊕⊕⊕©
MODERATE 134
664 per 1.000 531 per 1.000
(458 to 611)
Serum ferrit in (ng/ mL)
: mean change f rom
baseline and at end of
study
MD 454.42 higher
(337.13 higher to 571.
71 higher)
- 1002
(6 RCTs) 5
⊕⊕⊕©
MODERATE 134
LIC (mg Fe/ g dw) eval-
uated by biopsy or
SQUID: mean change
f rom baseline
MD 2.37 higher
(1.68 higher to 3.07
higher)
- 541
(1 RCT)
⊕⊕⊕©
MODERATE 134
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Satisfact ion with treat-
ment (very sat isf ied or
sat isf ied): part icipants
previously treated with
DFO
assessed with: ques-
t ionnaire
follow up: mean 52
weeks
Study populat ion RR 2.20
(1.89 to 2.57)
571
(1 RCT)
⊕⊕⊕©
MODERATE 1
1.330 per 1.000 1000 per 1.000
(1.000 to 1.000)
Adherence: discont inu-
at ions
Study populat ion RR 0.95
(0.60 to 1.50)
1211
(8 RCTs)
⊕⊕©©
LOW 16
54 per 1.000 52 per 1.000
(33 to 82)
AE: invest igat ions - iso-
lated serum creat inine
increase above ULN
Study populat ion RR 2.57
(1.88 to 3.51)
657
(2 RCTs)
⊕⊕©©
LOW 17
137 per 1.000 353 per 1.000
(258 to 482)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; DFO:deferiprone; dw: dry weight; FE: iron LIC: liver iron concentrat ion; MD: mean dif ference; RR: risk rat io; SQUID: superconduct ing
quantum interference device; ULN: upper lim it of normal.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Serious risk of bias: studies that carry large weight for the overall ef fect est imate rated as high risk of bias due to lack of
blinding and select ive report ing.
2 Serious imprecision: wide conf idence interval including both clinically relevant benef it as well as harm.
3 Serious inconsistency: dif f ering rat io of drugs between subgroups of one study.
4 Upgrade due to dose-response gradient: observed for both drugs. Ef fects therefore depending on rat io of drugs used in
comparisons.5
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5 A sensit ivity analysis without the results f rom four studies which were calculated according to Wan 2014 showed sim ilar
results.
6 Serious imprecision: Wide conf idence interval, including less discont inuat ions with deferoxamine treatment.
7 Serious indirectness: Surrogate of creat inine used for pat ient-important outcome of kidney failure.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
6
D
e
fe
ra
siro
x
fo
r
m
a
n
a
g
in
g
iro
n
o
v
e
rlo
a
d
in
p
e
o
p
le
w
ith
th
a
la
ssa
e
m
ia
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Thalassaemia, first described by Cooley and Lee in 1925 (Cooley
1925), is a hereditary anaemia resulting from a defect in haemo-
globin production (Weatherall 2000). The disruption in the syn-
thesis of either the α- or β-chains of haemoglobin, classified in α-
and β-thalassaemia, leads to an ineffective erythropoiesis (i.e. the
process by which red blood cells are produced) (Rund 2005). The
worldwide birth rate for symptomatic thalassaemia is about 0.44
per 1000 births (Angastiniotis 1998) summing up to more than
40,000 newborns per year (Modell 2008). An estimated number
of one to two million people with thalassaemia major, the severe
form of the condition, need regular blood transfusions worldwide
(Modell 2008; Weatherall 2000) of which only approximately
100,000 are treated as required (Modell 2008). The high frequency
of thalassaemia genes can be explained by a protective effect of
thalassaemia trait against malaria (Richer 2005;Weatherall 1998).
Due to various mutations in the different genes for the α- and β-
chain genes and other modifying factors, there is a broad spectrum
of clinical symptoms ranging from intrauterine death through to
severe anaemiawith the need for regular red blood cell transfusions
and to asymptomatic anaemia (Olivieri 1999).Diagnosis is usually
confirmed by either using electrophoretic techniques or molecu-
lar analysis. According to the clinical severity, the β-thalassaemia
syndromes can be classified into thalassaemia major, thalassaemia
intermedia and thalassaemia minor.
Whereas carriers with thalassaemia minor are often asymptomatic,
those with thalassaemia intermedia may need occasional red blood
cell transfusions (Peters 2013). To achieve sufficiently high hae-
moglobin levels for adequate growth and development, children
with thalassaemia major usually are transfusion-dependent, start-
ing within their first year of life. Several studies have shown
that a haemoglobin level above 9 to 10 g/dL is required to
successfully suppress ineffective erythropoiesis and to prevent
hepatosplenomegaly, as well as bone deformities due to extra-
medullary hematopoiesis (Olivieri 1999; Rund 2005; Weatherall
2000).
Iron overload in people with thalassaemia is mainly the result of
the additional iron load of up to 10 g per year by regular blood
transfusions (Kushner 2001). Particularly in people with thalas-
saemia intermedia, iron overload is also due to increased intesti-
nal iron absorption (Taher 2006). Since the human body has no
means of effectively excreting excess iron apart from gastrointesti-
nal mucosal shedding, loss via sweat or through any bleeding (e.g.
menstrual loss), iron chelation therapy is essential for these people.
Without iron chelation therapy, iron-mediated free radical dam-
age causes liver fibrosis, endocrine failure and myocardial damage
(Borgna-Pignatti 2005).
Description of the intervention
Deferasirox (4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazole-1-
yl)benzoic acid) also known as CGP 72670, ICL670, Exjade®,
Osveral®, Desirox®, Defrijet®, Asunra®, Desifer® or Jadenu™
is an oral chelator available for routine use. It is approved for the
treatment of secondary iron overload by the US Food and Drug
Administration (FDA) (FDA 2005) and the European Medicines
Agency (EMA) (EMEA 2007).
Adverse effects (AEs) known from experiences in people with tha-
lassaemia include gastrointestinal disturbances (nausea, stomach
pain or diarrhoea) that have generally been mild and a diffuse
rash being more common at higher doses (Cappellini 2006).More
rarely, fever, headache and cough have been encountered. The
main AEwith the use of deferasirox seems to be amild tomoderate
elevation of the creatinine level in approximately a third of indi-
viduals. Elevations of liver enzyme levels have also been described
with a lower incidence (5.6%) (Cappellini 2006). As with stan-
dard therapy (deferoxamine), hearing loss and ocular disturbances
including cataracts and retinal disorders have been reported with
a very low incidence (less than 1%).
With wider use outside of clinical studies, other more severe AEs
have been reported, such as cytopenias, Fanconi syndrome and
renal failure (Grange 2010; Rafat 2009; Yew 2010), liver failure
and gastrointestinal bleeding, which resulted in a boxed warning
by the FDA (FDA Boxed Warning 2010).
Deferoxamine (DFO, Desferal®), a further iron chelator, which
was reviewed in detail in a Cochrane Review (Fisher 2013a), has
been the treatment of choice for iron overload for the last 40 years.
Due to its long availability it is the only chelating agent for which
a profound effect on the long-term survival of a large cohort of
people with thalassaemia has been shown (Borgna-Pignatti 2004;
Brittenham 1994; Gabutti 1996; Zurlo 1989). To be clinically ef-
fective, deferoxamine has to be administered as a subcutaneous, or
less often an intravenous, infusion over 8 to 12 hours, five to seven
days per week. This regimen has been demonstrated to reduce the
body iron load, prevent the onset of iron-induced complications
and even reverse some of the organ-damage due to iron (Davis
2004; Olivieri 1994). But the arduous schedule of overnight sub-
cutaneous infusions often leads to reduced adherence (Cappellini
2005a; Modell 2000; Olivieri 1997). Another problem concerns
the toxicity of deferoxamine, particularly at higher doses. Toxici-
ties beside local skin reactions include ophthalmologic (optic neu-
ropathy, retinal pigmentation) and hearing problems (high fre-
quency sensorineural hearing loss). Rare AEs, such as growth re-
tardation, renal impairment (Koren 1991), anaphylactic reactions
and pulmonary fibrosis (Freedman 1990) have been reported. The
high cost of deferoxamine (approximately USD 10,000 per year)
(Delea 2008) and the consumables required (e.g. balloon infusers,
which imply additional costs) as well as its complicated mode of
administration limit its use in low-and middle-income countries.
Oral preparations have been highly sought after for many years.
In 1987 two studies showed that the orally active iron chelator
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deferiprone (1,2 dimethyl-3-hydroxypyrid-4-1, also known as L1,
CP20, Ferriprox® or Kelfer) could achieve effective short-term
iron chelation (Kontoghiorghes 1987a; Kontoghiorghes 1987b).
However, doubts on the efficacy to reduce liver iron and prevent
liver damage arose due to individualswith progression to overt liver
fibrosis (Olivieri 1998). However, the hypothesis of direct liver
toxicity of deferiprone could not be confirmed (Wanless 2002;
Wu 2006). In the meantime, several studies have shown the effi-
cacy of deferiprone for iron chelation (Ceci 2002; Maggio 2002)
and in particular its benefit on cardiac iron and cardiac morbid-
ity (Peng 2008). Adverse effects include gastrointestinal distur-
bances, arthropathy, neutropenia and agranulocytosis (Hoffbrand
1989). Studies on combination therapy of deferoxamine and de-
feriprone have been performed, most of which showed additive
rather than synergistic effects (Farmaki 2006; Galanello 2006;
Kattamis 2003; Kolnagou 2008; Origa 2005; Tanner 2007). An
extensive Cochrane Review on the effectiveness of deferiprone in
people with thalassaemia was updated in 2013 (Fisher 2013b).
How the intervention might work
Deferasirox is an oral iron chelator which is rapidly absorbed after
administration and has a bioavailability of about 70%. Safety and
tolerability were shown to be reasonable in a randomised dose esca-
lation study in people with β-thalassaemia in 2003 (Nisbet-Brown
2003). The eliminationhalf-life of 8 to 16hours allows a once daily
administration after the tablets have been added to water or juice.
A newer formulation approved in 2015 in the USA (Jadenu™)
(Novartis 2015) and in 2016 in the European Union (Exjade®
film-coated tablets) (EMA 2016) allows people to swallow the
tablets with water directly. Containing the same active ingredient
with comparable pharmacokinetics, the formulationwas approved
based on safety and efficacy studies investigating the original tablet
for suspension (Chalmers 2016).
As deferasirox is a tridentate chelator, two molecules of deferasirox
are needed to bind one molecule of iron. The excretion of the
bound iron is mainly via faeces.
Why it is important to do this review
Deferoxamine necessitates serious commitment from the user and
due to its AEs, deferiprone is only approved as second-line therapy
in some countries. Thus, much hope is being placed in the newer
oral chelator deferasirox which apparently offers a promising line
of treatment due to its iron chelation properties and safety and
tolerability profile (Cappellini 2007). Therefore, an update of our
previous Cochrane Review of the effectiveness and safety of de-
ferasirox according to state of the art Cochrane standards is needed
in the light of several studies being recently published (Meerpohl
2012).
O B J E C T I V E S
To evaluate the effectiveness and safety of oral deferasirox for man-
agement of iron overload in people with thalassaemia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled studies (RCTs) were considered for this
review.
Types of participants
People with thalassaemia regardless of age, type of thalassaemia
(e.g. thalassaemia major, thalassaemia intermedia) and setting (e.g.
country, primary or secondary care), who have developed iron
overload (defined as ferritin levels of over 1000 ng/mL on at least
two occasions in individuals with transfusion-dependent thalas-
saemia and over 300 ng/mL in those with non-transfusion-depen-
dent thalassaemia). People with thalassemia who have undergone
stem cell transplantation (SCT) are excluded.
Types of interventions
For oral deferasirox (all schedules and doses) the following com-
parisons were considered:
1. deferasirox compared with no therapy or placebo in people
with transfusion-dependent thalassaemia;
2. deferasirox compared with no therapy or placebo in people
with non-transfusion-dependent thalassaemia;
3. deferasirox compared with another iron-chelating treatment
(i.e. deferoxamine or deferiprone or any combination thereof ) in
people with transfusion-dependent thalassaemia;
4. deferasirox compared with another iron-chelating treatment
(i.e. deferoxamine or deferiprone or any combination thereof ) in
people with non-transfusion-dependent thalassaemia.
However, the necessity of chelation therapy in iron-overloaded
people is well-established and, if at all, only short-term (e.g. phar-
macokinetic studies) would be ethically justifiable. Longer-term
studies with no therapy or placebo in people with transfusion-de-
pendent thalassemia would not suffice the paradigm of equipoise.
Types of outcome measures
Primary outcomes
1. Overall mortality measured at any point in time
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Secondary outcomes
1. Reduced end-organ damage due to iron deposition
i) cardiac failure (necessitating medical treatment)
ii) endocrine disease (necessitating substitution hormone
therapy or treatment of diabetes)
iii) histological evidence of hepatic fibrosis
iv) pathological surrogate markers of end-organ damage
(i.e. elevated liver enzymes, elevated fasting glucose or
pathological oral glucose tolerance test (OGTT), pathological
measures (e.g. ejection fraction in echocardiography)
2. Measures of iron overload
i) serum ferritin (ng/mL)
ii) iron levels in biopsies of liver and other tissue (mg/g
liver dry weight)
iii) tissue iron assessment by superconducting quantum
interference device (SQUID) (mg/g liver wet weight)
iv) tissue iron assessment by magnetic resonance imaging
(MRI) (ms)
v) responder analysis (deletion of body iron, depending
on study definition)
3. Measures of iron excretion (urine and faeces) over 24 hours
(mg/kg/day)
4. Any AEs
i) raised levels of creatinine or kidney failure (above
upper normal limit or rise of more than 20% above baseline level)
ii) skin rash
iii) gastrointestinal disturbances
iv) neutropenia or agranulocytosis (absolute neutrophil
count (ANC) less than 1000/µl or less than 500/µL)
v) raised levels of liver enzymes (above upper normal
limit or rise of more than 20% above baseline level) or
progression to liver fibrosis
vi) hearing loss
vii) eye problems (e.g. retinal toxicity)
viii) unanticipated AEs as reported in the primary studies
5. Participant satisfaction (measured e.g. by a validated
questionnaire) and adherence to chelation treatment (measured
by the number of people in each arm that show adequate level of
adherence to treatment (intake or application of iron chelator on
five or more days per week))
6. Cost of intervention per year
Data from outcomes not defined a priori but which have arisen
from the review were also collected, if the outcome was considered
to be of clinical relevance.
Data were extracted at longest follow-up.
Search methods for identification of studies
No language restriction was applied.
Electronic searches
We searched for relevant studies in the Cystic Fibrosis and Ge-
netic Disorders Group’s Haemoglobinopathies Trials Register us-
ing the terms: (thalassaemia OR haemoglobinopathies general)
AND ICL670(A).
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue of theCochrane Library)
and quarterly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Health Research
Council Meetings; and the National Sickle Cell Disease Program
Annual Meeting. For full details of all searching activities for the
register, please see the relevant section of the Cochrane Cystic Fi-
brosis and Genetic Disorders Group’s website.
Date of most recent search of the Group’s Haemoglobinopathies
Trials Register: 12 August 2016.
We also searched:
• Cochrane Database of Systematic Reviews (2015, Issue 8);
Cochrane Central Register of Controlled Trials (CENTRAL;
2015, Issue 7); Database of Abstracts of Reviews of Effect
(DARE; 2015, Issue 2); Health Technology Assessment Database
(2015, Issue 3); NHS Economic Evaluation Database (2015,
Issue 2); Cochrane Methodology Register (2012, Issue 3) in the
Cochrane Library www.thecochranelibrary.com (searched 6
August 2015);
• MEDLINE OvidSP (2010 to July Week 5 2015);
• MEDLINE OvidSP in Process and Other Non-Indexed
Citations (searched 05 August 2015);
• MEDLINE OvidSP Daily Update (searched 05 August
2015)
• Embase OvidSP (2010 to 05 August 2015);
• PubMed www.pubmed.com [limited to MEDLINE subset
“supplied by publisher”] (1946 to 06 August 2015);
• Web of Science Core Collection via Thomson Reuters
(2010 to 04 August 2015);
• Biosis Previews via Thomson Reuters (2010 to 04 August
2015);
• Google www.google.com - searched for “Osferal” and also
“Osveral” (searched 07 January 2016)
An RCT filter was used for searches in MEDLINE, Embase, Bio-
sis Previews and Web of Science Core Collection. In MEDLINE,
we used the “Cochrane Highly Sensitive Search Strategy for iden-
tifying randomized trials in MEDLINE: sensitivity-maximizing
version (2008 revision); Ovid format” (Lefebvre 2011), but we re-
placed “randomized” with “randomi#ed”. For Embase, Biosis Pre-
views and Web of Science Core Collection, we devised the search
for RCTs and used textwords from the Cochrane RCT Filter we
used for the MEDLINE search. For details of the search strategies
see Appendix 1.
9Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Regarding the search with Google, we screened the first 50 results
of both searches. Every link which was suspected to obtain a rele-
vant study was looked at.
Since research into deferasirox treatment is ongoing, we searched
the following trial registers for all years available in all possible fields
using the basic search function (using separately the following
keyword terms: “deferasirox”, “ICL670”, “ICL 670”, “exjade”,
“desirox” and “jadenu”):
1. ClinicalTrials.gov: www.clinicaltrials.gov (searched 07
August 2015);
2. ICTRP: www.who.int/ictrp/en/ (searched 07 August 2015);
3. German Clinical Trial Register: www.drks.de (searched 07
August 2015).
For the previous version of this review, several databases and ongo-
ing trials registers were searched from 24th June to 1st July 2010.
Please see Appendix 2 for full details.
Searching other resources
Additionally, reference lists of all identified primary papers were
screened to identify other potentially relevant citations.
Contact was made with selected experts in the field as well as the
manufacturer of deferasirox (Novartis) to request information on
any unpublished studies that involved deferasirox.
Data collection and analysis
Selection of studies
One author (JM; for the update: CB or LS) screened all titles and
abstracts of papers identified by the search strategies for relevance.
We only excluded citations which were clearly irrelevant at this
stage. We obtained full copies of all potentially relevant papers.
At this stage two review authors (JM and DB; for the update: CB
and RA or LS and JM) independently screened the full papers,
identified relevant studies and assessed eligibility of studies for in-
clusion. We resolved any disagreement on the eligibility of studies
through discussion and consensus or if necessary through a third
party (GA; for the update: JM). We excluded all irrelevant records
and recorded details of the studies and the reasons for exclusion.
Data extraction and management
In addition to details relating to the risk of bias of the included
studies, we extracted two sets of data.
1. Study characteristics: place of publication; date of
publication; population characteristics; setting; detailed nature of
intervention; detailed nature of comparator; and detailed nature
of outcomes. A key purpose of this data was to define unexpected
clinical heterogeneity in included studies independently from the
analysis of the results.
2. Results of included studies with respect to each of the main
outcomes indicated in the review question. We carefully
recorded reasons why an included study did not contribute data
on a particular outcome and considered the possibility of
selective reporting of results on particular outcomes.
Two review authors (JM, DB; for the update: CB and RA or LS
and JM) independently undertook data extraction using a data
extraction form developed by the authors (except for one Chinese
study which was extracted by one Chinese reviewer only). The re-
view authors resolved any disagreements by consensus or through
discussion with a third review author (GA ; for the update: JM).
Once we had resolved disagreements, we recorded the extracted
data on the final data extraction form. One review author (JM; for
the update: CB or LS) transcribed these into RevMan 5.3 (Review
Manager 2014). Another review author (DB; for the update: JM)
verified all data entry for discrepancies. We extracted data primar-
ily from full publications of studies; however, if additional ab-
stracts or results records in clinicaltrials.gov were available, these
data were also considered. When only abstracts were available, we
extracted data therefrom as far as possible.
Assessment of risk of bias in included studies
Two review authors (JM, DB; for the update: CB, RA or LS, JM)
assessed every study using a simple risk of bias form and following
the domain-based evaluation as described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a).
We assessed the following domains as having either a low, unclear,
or high risk of bias:
1. randomisation;
2. concealment of allocation;
3. blinding (of participants, personnel and outcome assessors);
4. incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias.
We reviewed the assessments and discussed any inconsistencies be-
tween the review authors in the interpretation of inclusion criteria
and their significance to the selected studies. We resolved any dis-
agreements through discussion with a third author (GA or JM).
We did not automatically exclude any study as a result of a rating
of ’unclear risk of bias’ or a ’high risk of bias’. We presented the
evaluation of the risk of bias in included studies in tabular form
in the Results section of the review.
Measures of treatment effect
We analysed extracted data using the most up-to-date version of
the RevMan 5 software available at the time of analysis (Review
Manager 2014).
We planned to extract hazard ratios (HR) with their 95% con-
fidence intervals (CI) for the time-to-event outcomes mortal-
ity and end-organ damage. If reports did not provide HRs, we
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planned to use indirect estimation methods described by Par-
mar andWilliamson to calculate them (Parmar 1998; Williamson
2002).
If we were unable to either extract these data from the study re-
ports or receive the necessary information from the primary inves-
tigators, alternatively we used, where appropriate, the proportions
of participants with the respective outcomes measured at certain
time points (i.e. three months, six months, then six-monthly in-
tervals) to be able to calculate risk ratios (RR). We also extracted
data from other time points if available.
We expressed any results for binary outcomes as RR with 95% CIs
as measures of uncertainty. Continuous outcomes were expressed
as mean differences (MD) with 95% CIs as measures of uncer-
tainty.
Outcomes were not described as means and standard deviations
(SD) in all studies, therefore, in order to enter and analyze as many
data in RevMan as possible, we undertook further calculations
wherever possible. If studies only reported median and range, CI
or interquartile range, we estimated means and SDs as described
by Wan (Wan 2014). If studies only reported standard error (SE)
of the mean (SEM), we used the following calculation: SD =
SEM*sqrt(n). If studies provided P values, n and mean, we calcu-
lated the SD with the calculator integrated in RevMan 5 (Review
Manager 2014). If studies provided Z values, we calculated the
SD for the change from baseline. For heavily skewed data, analysis
based onmeans is not appropriate. Although the study authors did
not always explain the reasons, means were presented as geometric
means (Gmeans) in some cases. We therefore analysed the data on
a log scale and report these data as the ratio of Gmeans.
Reporting of results was ambiguous in some studies, so we had to
make the following assumptions.
• One study reported the percentage of participants with dose
reductions and interruption and the values for adherence, but
the number of participants included for each outcome was not
clear (Pennell 2014). For our analysis we assumed that all those
who had received the study drug were included.
• Where results of individual studies were displayed only
graphically and we considered estimation to be reasonable, we
estimated values visually from the graphs.
• We assumed that the values of means and SD in neutrophil,
alanine transaminase (ALT), aspartate transaminase (AST), and
alkaline phosphatase (ALP) levels were confused in one study
(Molavi 2014) so we used corrected values for our meta-analysis.
• A further study reported different P values for the same
outcome “QoL (end of study-baseline)” in the same journal
publication (Elalfy 2015b). We calculated the SD for change
from baseline using the most conservative P values given.
• When the P value was reported as P < 0.001, we used P =
0.001 for our calculation of SD.
• One study lost three participants across the term of the
study (Elalfy 2015a). For calculating change from baseline, we
included all 30 participants for our conservative analysis.
• Sometimes we realised discrepancies in results reported in
journal publications and in abstracts or trial registers. In these
cases, we usually extract results from full journal publications.
• For some outcomes, a possible perception of the
comparison might be whether deferasirox is not inferior to
standard treatment with deferoxamine. Therefore, for these
outcomes a per protocol analysis might be chosen.
Unit of analysis issues
We found two three-armed studies comparing the three different
iron chelation monotherapies deferasirox, deferiprone and defer-
oxamine (Chirico 2013; Elalfy 2015a). To include the results in
our meta-analysis, we divided the number of participants in the
deferasirox arms as suggested in chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011b).
One four-arm study compared two different doses of deferasirox
to equivalent placebos, but results of both placebo groups were
not reported individually, so we split the placebo group for both
comparisons (Taher 2012).
We did not include any cross-over studies in this review. However,
for future updates, we plan to use the methods recommended
by Elbourne for combining results from such studies (Elbourne
2002). We will use the methods described by Curtin to combine
results from parallel and cross-over studies (Curtin 2002a; Curtin
2002b; Curtin 2002c).
The study investigators planned that the included phase III study
would be a non-inferiority study (Cappellini 2005b). Therefore,
they did not report efficacy outcomes based on an intention-to-
treat (ITT) analysis. For our review, we used the data as presented,
i.e. per protocol.
We did not use any of the below mentioned strategies outlined
by Witte (Witte 2004) in this version of the review, because only
a few studies could be pooled per outcome. However, for future
updates we will consider applying one of these strategies according
to the data available.
1. If all studies report only an ITT analysis (or all studies
report only a per protocol analysis), we will perform a non-
inferiority meta-analysis based on Witte’s ’perfect case’ proposal.
2. If some studies report only an ITT analysis and others only
a per protocol analysis (exclusively), we will perform meta-
regression with analysis type as a covariate.
3. If some studies report only an ITT analysis and others only
a per protocol analysis, whilst others report both, we will
undertake a sensitivity analysis.
4. If all studies give enough information to do both analyses,
we will analyse data using a bivariate model.
To interpret results according to a non-inferiority scenario, we will
use the following definitions.
For time-to-event data, non-inferiority is given, if the relative dif-
ference in HRs is less than 10%. For RRs, non-inferiority is de-
fined as a relative RR difference of less than 10% in treatment fail-
ures compared to standard therapy. For the continuous outcomes
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of “measures of iron overload and iron excretion” as well as “costs”,
a relative difference of less than 10% is considered equivalent.
Dealing with missing data
We contacted the original investigators to clarify some method-
ological issues and to request additional data from two studies
during the development of the previous review version (Galanello
1999;Nisbet-Brown 2001); however, to date, we have not received
any additional data to that presented in the primary reports. For
this version of the review, we contacted investigators of 11 stud-
ies (Chirico 2013; Elalfy 2015a; Elalfy 2015b; Habibian 2014;
Hagag 2015; Kakkar 2014; Kakkar 2015; Molavi 2013; Molavi
2014; Pennell 2014; Taher 2012) and the manufacturer of de-
ferasirox regarding two studies (Pennell 2014: Taher 2012). We
could clarify some issues and the original investigator confirmed
that our list of included studies is complete. However, additional
data on investigator-sponsored studies have to be requested via a
data request platform in most cases. We plan to request available
data via this platform for all manufacturer sponsored studies for a
future update.
Assessment of heterogeneity
Where feasible, we considered clinical heterogeneity by presenting
results of subgroups according to differences in dose of interven-
tion and baseline measures of iron overload. We examined statis-
tical heterogeneity in the results of studies using the I² and Chi²
statistics (Higgins 2002; Higgins 2003).
Assessment of reporting biases
We made a great effort to identify unpublished studies and min-
imise the impact of possible dissemination bias by using a com-
prehensive search strategy and contacting the manufacturer of de-
ferasirox for the previous version. We did not use funnel plots to
assess dissemination bias, since asymmetry is difficult to detect
with a small number of studies (i.e. less than 10) and we could
only include 16 studies overall in this review, with no more than
eight studies per outcome. If in future we are able to include more
than 10 studies for a given outcome in the review, we will use
funnel plots to graphically assess the likelihood of dissemination
bias. We took care in translating the results of the included studies
into recommendations for action by involving all review authors
in drawing conclusions.
Data synthesis
While extracting data, we had to take the following decisions. Al-
though we would have preferred to consistently present data sepa-
rately for the different dose groups, we decided to pool safety data
of the different dose groups from the Nisbet-Brown study, since
splitting the placebo group (N = 5) did not seem reasonable due
to the small size (Nisbet-Brown 2001). Due to the huge amount
of different AE types reported, we decided to pool AEs for the
different dose groups for three studies rather than presenting the
various subgroups for all AEs (as in the previous version of this
review) (Cappellini 2005b; Piga 2002; Taher 2012).
We conducted meta-analyses of pooled data from all contribut-
ing studies using a fixed-effect model. We took heterogeneity of
the pooled data into account by using subgroup analysis or the
random-effects model (or both) (see Effects of interventions for
specific details).
’Summary of findings’ tables
We created ’Summary of findings’ tables for each comparison apart
from deferasirox versus placebo in people with transfusion-depen-
dent thalassemia, because abstaining from iron chelation treat-
ment in this patient group is ethically not justified and therefore
not patient-relevant.
The following outcomeswere selected for presentation in the ’sum-
mary of findings’ tables because we considered these outcomes
most relevant for decision-making given the limitations of the
available evidence:
1. overall mortality measured at any point in time;
2. responder analysis (deletion of body iron, depending on
study definition);
3. serum ferritin (ng/mL);
4. iron levels in liver measured by biopsies (mg/g liver dry
weight) or SQUID (mg/g liver wet weight) or MRI (ms);
5. adherence to chelation treatment (measured by the number
of people in each arm that show adequate level of adherence to
treatment (intake or application of iron chelator on five or more
days per week, or number of patients who discontinued as form
of adherence));
6. participant satisfaction (measured e.g. by a validated
questionnaire);
7. AEs: raised levels of creatinine or kidney failure (above
upper normal limit or rise of more than 20% above baseline
level).
We used the five Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) considerations (risk of bias,
inconsistency, indirectness, imprecision and publication bias) to
assess the quality of the body of evidence as it relates to the studies
that contributed data to the meta-analyses as described in chap-
ters 11 and 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We used footnotes to justify all
decisions to down- or upgrade the quality of evidence and we
made comments to aid readers’ understanding of the review where
necessary. We generated ’Summary of findings’ tables using the
Gradepro software (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
If data were available, we presented subgroups according to base-
line measures of iron overload or doses of intervention as they
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were reported in the studies. If relevant, other subgroup analysis as
defined in study publications are presented. Due to the amount of
reported adverse events, we merged AEs for different subgroups.
For future updates of this review, we will assess clinical hetero-
geneity, if possible, in addition by examining differences due to:
• age of participants (e.g. zero to two years, three to five years,
6 to 11 years; 12 to 17 years, 18 years or older);
• age at commencement of the intervention (e.g. zero to two
years, three to five years, 6 to 11 years, 12 to 17 years, 18 years or
older).
Additional subgroup analyses are planned for different:
• subtypes of thalassaemia (e.g. thalassaemia major,
thalassaemia intermedia, haemoglobin E thalassaemia) where
applicable.
Sensitivity analysis
Wewere only able to include amaximumof nine published studies
for each of our comparisons and no additional unpublished studies
nor studies with a low risk of bias were identified. Due to missing
data regarding SD, we did some calculations according to Wan
and undertook sensitivity analysis (Wan 2014). For future updates
of this review, we plan to perform additional sensitivity analyses
based on assessment of risk of bias (evaluating only studies of low
risk of bias) and publication status (unpublished and published
studies).
R E S U L T S
Description of studies
Results of the search
Updated searches
The updated searches for this current version of the review (last
search ran in August 2016) identified 1211 citations, including
477 duplicates (Figure 1). The title and abstract screening of the
remaining 734 citations identified 71 as potentially eligible for this
review.After screening of the full texts, eight new studies (described
in 23 references) and a reference to a previously included study
were included in the updated version of this review. Four addi-
tional studies (reported in five references) were identified through
Google-searches resulting overall in a total of 16 included studies.
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Figure 1. Study flow diagram.
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Previous searches
For the previous version of this review, the last search was run in
November 2011 (see Figure 1). Altogether, 2171 citations, includ-
ing 1195 duplicates, were identified. After title and abstract screen-
ing of the 976 unique citations, 687 citations could be excluded.
A total of 289 full texts were screened and four RCTs (described in
33 references) were identified (Cappellini 2005b; Galanello 1999;
Nisbet-Brown 2001; Piga 2002).
The search of the three trial registers (last run on 30 June 2010)
identified 49 unique references to studies. One ongoing RCT was
identified, which has now been published and was therefore in-
cluded in this updated review (Pennell 2014).
Included studies
Sixteen studies met the inclusion criteria (Characteristics of
included studies) including 1807 randomised participants (range
23 to 586 per study). Twelve studies included two treatment
arms comparing deferasirox to placebo (Galanello 1999; Nisbet-
Brown 2001) or deferoxamine (Cappellini 2005b;Habibian 2014;
Hassan 2016; Molavi 2013; Peng 2013; Pennell 2014; Piga 2002;
) or deferiprone (Sanjeeva 2015) or comparing the combination
of deferasirox and deferoxamine to deferoxamine alone (Molavi
2014). One study compared the combination of deferasirox and
deferiprone to deferiprone in combination with deferoxamine
(Elalfy 2015b). Three studies included three treatment arms com-
paringdeferasirox to deferoxamine anddeferiprone (Chirico 2013;
Elalfy 2015a) or the combination of deferasirox and deferiprone
to deferiprone and deferasirox monotherapy respectively (Kakkar
2014). One study included four treatment arms, comparing two
different doses of deferasirox to matching placebo groups (Taher
2012). One identified abstract is a report of a previously included
study (Cappellini 2005b).
1. Transfusion-dependent thalassaemia: deferasirox versus
placebo
The two relevant studies comparing deferasirox to placebo are
short-term studies examining mainly safety and pharmacokinetic
outcomes while on deferasirox therapy (Galanello 1999; Nisbet-
Brown 2001).
The first study was reported in one full article and one abstract
(Galanello 1999). Twenty-four individuals were allocated to three
groups: all groups received two single doses of deferasirox at an
interval of at least seven weeks. Group 1 received single doses of
2.5 mg/kg and 20 mg/kg, Group 2 single doses of 5 mg/kg and 40
mg/kg and Group 3 single doses of 10 mg/kg and 80 mg/kg. In
each treatment period, two of eight participants received placebo
in such a way that a given participant did not receive placebo more
than once. Usual deferoxamine and transfusion therapy was given
in the interval between the two doses. This study by Galanello on
deferasirox focused on safety, tolerability and pharmacokinetics.
The second study was reported in one full article and two abstracts
(Nisbet-Brown 2001). It was designed as a dose-escalation study
focusing on effectiveness and safety; treatment duration was 12
days. A total of 23 individuals were randomly assigned to placebo
(n = 5), 10 mg/kg/day of deferasirox (n = 5), 20 mg/kg/day of de-
ferasirox (n = 6) and 40 mg/kg/day of deferasirox (n = 7). Primary
objectives included assessment of safety and tolerability (measured
by adverse events and clinical laboratory monitoring), pharma-
cokinetics (measured as drug and drug-iron complex), and cumu-
lative net iron excretion (measured by faecal and urine output mi-
nus food input).
2. Transfusion-dependent thalassaemia: deferasirox versus
deferoxamine
One of the seven studies comparing deferasirox to deferoxamine
was reported in one full article and four abstracts (Piga 2002). This
is a randomised open-label phase II study including 71 people
with β-thalassaemia aged over 18 years from four centres in Italy.
The primary objective was to determine the safety and tolerability
of deferasirox at daily doses of 10 and 20 mg/kg in comparison
with a standard dose of deferoxamine 40 mg/kg in individuals
with transfusional haemosiderosis. Secondary objectives included
evaluation of the effects of deferasirox on liver iron concentration
(LIC), serum ferritin, serum iron, transferrin and transferrin sat-
uration. The ITT principle was used for analyses.
Results from the second study were reported in five full articles, 19
abstracts (and two responses to letters) (Cappellini 2005b). This
phase 3 open-label randomised study was planned as a non-infe-
riority study with a predefined delta of 15% (two-sided 95% CI).
There were 591 participants actually randomised, but five with-
drew consent prior to any study medication; 586 participants were
included in the study, of which 541 completed one year of therapy.
After randomisation, stratified by three age groups, people were
assigned to a treatment dose of either deferasirox or deferoxamine
according to baseline LIC; the mean ratio of doses between de-
ferasirox and deferoxamine varied from 1:5.5 to 1:1.8. The pri-
mary endpoint was maintenance or reduction of LIC. Secondary
criteria for response included evaluation of the change in serum
ferritin levels over time and evaluation of net body iron balance.
A third study, a randomised, controlled study in Iran, was reported
in one journal article (Molavi 2013). A total of 138 people with
thalassaemia major and intermedia with serum ferritin more than
1000 ng/mL and older than two years were randomised to 20 mg/
kg oral Osveral® (Iranian generic product of deferasirox) daily or
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40 mg/kg to 50 mg/kg subcutaneous Desferal® (deferoxamine)
for six nights a week. Due to the different administration routes,
we assumed that no blinding took place. Primary outcome was
serum ferritin, secondary outcomeswere serum levels of ALT, AST,
creatinine, haemoglobin and drug side effects (leukopenia, throm-
bocytopenia).
A further study (reported in one full article in Chinese) compared
deferasirox to deferoxamine and was a single-centre RCT in China
(blinding not mentioned) (Peng 2013). A total of 24 people with
severe β-thalassaemia were randomised to oral deferasirox 40 mg/
kg daily or deferoxamine 50mg/kg at least five days aweek.During
the 12month followup, serum ferritin and liver R2*were assessed.
A larger multi-centre, open-label study was reported in two full ar-
ticles and two abstracts (Pennell 2014). A total of 197 people with
β-thalassaemia major (aged 10 years and over) were randomised
to 40 mg/kg/day oral deferasirox or deferoxamine 50 mg/kg/day
to 60 mg/kg/day as subcutaneous infusion over eight to 12 hours,
five to seven days a week. Regarding the primary outcome, change
in myocardial T2* during one year follow-up, the study was de-
signed as a non-inferiority study with a non-inferiority margin of
90%. Secondary endpoints were change in left ventricular ejec-
tion fraction (LVEF), LIC and serum ferritin. Adverse events and
adherence were also reported. Data from the one-year extension
phase were not included in this review due to the high number
of individuals who did not continue with deferoxamine therapy
after the core phase.
A small study including 30 people with thalassaemia major was
only reported in a conference abstract (Habibian 2014). After 12
months, serum ferritinwasmeasured.More information regarding
dosing or other outcomes was not reported.
One study, reported in a journal publication, investigated 60 indi-
viduals with thalassaemia major (Hassan 2016). Participants were
randomised to receive deferasirox (single oral daily dose of 20 to
40 mg/kg/day) or deferoxamine (20 to 50 mg/kg/day via a sub-
cutaneous infusion over 8 to 10 hours, five days a week) for one
year. Serum ferritin, ALT, AST, blood urea, serum creatinine, neu-
trophilic and platelet counts and some adverse events were re-
ported.
3. Transfusion-dependent thalassaemia: deferasirox versus
deferiprone
One single randomised study compared deferasirox 20 mg/kg/
day to deferiprone 75 mg/kg/day divided in three doses (Sanjeeva
2015). The study included 41 regularly transfused children with
ferritin over 1000 ng/mLwhowere not on chelation therapy previ-
ously. Serum ferritin level (primary outcome) and AEs (secondary
outcomes) were assessed during a follow up of 12 months. The
study was reported as a journal article and a doctoral thesis.
4. Transfusion-dependent thalassaemia: deferasirox and
deferoxamine versus deferoxamine
The combination of deferasirox (20 mg/kg to 40 mg/kg) and de-
feroxamine (50 mg/kg, three times a week) was compared to de-
feroxamine monotherapy in one study, reported in one journal ar-
ticle (Molavi 2014). A total of 100 people with thalassaemia major
were randomised to one of the groups at a medical centre in Iran.
Six participants were excluded after randomisation but before start
of the study. Serum ferritin, liver enzymes, ALP, neutrophils, cre-
atinine and haemoglobin were measured.
5. Transfusion-dependent thalassaemia: deferasirox and
deferiprone versus deferiprone and deferoxamine
One randomised study included two treatment arms and com-
pared two combination regimes: the first group received oral de-
feriprone 75 mg/kg/day divided into two doses and deferoxam-
ine 40 mg/kg/day by subcutaneous infusion over 10 hours for six
days a week, the second group received in addition to deferiprone
(75 mg/kg/day) deferasirox 30 mg/kg/day for seven days a week
(Elalfy 2015b). The open-label study was reported in one full ar-
ticle and two abstracts. A total of 96 people with thalassaemia
major were randomised into two equal groups. Primary outcomes
were change in serum ferritin, LIC and cardiac MRI, secondary
outcomes were AEs, serious AEs (SAEs), participant’s adherence,
participant’s satisfaction and health-related quality of life.
6. Transfusion-dependent thalassaemia: deferasirox versus
deferoxamine versus deferiprone
Two studies compared all three iron-chelators against each other
(Chirico 2013; Elalfy 2015a).
The first study was published as one full article and one abstract
(Chirico 2013). The full study had a duration of eight years, but
only the last two years were designed as a randomised controlled
study. A total of 37 individuals who had not developed a thyreopa-
thy under treatment with deferoxamine in the last six years were
randomised to either deferasirox (n = 12), deferoxamine (n = 13)
or deferiprone (n = 12) monotherapy. The number of participants
with thyroid disease and serum ferritin after two years of follow-
up were reported.
The other study comparing the three iron chelator monotherapies
was reported in one full-text and two abstracts (Elalfy 2015a). The
aim of this study was to investigate the effects of vitamin C as
an adjuvant therapy to iron chelation in a factorial study with six
arms. Therefore, 180 people with iron-overloaded thalassaemia
major with serum ferritin from 1000 ng/mL to 2500 ng/mL and
vitamin C deficiency were randomised in a 1:1:1 ratio to defer-
oxamine 40 mg/kg/day (five days a week), deferiprone 75 mg/kg/
day or deferasirox 25 mg/kg/day. Participants were further equally
randomised either to receive vitamin C supplementation (100 mg
daily) or not. The primary efficacy endpoint was change of serum
ferritin, LIC and cardiac MRI T2* during one year of follow-up.
The occurrence of any adverse effects was a secondary outcome
measure.
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7. Transfusion-dependent thalassaemia: deferasirox versus
deferiprone versus deferasirox and deferiprone
In one study, 40 people were randomised to deferasirox 30 mg/
kg/day to 40 mg/kg/day (n = 10), deferiprone (75 mg/kg/day to
100 mg/kg/day) (n = 10), or both drugs administered sequentially
every alternate week (n = 20) (Kakkar 2014). Cardiac and liver
MRI, serum ferritin, complete blood count (CBC), liver enzymes
and renal function tests were performed. Duration of follow-up
was not reported. The study was only reported as a conference
abstract.
8. Non-transfusion-dependent thalassaemia: deferasirox
compared to placebo
One study included participants with non-transfusion-dependent
thalassaemia with iron overload (Taher 2012). We identified no
other RCT evaluating people with non-transfusion-dependent
thalassaemia. A total of 166 individuals were randomised in a 2:1:
2:1 ratio to starting doses of 5 or 10 mg/kg/day or matching place-
bos. The primary efficacy endpoint was the change in LIC dur-
ing the 52-week treatment duration. Secondary endpoints were
change in serum ferritin, correlation of serum ferritin and LIC,
AEs and adherence. The study lasted for one year and was pub-
lished in two journal publications and six abstracts.
Excluded studies
Updated searches
Several reports of the extension phases of studies were not in-
cluded, since after completion of the core first year, cross-over
to deferasirox treatment took place during the extension phase
(Cappellini 2005b; Taher 2012). Therefore, data collected during
the extension phase represent observational data on a large cohort
of deferasirox-treated individuals; there is no longer a comparison
group and participants were not analysed according to their ini-
tially assigned group. Due to a high number of participants who
did not continue in the deferoxamine treatment group after the
core phase, the extension phase of the Pennell study was also ex-
cluded (Pennell 2014).
Overall, the reasons for exclusion of 44 reports were:
• included people with disease other than thalassaemia (n =
3);
• included people with thalassaemia who had received
curative stem cell transplantation (n = 5);
• review/other, no primary data containing articles (n = 3);
• intervention/comparison other than deferasirox (n = 2);
• pharmacokinetic studies (n = 2);
• non-randomised data on participants with thalassaemia (n
= 29)
◦ extension phases of core studies (n = 13)
◦ other non-randomised data (n = 16).
Previous searches:
256 references were excluded. Reasons for exclusion were:
• included people with disease other than thalassaemia
◦ only sickle cell disease (n = 16)
◦ only myelodysplastic syndrome (n = 53)
◦ other condition (n = 9);
• review article, editorial or comment (n = 49);
• intervention other than deferasirox (n = 2);
• cost-effectiveness analysis (n = 8);
• non-randomised data on people with thalassaemia (n = 119)
(for selected references see Characteristics of excluded studies)
◦ EPIC study (n = 16)
◦ ESCALATOR study (n = 13)
◦ extension phases of core studies (n = 21)
◦ other non-randomised data (n = 69).
Studies awaiting classification and ongoing studies
Three studies identified through searches in electronic databases
were classified as ’awaiting classification’, because it was not clear
if randomisation of participants really took place in two studies
(Hagag 2015; Ansari 2015;) and the conference abstract of an-
other study did not mention the number of included participants
(Kakkar 2015). Authors of all studies were contacted for clarifica-
tion; however, we have not yet received any further information.
The searches in trial registers identified four ongoing studies
(Cutino 2009; DEEP-2 2012; NCT02125877; NCT02435212)
as well as two unpublished completed studies (EUCTR2010-
023217-61-GB; NCT02198508). The Google search also re-
vealed a registry entry of an RCT in the Iranian Registry of Clini-
cal Trials, which met our inclusion criteria and was added as study
awaiting classification IRCT201110087677N1).
We contacted the investigators of unpublished completed stud-
ies (as far as contact addresses could be identified) to request in-
formation on study results. If these studies are published within
two years of this update (as per the standard Cochrane updating
guidelines), this will trigger an earlier update of this review.
Risk of bias in included studies
The risk of bias for the 16 included studies in this review was
classified as previously described (Assessment of risk of bias in
included studies).
The three blinded studies comparing deferasirox to placebo were
judged overall as having an ’unclear’ risk of bias (Galanello 1999;
Nisbet-Brown 2001; Taher 2012). These assessments were mainly
based on the inadequate reporting of several of the criteria that are
considered to be important in the evaluation of methodological
rigour in terms of study design and conduct.
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All other included studies were predominantly classified as having
an overall ’high’ risk of bias, mainly due selective reporting of
secondary outcomes and lack of blinding.
For further details see the risk of bias tables in Characteristics of
included studies, the risk of bias graph (Figure 2) and the risk of
bias summary (Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The methods to generate the allocation sequence were not de-
scribed in 11 studies (Galanello 1999; Habibian 2014; Hassan
2016; Nisbet-Brown 2001; Cappellini 2005b; Chirico 2013;
Kakkar 2014; Molavi 2013; Molavi 2014; Peng 2013; Taher
2012). Three studies used computer-generated randomisation se-
quences and were therefore assessed as low risk of bias (Elalfy
2015a; Elalfy 2015b; Sanjeeva 2015). One study used a “validated
system that generates an automated random assignment of num-
bers to treatment groups” (Piga 2002). One study described ran-
domisation based on permuted blocks which was considered as
low risk of bias (Pennell 2014).
Since no details were given in the reports with regard to alloca-
tion concealment, it remains unclear whether allocation conceal-
ment was achieved in 12 studies (Cappellini 2005b; Chirico 2013;
Galanello 1999; Habibian 2014; Hassan 2016; Kakkar 2014;
Molavi 2013; Molavi 2014; Peng 2013; Pennell 2014 Piga 2002;
Sanjeeva 2015). One study reported using sealed envelopes but it
was unclear if these were opaque and numbered (Nisbet-Brown
2001). Three studies were assessed as low risk of bias regarding
allocation concealment. One Elalfy study used opaque and num-
bered sealed envelopes (Elalfy 2015a), a second ensured allocation
concealment through assigning participants to treatment groups
by telephone contact from the co-ordinating centre (Elalfy 2015b).
In one study the investigator had to contact an interactive voice
system to obtain the linked randomisation number (Taher 2012).
Blinding
Blinding was done in the three placebo-controlled studies (
Galanello 1999; Nisbet-Brown 2001; Taher 2012), although in
the Taher study blinding with regard to the different doses used
was not done (Taher 2012).
The remaining12 studieswere open-label, the reason being the ob-
vious difference in application mode, deferasirox and deferiprone
being orally taken, while deferoxamine needs to be applied sub-
cutaneously over several hours and the different frequency of in-
take regarding both oral iron chelators. One study reported that
“patients, physicians, laboratory staff and the epidemiologist who
analysed the data were not aware of the intervention for each
group” (Chirico 2013). However, no placebo treatment was men-
tioned, so we assumed that no adequate blinding took place.
Incomplete outcome data
Since the Cappellini and Pennell studies were planned as non-in-
feriority studies, efficacy data were not consistently reported on an
ITT basis (Cappellini 2005b; Pennell 2014). In the Pennell study,
the provided ITT analysis did not include all randomised par-
ticipants (Pennell 2014). Two studies did not address how many
participants reached the end of the study (Habibian 2014; Kakkar
2014). One study reported three dropouts due to AEs; a per pro-
tocol analysis was done for most of the outcomes, which was as-
sessed as having a high risk of bias (Sanjeeva 2015). One of the
Elalfy studies reported discontinuing participants in an abstract
publication, whereas in a later full publication, all participants ap-
parently reached the end of the study (Elalfy 2015b). One study
reported that “efficacy was assessed for the full analysis set (all
randomised patients)” in the journal publication, but the data set
on clinicaltrials.gov states a lower number of analysed participants
(Taher 2012). The author confirmed that the change could only
be calculated for participants with both a baseline and at least
one post-baseline value. The remaining nine studies fully reported
or addressed adequately incomplete outcome data (Chirico 2013;
Elalfy 2015a; Galanello 1999; Hassan 2016;Molavi 2013;Molavi
2014; Nisbet-Brown 2001; Peng 2013; Piga 2002).
Selective reporting
Only one study was assessed as low risk of bias regarding selective
reporting (Hassan 2016). Data on a broad spectrum of AEs were
usually collected. However, only limited AE data were reported,
often only qualitatively. Commonly, laboratory parameters were
apparently measured but not reported. However, end of study
results for the primary outcome were reported in all studies.
Evidence of publication bias could not be detected.
Other potential sources of bias
Four studies were assessed as unclear, because no or limited in-
formation on baseline characteristics was provided (Chirico 2013;
Elalfy 2015a; Habibian 2014; Kakkar 2014).
Support and sponsorship
Six studies were conducted with support and involvement of the
producer of deferasirox (Novartis) (Cappellini 2005b; Galanello
1999;Nisbet-Brown 2001; Pennell 2014; Piga 2002; Taher 2012).
Also, many authors of these studies were affiliated with Novartis.
The relevance of these conflicts of interest is open to interpretation.
Four studies declared tohave no conflicts of interest (Chirico 2013;
Elalfy 2015b; Elalfy 2015a; Hassan 2016), whereas conflicts of
interest were not reported at all in five other studies (Kakkar 2014;
Sanjeeva 2015;Molavi 2013;Molavi 2014; Habibian 2014 ). One
study was funded by a public grant (Peng 2013).
Effects of interventions
See: Summary of findings for the main comparisonDeferasirox
compared to deferoxamine in people with transfusion-dependent
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thalassemia; Summary of findings 2 Deferasirox compared to
deferiprone in people with transfusion-dependent thalassemia;
Summary of findings 3 Deferasirox alone compared to
combined deferasirox and deferiprone in people with transfusion-
dependent thalassemia; Summary of findings 4 Combined
deferasirox and deferiprone compared to deferiprone alone
in people with transfusion-dependent thalassemia; Summary
of findings 5 Deferasirox and deferoxamine compared to
deferoxamine in people with transfusion-dependent thalassemia;
Summary of findings 6 Deferasirox and deferiprone compared
to deferiprone and deferoxamine in people with transfusion-
dependent thalassemia; Summary of findings 7 Deferasirox
compared to placebo in people with non-transfusion-dependent
thalassemia
1. Transfusion-dependent thalassaemia: deferasirox
compared to placebo
Two studies compared deferasirox to placebo (Galanello 1999;
Nisbet-Brown 2001). Due to both its design and the presentation
of results in the paper, data could not be extracted quantitatively
from the Galanello study (Galanello 1999). Regarding safety data,
it was not clear whether participants contributed more than one
episode to the count of one AE (such as headache) since safety
parameters were assessed after each dose. So, a single participant
could theoretically contribute more than one episode of an event
such as headache. For this reason, we do not present these data
in a forest plot. We have contacted the authors but have not yet
been able to clarify all details. Therefore, we decided to report
important information in a narrative manner as done by Galanello
(Galanello 1999).
Primary outcomes
1. Overall mortality measured at any point in time
No deaths were observed during these two short-term studies
(47 participants) (Galanello 1999; Nisbet-Brown 2001) (Analysis
1.1).
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
No data on end-organ damage were available from either study.
2. Measures of iron overload
Efficacy was not a focus of the Galanello study and no consis-
tent trend on serum iron and transferrin could be observed (as ex-
pected after single-dose administration) (Galanello 1999). Other
measures of efficacy were not reported.
For the Nisbet-Brown study, ferritin levels were reported at base-
line and end of study for each group (Nisbet-Brown 2001). How-
ever, since no SD was given for mean change of ferritin and since
we were unable to obtain these data from the authors, the mean
ferritin levels (µg/L) and SDs at baseline and end of study are pre-
sented here (as reported in the primary study):
Serum ferritin (mean
(SD) [µg/L])
Placebo 10 mg/day 20 mg/day 40 mg/day
Baseline 4265 (3882) 2452 (869) 4753 (3168) 2644 (1320)
End of study 5215 (5430) 2344 (1606) 4872 (2511) 1756 (793)
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We decided against estimating SDs because imputation from an-
other study would require studies similar in design and conduct
which are not available (due to the fact that we are dealing here
with an early phase dose escalation study). We decided against use
of post-treatment values only, since there were large, clinically rel-
evant differences between groups at baseline due to small sample
size despite randomisation.
3. Measures of iron excretion (urine and faeces) over 24
hours (mg/kg/day)
In the Galanello study, the authors note that the majority of iron is
excreted in the faeces; however, data are only given for urinary iron
excretion (Galanello 1999). These data are presented as urinary
iron excretion over 24-hour intervals for each dose. To minimize
the influence of outliers, medians and ranges are given (see table).
Iron excretion over 24 hours: median (range) (mg/kg/24 hours)
Placebo 2.5 mg
deferasirox
5 mg deferasirox 10 mg
deferasirox
20 mg
deferasirox
40 mg
deferasirox
80 mg
deferasirox
0.017
(0.006 - 0.629)
0.009
(0.005 - 0.031)
0.010
(0.006 - 0.028)
0.010
(0.004 - 0.014)
0.016
(0.006 - 0.119)
0.193
(0.053 - 0.508)
0.391
(0.121 - 0.842)
Therefore, we were unable to extract these data to include them
in the RevMan graphs. We are trying to obtain additional data on
faecal iron excretion.
The Nisbet-Brown study measured net iron excretion (Nisbet-
Brown 2001). Since the actual data were not given in the publi-
cations and we have not received these from the authors, we es-
timated the values from the figures of the paper and performed
an analysis of variance for the three dose groups using the placebo
group as reference (Software: R). The mean and SE (mg Fe/kg/
day) are 0.03 (0.10) for placebo, 0.12 (0.14) for 10 mg/day de-
ferasirox, 0.31 (0.14) for 20 mg/day and 0.47 (0.13) for 40 mg/
day.
4. Any adverse events
Galanello reported that “Adverse events were infrequent and of
mild intensity. The most frequently reported adverse event was
headache, with no association to the dose level (four participants
at 2.5 mg/kg, one participant at 20 mg/kg, and one participant at
placebo). Nausea and diarrhoea occurred in the 80-mg/kg group
only (three of eight participants, all from one centre), suggesting
that these symptoms were either drug related or possibly related to
the dense oral suspension administered. Single occurrences of in-
fluenza, joint pain, and vertigo were not dose associated and were
not suspected to be drug related. No consistent effect on individ-
ual laboratory values was observed. In single cases, hematologi-
cal, biochemical, and special kidney parameters were outside the
normal range, including at baseline, but no correlation with treat-
ment could be observed. Notable parameters outside the normal
ranges (and order of magnitude) were as follows: bilirubin, alanine
aminotransferase, and aspartate aminotransferase (up to 1.5- to 3-
fold increase); alkaline phosphatase (up to 1.5-fold increase); and
creatinine kinase (0.3- to 0.6-fold decrease). A couple of creatinine
values were just below the normal ranges (with the exception of
a single value observed at screening, which was below the lower
limit by a factor of 0.8). Abnormally low hematocrit, haemoglo-
bin, and erythrocytes were frequent but had no association to the
dose level, while other hematological parameters were abnormally
high, such as platelet, eosinophils, lymphocytes, monocytes, and
neutrophils, with an order of magnitude of 1.2 to 1.5. These find-
ings are suspected to be caused by the underlying disease and by
frequent blood sampling during the study. As expected in this
study population, all patients had elevated ferritin values prior to
the study, ranging from 1422 to 4780 ng/mL. No notable change
in the levels of the trace elements was observed (zinc, copper, mag-
nesium, and calcium). Among the special kidney function param-
eters, values of α-glutathione-S-transferase and β2- microglobulin
were in single instances above the range of the normal values by a
factor of 2- to 5-fold (including at baseline) and, in the extreme
case, by a factor of more than 10- and 30-fold, respectively, for
each parameter. The urinalysis sometimes showed pH values up
to 6.5 to 7, as well as traces of urine bilirubin, glucose, ketones,
leukocytes, and protein.” (Galanello 1999).
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Some data reported by Nisbet-Brown regarding AEs (23 partic-
ipants) (Analysis 1.2) could be extracted (Nisbet-Brown 2001).
Other safety and tolerability data are only available descriptively.
“No clinically relevant changes in any safety variable were seen
between ICL670 and placebo groups. Specifically, no relevant
changes were reported in haematological variables, mean concen-
trations of serum calcium, phosphorus, magnesium, uric acid, cre-
atinine, urea nitrogen, albumin, creatine kinase, triglycerides, or
total cholesterol. No abnormalities of renal sediment were noted.
Further, no relevant changes frombaseline in electrocardiographic,
audiometric, or ophthalmologic examinations were noted, with
the exception of one patient in whom amyelinated fibre bundle or
retinal infarct was seen after seven days of treatment with ICL670
at 20mgkg−1 day−1. This patientwas reviewedby an independent
ophthalmologist, and the change was thought to be secondary to
his underlying diabetes mellitus. No significant changes between
ICL670 and placebo were seen in copper or zinc concentrations
in blood over the study period, indicating thus that ICL670 was
highly selective for iron.” (Nisbet-Brown 2001).
5. Participant satisfaction and adherence
Only data on discontinuations due to serious adverse events could
be extracted (Analysis 1.3). Nisbet-Brown reported that nine par-
ticipants in total discontinued treatment for serious AEs, eight of
whichwhere receivingdeferasirox (24participants) (Nisbet-Brown
2001) (Analysis 1.3). However, two participants did not complete
a single treatment day and only three discontinuations due to rash
were deemed to be drug-related.
6. Cost of intervention per year
No data on costs of intervention were available from either study
(Galanello 1999; Nisbet-Brown 2001).
7. Other additional outcomes
No other additional outcomes were reported.
2. Transfusion-dependent thalassaemia: deferasirox
compared to deferoxamine
Seven studies compared deferasirox to deferoxamine (Cappellini
2005b; Habibian 2014; Hassan 2016; Molavi 2013; Peng 2013;
Pennell 2014; Piga 2002). Two additional studies compared all
three iron chelators (Chirico 2013; Elalfy 2015a). To include data
in the comparison of deferasirox and deferoxamine as well as de-
ferasirox and deferiprone, the number of participants in the de-
ferasirox group was split for each comparison.
While mainly earlier studies which specified the treatment used
lower deferasirox doses (Cappellini 2005b: 5 to 30 mg/kg/day,
Molavi 2013: 20mg/kg/day, Piga 2002: 10or 20mg/kg/day, Elalfy
2015a: 25 mg/kg/day), newer studies extended the upper limit of
doses to 40 mg/kg/day (Hassan 2016: 20 to 40 mg/kg/day, Peng
2013: 40 mg/kg/day, Pennell 2014: 40 mg/kg/day). Higher doses
might affect safety and cause higher costs.
For the Cappellini study, discrepancies between those who discon-
tinued (n = 29) or those who died (n = 4), who were not included
in the primary efficacy population (n = 33) and those who did not
complete one year of study (n = 45 according to the primary report
and n = 29 according to the report on patient-reported outcomes)
were not clearly addressed (Cappellini 2005b). The success rate
analysis (Analysis 2.16) was based on the primary efficacy popu-
lation (n = 553), while changes in ferritin were based on n = 563
(Analysis 2.10), and both changes in LIC and iron excretion to
intake ratio were based on those only who compared one year of
study (n = 541) (per protocol analysis) (Analysis 2.14; Analysis
2.20). In the Elalfy study, participants were randomised twice: to
three iron chelators and to treatment with vitamin C or no treat-
ment with vitamin C, but results are only reported for those who
received vitamin C (Elalfy 2015a).
Primary outcomes
1. Overall mortality measured at any point in time
Mortality was reported in eight studies (Cappellini 2005b; Hassan
2016; Molavi 2013; Elalfy 2015a; Pennell 2014; Chirico 2013;
Peng 2013; Piga 2002). Piga 2002 reported mortality for both 10
and 20 mg/kg/day subgroups.There was no significant difference
in mortality observed; data were pooled despite range from eight
months to two years (1170 participants) (Analysis 2.1). However,
the number of participants and in particular the number of events
was limited. Cappellini reported that all four deaths were felt to
be unrelated to the administration of the study drug by the inde-
pendent Program Safety Board (Cappellini 2005b) (Analysis 2.1).
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
One study assessed LVEF (%) (172 participants) (Pennell 2014)
(Analysis 2.2). Data for mean change from baseline was extracted
from clinicaltrials.gov as least squares mean and SEM, SD was
calculated. LVEF remained stable in both groups, showing no sig-
nificant difference between both groups after one year. No signifi-
cant difference was also seen in the number of individuals for both
subgroups with improvement from abnormal LVEF at baseline to
normal range (21 participants) (Analysis 2.3) and from normal
LVEF at baseline to below lower limit of normal at end of study
(151 participants) (Analysis 2.3).
The incidence of thyroid disease was assessed in one study (19
participants) (Chirico 2013) (Analysis 2.4). No difference was
observed after two years of treatment, but the included population
was very small.
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Two studies reported detailed information on ALT levels and crea-
tinine clearance (Hassan 2016; Pennell 2014). Overall mean (SD)
ALT levels had decreased in both treatment groups after one year
(deferasirox: -3.5 (80.4) U/L; deferoxamine: -18.9 (35.5) U/L) in
the Pennell study, but due to missing number of included partic-
ipants, we were not able to include these data in our meta-anal-
ysis (Pennell 2014). Among participants with abnormal baseline
ALT, levels had improved to within the normal range in a similar
number of participants in both groups (119 participants) (Analysis
2.5). In the Hassan study, AST (U/L) and ALT (U/L) levels were
significantly different at end of study (Hassan 2016), but values
were already significant different at baseline. While ALT levels in-
creased (60 participants), AST levels decreased in both treatment
groups (60 participants) during the study (Analysis 2.6; Analysis
2.7). Another study reported, that 32% of participants had in-
creased ALT at baseline, but most participants had normal AST
at baseline (Piga 2002). The authors assume liver damage due to
chronic viral hepatitis and/or iron overload. No participant had
consistent or progressive elevations in transaminase levels during
the study.
Hassan reported serum creatinine at end of study (Hassan 2016).
The difference between both treatment groups was not signifi-
cantly different (60 participants) (Analysis 2.8). In the Pennell
study, mean (SD) creatinine clearance had decreased in both
groups after one year of treatment (deferasirox: -37.0 (42.9) mL/
min; deferoxamine: -23.1 (36.6) mL/min), but the number of in-
cluded participants was not mentioned (Pennell 2014). One study
reported, that blood ureawas significantly higher in the deferasirox
group at end of study (60 participants), MD 7.10 (95% CI 4.01
to 10.19) (Hassan 2016) (Analysis 2.9).
2. Measures of iron overload
a. Serum ferritin concentration
In the Cappellini study the mean ratio of deferasirox to deferox-
amine varied between the predefined subgroups according to iron
overload measures at baseline and different effects were seen in the
different subgroups accordingly (Cappellini 2005b). Data from
Cappellini showed a clear dose-response effect for serum ferritin
levels (Analysis 2.10). At a ratio of less than 1:2.2 of deferasirox
to deferoxamine, the latter was statistically more effective; similar
efficacy was achieved only in the highly iron-overloaded subgroup
at a mean ratio of 1:1.8.
One study reported serum ferritin as mean change from baseline
(Molavi 2013). For the following studies we used the methods as
described byWan to calculate themeans and SDs for our analysis (
Wan 2014).One study reportedmedian change and range (Pennell
2014). The Peng study reported median and range at end of the
study; additionally Z values for change from baseline were given
for both treatment groups, so we were able to calculate change
frombaseline values (Peng 2013). A further study reportedmedian
and interquartile ranges at end of study (Elalfy 2015a). A sixth
study reported median and range at end of study; due to a given
P value for change from baseline (P < 0.001), SD for change from
baseline could be calculated (Hassan 2016).
Combined evidence from the meta-analysis of all six studies
showed a significant difference between treatment arms, favour-
ing deferoxamine, MD 454.42 (95% CI 337.13 to 571.71) (1002
participants) (Analysis 2.10). Heterogeneity was very high (I² =
92%), likely due to different baseline iron overload and different
chelation doses. Using the random-effects model, results remained
statistically significant, MD 743.14 (95% CI 263.18 to 1223.09).
A sensitivity analysis was undertaken for serum ferritin without all
values which were calculated according to Wan (Wan 2014) (701
participants) (Analysis 2.11). The results of the Cappellini and
Molavi studies were pooled and remained statistically significant,
favouring deferoxamine, MD 418.94 (95% CI 297.23 to 540.65)
(Cappellini 2005b; Molavi 2013).
In the Piga study, data for serum ferritin are presented only in
a figure giving means and SDs at various time points; since no
information was given with regard to change in mean serum fer-
ritin with respective SDs, we were unable to extract data on fer-
ritin (Piga 2002). In the Chirico study, data on serum ferritin
could not be extracted as it was unclear if mean or median, range
or interquartile range were reported (Chirico 2013). The authors
stated, that they did not find statistical differences between serum
ferritin changes in all treatment groups after therapy. Although
Habibian measured serum ferritin, no data were presented that
would allow for inclusion in our meta-analysis (Habibian 2014).
The authors reported that “mean ferritin level was alike between
two groups except for third month follow up that was significantly
higher in Osveral® group (P < 0.03).” Data from Elalfy were only
available for half of the participants receiving adjuvant vitamin C,
but data on participants without vitamin C supplementation was
missing and could not be included in our meta-analysis (Elalfy
2015a). The author only describes that serum ferritin was signif-
icant improved in iron chelation subgroups receiving vitamin C
compared to those receiving no vitamin C.
b. Liver iron concentration (LIC)
LIC was measured in one study (Peng 2013) by R2* after 12
months of treatment (24 participants) (Analysis 2.12). Based on
given median and range at end of study, mean and SD could be
calculated as stated in our methods. Due to given Z values for
change from baseline, mean change and SDs could be calculated.
No significant difference was observed, but the study included
only a small population of 24 participants.
Change in LIC measured by MRI (R2) was significantly differ-
ent favouring deferoxamine in one study (Pennell 2014). Elalfy
also presented MRI R2* measurements at end of study for those
participants receiving vitamin C, (SDs for change could be cal-
24Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
culated from P values (both given as < 0.001)), but no difference
in LIC was observed between both groups (Elalfy 2015a). When
data from the two studies were pooled, the change in LIC was not
significantly different between the two groups, but heterogeneity
was very high (I² = 79%) (217 participants) (Analysis 2.13). No
significant difference was observed when the analysis was repeated
using the random effects model. In the Elalfy study, data for the
iron chelation subgroups not receiving vitamin C were not given,
but the author describes that LIC was significantly improved com-
pared to those who didn’t receive vitamin C (Elalfy 2015a).
In most participants in the Cappellini study, the LIC was mea-
sured by biopsy (n = 454) and only in a minority by SQUID (n =
87) (Cappellini 2005b). According to the authors, SQUID mea-
surement underestimated LIC; however, since this applies to both
groups and data were not completely given for all relevant out-
comes, we did not examine these data for the subgroups separately,
but rather decided to extract the data on LIC for the combined
group measured by either biopsy or SQUID (Analysis 2.14). At
a ratio of 1:1.8 deferasirox showed a significantly better efficacy
than deferoxamine in the subgroup of highly iron-overloaded peo-
ple, while deferoxamine showed higher efficacy in the other three
subgroups at ratios of 1:2.2, 1:3.6 and 1:5.5 (541 participants),
MD 2.37 (95% CI 1.68 to 3.07) (Analysis 2.14). For both drugs a
clear dose-effect relation was shown. The primary objective of the
Cappellini study was to investigate if deferasirox is non-inferior to
deferoxamine regarding success rate in LIC (Cappellini 2005b).
Across all dose groups, non-inferiority was not achieved, because
the lower limit of the 95% CI was less than -15% (predefined by
authors, less conservative than our definition of non-inferiority).
Two studies also did special responder analysis (Cappellini 2005b;
Piga 2002). Responder-definition varied between the studies (de-
crease in LIC more than 10% in the Piga study (67 participants)
(non-significant result) (Analysis 2.15). TheCappellini study (553
participants) used a definition of LIC ranging from 1 to less than
7 mg Fe/g dry weight after one year, significantly favouring defer-
oxamine, RR 0.80 (95% CI 0.69 to 0.92) (Analysis 2.16).
Results for mean change in LIC could not be included in the
analysis from the Piga study due to missing SDs (Piga 2002).
However, results for mean change in LIC were reported: -0.4 mg
Fe/g dry weight for the 10 mg/kg/day deferasirox dose group, -2.1
mg Fe/g dry weight for the 20 mg/kg/day dose group and -2.0 mg
Fe/g dry weight for the 40 mg/kg/day deferoxamine group.
c. Myocardial iron concentration
Two studies measured cardiac T2* (Elalfy 2015a; Pennell 2014).
One study measured myocardial T2* after one year of treatment
(Pennell 2014). Results are presented as geometricmeans and coef-
ficients of variance (%) for both groups in the journal publication,
so it was not possible to calculate means and SDs for inclusion in
our meta-analysis. Efficacy is reported as ratio of the Gmeans of
deferasirox versus deferoxamine. For the ITT-population, which
only included 180 of 197 randomised participants, the ratio was
1.055 (repeated 95% CI, 0.999 to 1.129). Analysing the per pro-
tocol population, a ratio of 1.056 (repeated 95% CI, 0.998 to
1.133) was calculated. Both analyses showed no significant dif-
ference between the two treatment arms. The Pennell study was
designed as a non-inferiority study regarding myocardial iron re-
moval (Pennell 2014). The authors defined a non-inferiority mar-
gin of 90% (as we did in our review). The results for myocardial
T2* revealed that the lower bound of the 95% CI was greater than
prespecifiedmargin of 0.9, which demonstrated non-inferiority of
deferasirox compared to deferoxamine.
The second study reportedmyocardial T2* for participants receiv-
ing vitamin C also after one year (Elalfy 2015a). We were able to
calculate the change from baseline due to given P values for change
from baseline. Meta-analysis revealed no significant difference be-
tween the two groups (Analysis 2.17, 45 participants). In the Elalfy
study, data are not given for participants not receiving vitamin
C, but the author describes that cardiac MRI T2* was increased
compared to groups not receiving vitamin C (Elalfy 2015a).
The Pennell study authors derived myocardial iron concentration
frommyocardial T2* values based on a formula described by Car-
penter (Carpenter 2011) (Pennell 2014). No significant difference
was seen for all participants and for the subgroups of participants
with myocardial T2* < 10 ms and ≥ 10 ms at baseline (Analysis
2.18, 172 participants). Improvement in myocardial T2* was de-
fined as increase from a range of 6 to < 10 milliseconds at baseline
to 10 to 20 ms at end of study. Worsening of myocardial iron was
defined as decrease from a range of 10 ms to ≤ 20 ms at base-
line to 6 to < 10 ms. Significantly more participants treated with
deferasirox reached normalized myocardial T2* than participants
with deferoxamine, RR 2.85 (95% CI 1.09 to 7.43) (Analysis
2.19, 172 participants). No significant difference was found for
improvement and worsening between the two groups (Analysis
2.19).
d. Other measures of iron overload
One study evaluated the iron excretion-intake ratio (Cappellini
2005b). The results reflect the dose-response and ratio effect seen
for ferritin, MD -0.18 (95% CI -0.24 to -0.12) (Analysis 2.20,
541 participants). Deferoxamine showed higher efficacy at ratios
of 1:2.2, 1:3.6 and 1:5.5, while deferasirox at a ratio of 1:1.8
showed significantly higher efficacy in the subgroup of highly iron-
overloaded people.
3. Measures of iron excretion (urine and faeces) over 24
hours (mg/kg/day)
No data on iron excretion were available from any study.
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4. Adverse events
Five studies reported in a detailed manner on AEs (Cappellini
2005b; Molavi 2013; Piga 2002; Pennell 2014; Hassan 2016). In
the Cappellini study, it is not clearly stated whether all 586 par-
ticipants were included in this analysis; however, since discontin-
uations are reported, we assume that all 586 participants were in-
cluded (Cappellini 2005b). From the Piga phase II study reports,
some safety data were reported by dose group. Our intention was
to pool the data with the results of other studies, so we summed the
number of AEs of both dose subgroups. Only common (observed
in ≥ 5% of participants) adverse events of the Pennell study were
reported in the journal publication. On clinicaltrials.gov more ad-
verse events were reported, but due to unexplained differences be-
tween journal publication and register entry in the numbers of
some adverse events, we extracted the data from the peer-reviewed
journal publication.
Two studies reported the number of participants affected by SAEs
(773 participants) (Cappellini 2005b; Pennell 2014) (Analysis
2.21). The pooled results revealed no significant difference be-
tween both treatment groups. One study reported SAEs in detail
(Pennell 2014). No significant differences were seen in all SAE
between the two groups (187 participants) (Analysis 2.22).
No statistically significant difference was found between de-
ferasirox and deferoxamine with regard to the number of partici-
pants experiencing “any adverse events” (Pennell 2014; Piga 2002,
258 participants); heterogeneity was high (I² = 74%) (Analysis
2.23). No significant difference was observed using random-ef-
fects model. Different types of AEs were reported, but only iso-
lated increases of creatinine occurred significantlymore oftenwhile
on deferasirox treatment compared to deferoxamine (657 par-
ticipants) (Analysis 2.24). However, likelihood for a false-posi-
tive finding is high due to the large number of AEs reported
and compared. All other reported AEs such as thrombocytope-
nia, agranulocytosis, neutropenia, leukopenia, cardiac AEs, hear-
ing loss, lens and retinal abnormalities, different gastrointestinal
disorders, asthenia, influenza-like illness, pyrexia, allergic conjunc-
tivitis, bronchitis, upper respiratory tract infection, urinary tract
infection, increased ALT, elevated ALT (> 2 x ULN), increased
AST, increased blood creatinine, increased platelet count, arthral-
gia, back pain, osteoporosis, headache, vertigo, proteinuria, cough,
influenza, nasopharyngitis, oropharyngeal and pharyngolaryngeal
pain, pharyngitis, rhinitis and rash were either not observed at all
or at frequencies that were not statistically different between both
treatments (Analysis 2.24). Heterogeneity regarding the pooled
data for diarrhoea was high (I² = 53%), but results remained not
statistically significant using a random-effects model.
Cappellini describes mild, dose-dependent increases in serum cre-
atinine in 38% deferasirox participants, mostly in the 20 and
30 mg/kg/day groups in those participants with the highest de-
creases in LIC and serum ferritin (Cappellini 2005b). Increases
were sometimes transient and generally within the normal range.
The increases never exceeded 2x ULN. 14% of participants in the
deferoxamine group experienced similar increases. Eight partici-
pants in the deferasirox and seven participants in the deferoxamine
group experienced deafness, neurosensory deafness or hypoacusis.
For two participants in the deferasirox group and five participants
in the deferoxamine group, cataracts or lenticular opacities were
reported. Electrocardiograms were performed for 258 participants
in the deferasirox group and 245 participants in the deferoxamine
group. The authors reported that no cardiac safety concerns re-
garding deferasirox were identified and a similar percentage of par-
ticipants receiving deferasirox (5.1%) and deferoxamine (6.9%)
experienced cardiac AEs.
Pennell assessed drug-related AEs and reported the ones affecting
≥ two participants (Pennell 2014). Hassan also reported different
kinds of drug-related AEs, but not in a systematic way (Hassan
2016). As far as possible, these were included in the analyses; no
significant differences were observed regarding the number of par-
ticipants experiencing drug-related AEs (Analysis 2.25, 187 par-
ticipants) or the different kinds of drug-relatedAEs (Analysis 2.26,
247 participants). In the Cappellini study, the authors describe the
most common AEs with an apparent relationship to deferasirox
were transient gastrointestinal events (15.2% of participants) and
skin rash (10.8%) (Cappellini 2005b). Median duration of the
gastrointestinal events were eight days or less, therefore dose ad-
justment or discontinuation of deferasirox was rarely required.
Two participants receiving deferasirox developed ALT levels > 2x
ULN, which was felt by the investigator to be drug-related. Of
the participants experiencing deafness, neurosensory deafness or
hypoacusis, these symptoms were considered drug-related in one
participant receiving deferasirox and five participants receiving de-
feroxamine. Cataracts or lenticular opacities were reported in one
participant receiving deferasirox and four participants receiving
deferoxamine. There was no drug-related agranulocytosis reported
in this study.
5. Participant satisfaction and adherence
Satisfactionwith, convenience of andwillingness to continue treat-
ment was significantly higher in the group receiving deferasirox
who had previously been treated with deferoxamine, although dif-
ferences were not as marked in the small group of deferoxamine-
naive participants (Analysis 2.27; Analysis 2.28; Analysis 2.29)
(even when those who did not respond to the questionnaire were
counted as not satisfied or unwilling to continue treatment). Time
lost from normal activities due to treatment was significantly less
with deferasirox (Analysis 2.30, 187 participants). For the out-
comes “willingness to continue” (Analysis 2.29) and “time lost
from normal activities” (Analysis 2.30), the number of partici-
pants who responded at end of study were not given; however, to
incorporate these data, we assumed that all participants provided
this information.
Adherence was evaluated in one study and defined as percentage
of the planned dose taken by participants (Pennell 2014). No
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significant differencewas seenbetweenboth groups (Analysis 2.31,
187 participants).
Another study measured adherence by either pill or vial count, but
no results were reported (Elalfy 2015a). Five participants in the
deferoxamine subgroup did not continue till the end of study be-
cause of poor adherence, but it was unclear if participants actively
discontinued the study or were excluded by the investigators.
One study reported, that all participants were adherent, but ad-
herence was not defined (Hassan 2016).
The number of participants who discontinued the study was not
statistically significant different between both groups in eight stud-
ies (Analysis 2.32, 1211 participants). In the Piga study, two par-
ticipants each in the deferasirox 20 mg/kg/day and deferoxamine
groups were withdrawn prematurely from the study (Piga 2002).
One participant in the deferasirox 20 mg/kg/day group was ex-
cluded due to unsatisfactory therapeutic effect and QTc prolon-
gation. The other three participants were excluded due to adverse
events. The AEs of one participant in the deferoxamine group
(arthralgia, headache and fever) were considered to be study drug-
related by the investigator. In the Elalfy study, five participants in
the deferoxamine treatment group discontinued because of poor
compliance (Elalfy 2015a). It remains unclear if participants left
the study deliberate or were excluded by investigators.
One study reported the number of participants with dose adjust-
ments or dose interruptions, but no significantly difference be-
tweenboth treatmentswas observed (586participants) (Cappellini
2005b) (Analysis 2.33); approximately 5% of people discontin-
ued, while dose adjustments were required in approximately one
third of people.
Another study evaluated number of participants with at least one
dose interruption (187 participants) (Analysis 2.34) or dose reduc-
tion (187 participants) (Analysis 2.35) separately (Pennell 2014).
No significant differences between both groupswere observed.The
main reason for interruption (deferasirox: 21/96; deferoxamine:
19/91) and dose reduction (deferasirox: 24/96; deferoxamine: 21/
91) was an AE. One study reported the number of participants
with dose adjustments (71 participants) (Piga 2002); there were
significantly more participants with dose adjustments in the de-
ferasirox group, RR 3.23 (95% CI 1.28 to 8.16) (Analysis 2.36).
However, there was no significant difference in the number of par-
ticipants with dose interruptions due to an AE in this study (71
participants) (Analysis 2.37).
6. Cost of intervention per year
No data on costs of intervention were available from any study.
7. Other reported outcomes not predefined
In the Elalfy study, also transfusion index, haemoglobin, iron, to-
tal iron binding capacity, transferrin saturation and vitamin C at
baseline and end of study are reported (Elalfy 2015a).We included
transfusion index, haemoglobin and transferrin saturation in our
analysis. Due to missing P values, we were not able to calculate the
SD for change from baseline. Haemoglobin at end of study was
significant higher in the deferoxamine group, MD -0.70 (95% CI
-1.33 to -0.07) (Analysis 2.38). In the Molavi study, change in
haemoglobin levels from beginning to end of study were signifi-
cant, MD -0.46 (95% CI -0.81 to -0.11) (Molavi 2013). Pooled
results of both studies showed a significant lower hemoglobin in
the deferasirox group, MD -0.52 (95% CI -0.82 to -0.21) (180
participants) (Analysis 2.38). No significant difference was ob-
served for either transfusion index or transferrin saturation at end
of the Elalfy study (42 participants) (Elalfy 2015a) (Analysis 2.39;
Analysis 2.40). This study provides only data on participants re-
ceiving vitamin C, but the author describes, that improvement in
transfusion index, serum iron, Tsat and hemoglobin was signif-
icant improved in those receiving vitamin C compared to those
not receiving vitamin C.
Hassan reports no significant difference regarding platelet count
(x10³/mm³) and absolute neutrophilic count (/mm³) (Hassan
2016) (Analysis 2.41; Analysis 2.42).
In the Piga study, all treatment groups had transient and low grade
(< 10-fold above the ULN) elevations of urinary b-2 microglob-
ulin, but the elevations were more frequent in those receiving de-
ferasirox 20mg/kg/day (Piga 2002). The elevations tended to nor-
malize, although the study drug was continued in most cases. In
three participants in the deferasirox group, treatment was discon-
tinued and values normalized within seven to 10 days. Two par-
ticipants in the deferasirox 20 mg/kg/day group had the highest
evaluations, the dose was reduced to 10 mg/kg/day which resulted
in a normalization of the b-2 microglobulin levels. Moreover, Piga
reported that there were no consistent changes in urinaryN-acetyl-
beta-glucosaminidase levels (Piga 2002).
Serum copper and zinc levels fluctuated in participants in the Piga
study, but no progressive decreases occurred (Piga 2002). In the
Cappellini study, the authors describe that zinc and copper levels
at the end of the study were comparable in both treatment groups
(Cappellini 2005b).
Growth and development was described as normally within chil-
dren who were receiving deferasirox (Cappellini 2005b).
3. Transfusion-dependent thalassaemia: deferasirox
compared to deferiprone
One study compared deferasirox to deferiprone (Sanjeeva
2015). Two additional studies compared all three iron chelation
monotherapies (Chirico 2013; Elalfy 2015a). A further study com-
pared deferasirox to deferiprone monotherapy and combination
of both (Kakkar 2014). To include data from these multi-armed
studies into meta-analysis, deferasirox groups were split.
Primary outcomes
1. Overall mortality measured at any point in time
27Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
No deaths were observed (146 participants) (Chirico 2013; Elalfy
2015a; Sanjeeva 2015) (Analysis 3.1).
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
One study evaluated the incidence of thyroid disease after two
years of treatment (18 participants) (Chirico 2013) (Analysis 3.2).
No significant difference was seen between both groups, but the
population (n = 18) was very small.
One study reported AST, ALT, urea and creatinine levels and neu-
trophil count at nine months (38 participants) (Sanjeeva 2015)
(Analysis 3.3; Analysis 3.4; Analysis 3.5; Analysis 3.6Analysis 3.7).
P values for change from baseline were given, so we were able to
calculate the SD for change from baseline. No significant differ-
ences between both groups were observed.
AlthoughKakkar reported the performance ofmonthly renal func-
tion tests and measurements of liver enzymes, no results were pre-
sented (Kakkar 2014).
2. Measures of iron overload
a. Serum ferritin
Two studies measured serum ferritin concentration at end of study
(Sanjeeva 2015; Elalfy 2015a). Mean change from baseline was
calculated from P values (baseline to end-value) for the Sanjeeva
study (Sanjeeva 2015). The thesis document additionally reported
serum ferritin in different subgroups which were categorized ac-
cording to their baseline serum ferritin. The second study reported
median and interquartile ranges, so we calculated mean and SD
at end of study (Elalfy 2015a). No significant difference between
both treatment groups was observed for all participants and for
subgroups split according to baseline ferritin values (83 partici-
pants) (Analysis 3.8).
Two other studies measured serum ferritin every three months,
but data could not be extracted (Chirico 2013; Kakkar 2014). In
the Chirico study, data on serum ferritin could not be extracted
due to insufficient information on the data (Chirico 2013): it
was unclear if mean or median, range or interquartile range were
given. The authors described, that they did not find statistical
differences between serum ferritin changes in all treatment groups
after therapy. In theKakkar study, the authors describe that “serum
ferritin reduced significantly in group I [DFP] and II [DFX] [...]”
(Kakkar 2014).
b. Liver iron concentration (LIC)
One study measured LIC by MRI R2* at end of study (Elalfy
2015a). We calculated the SD for change from baseline from P
values. No significant difference was seen between both treatment
groups (45 participants) (Analysis 3.9).
A further study measured liver MRI T2* but no data could be
extracted (Kakkar 2014). Mean values for liver MRI T2* were
reported, but it remains unclear if these values represent baseline
or end of study data.
c. Myocardial iron concentration
One study measured cardiac T2* at end of study (Elalfy 2015a).
We calculated the SD for change from baseline from P values. No
significant difference was seen between both treatment groups (45
participants) (Analysis 3.10).
Data from the Kakkar study measuring cardiac T2* could not be
extracted (Kakkar 2014). The authors describe, that cardiac MRI
T2* at the end of the study were slightly better in [deferiprone]
group as compared to [deferiprone and deferasirox] group, al-
though this was not statistical significant (P = 0.07).
3. Measures of iron excretion (urine and faeces) over 24 hours
(mg/kg/day)
No data on iron excretion were available from any study.
4. Adverse events
Three studies provided information on AEs (Elalfy 2015a; Kakkar
2014; Sanjeeva 2015).
In the Sanjeeva study, AEs were very common in the deferiprone
(15 out of 22, 68.2%) and deferasirox group (seven out of 19,
36.8%), but overall no significant difference was observed (41 par-
ticipants) (Sanjeeva 2015) (Analysis 3.11). Significantly more par-
ticipants experienced arthralgia in the deferiprone group compared
to the deferasirox group, RR 0.13 (95% CI 0.02 to 0.93) (41 par-
ticipants) (Analysis 3.12), resulting in three participants discontin-
uing deferiprone treatment. Due to the high number of different
types of AEs reported and compared, likelihood for a false-posi-
tive result is increased. Nausea and vomiting appeared frequently
in both groups: deferasirox 31.5% (six out of 19), deferiprone
27.2% (six out of 22), respectively, with no significant differences
between both groups (41 participants) (Analysis 3.12). One par-
ticipant in the deferiprone group had abdominal pain (Analysis
3.12, 41 participants). None of the participants experienced rashes
or diarrhoea (41 participants) (Analysis 3.12). One participant in
the deferiprone group experienced neutropenia, however, agranu-
locytosis was not observed in any of the groups (38 participants)
(Analysis 3.12). The number of participants with ALT or AST
levels of 2x above ULN was equal in both treatment groups (38
participants) (Analysis 3.12). One participant in the deferasirox
group had 50% increase in serum creatinine levels from baseline
(Analysis 3.12, 38 participants). Renal failure was not observed in
any of the groups (38 participants) (Analysis 3.12).
Elalfy only states that “no serious adverse reaction to iron chela-
tors nor to vitamin C administration have been reported” (Elalfy
2015a). No data on adverse events could be extracted from the
Kakkar study (Kakkar 2014).
5. Participant satisfaction and adherence
No data on participant satisfaction and adherence could be ex-
tracted from any study.
One study measured adherence by either pill or vial count, but no
results were reported (Elalfy 2015a).
No significant difference was observed in the number of partici-
pants discontinuing the study overall (Chirico 2013; Elalfy 2015a;
Sanjeeva 2015) (Analysis 3.13, 179 participants) or discontinuing
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the study due to AEs (41 participants) (Analysis 3.14).
6. Cost of intervention per year
No data on cost of intervention were available from any study.
7. Other additional outcomes
Comparing deferasirox to deferiprone in the identified studies,
other, in this review not a priori defined outcomes were mea-
sured. A significant higher transferrin saturation was seen in the
deferiprone group at end of one study (45 participants), MD
-7.40 (95% CI -13.28 to -1.52) (Elalfy 2015a) (Analysis 3.15).
No significant differences were observed regarding haemoglobin
or transfusion index in this study (45 participants) (Analysis 3.16,
Analysis 3.17). Additionally, ALP levels were reported at nine
months in one study (Sanjeeva 2015). Due to P values for change
from baseline given, we were able to calculate the SD for change
from baseline. No significant difference was observed (38 partic-
ipants) (Analysis 3.18). Moreover, the thesis document reporting
the Sanjeeva study also reported phosphorous and calcium levels,
which we did not include in our review (Sanjeeva 2015). In the
Elalfy study, also iron, total iron binding capacity and vitamin C
at end of study are reported (Elalfy 2015a).
4. Transfusion-dependent thalassaemia: deferasirox
compared to deferasirox in combination with
deferiprone
One study with 40 participants reported in one abstract included
the comparison of deferasirox versus deferasirox and deferiprone
administered sequentially (Kakkar 2014).
Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and
renal function tests were assessed during the study. Results for
liver MRI, serum ferritin and adverse events were only reported
narratively and no data could be extracted:
“Liver MRI T2* was not significantly different before and after
the study. Serum ferritin reduced significantly in group I [DFP]
and II [DFX] but not in group III [DFX+DFP]. Group receiving
combination therapy did not show any untoward side effects as
compared to single drug regimen.”
No results regarding cardiac MRI, CBC, liver enzymes and renal
function tests were reported.
5. Transfusion-dependent thalassaemia: deferasirox in
combination with deferiprone compared to
deferiprone alone
One study with 40 participants reported in one abstract included
the comparison of deferiprone versus deferasirox and deferiprone
administered sequentially (Kakkar 2014).
Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and
renal function tests were assessed during the study. Results for
cardiac and liverMRI, serum ferritin and adverse events were only
reported narratively and no data could be extracted:
“Cardiac MRI T2* at the end of the study was slightly better in
group I [DFP] as compared to group III [DFP + DFX] although
was not statistical significant (p=0.07). [...] Liver MRI T2* was
not significantly different before and after the study. Serum ferritin
reduced significantly in group I [DFP] and II [DFX] but not in
group III [DFP+DFX]. Group receiving combination therapy did
not show any untoward side effects as compared to single drug
regimen.”
No results regarding CBC, liver enzymes and renal function tests
were reported.
6. Transfusion-dependent thalassaemia: deferasirox in
combination with deferoxamine compared to
deferoxamine alone
One study compared deferasirox in combination with deferoxam-
ine to deferoxamine alone (Molavi 2014).
Primary outcomes
1. Overall mortality measured at any point in time
No loss-to-follow-up was reported in the study (94 participants)
(Molavi 2014) (Analysis 6.1). Therefore, we assumed no deaths
occurred in any of the groups.
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
Molavi measured neutrophils, ALT, AST at baseline and at 12
months (Molavi 2014). Due to missing P values for change from
baseline, no SDs for change from baseline could be calculated.
No significant differences were observed in neutrophils, ALT, and
AST levels (94 participants) between the two groups at 12 months
(Analysis 6.2; Analysis 6.3; Analysis 6.4).
No other data on end-organ damagewere available from this study.
2. Measures of iron overload
a. Serum ferritin
The Molavi study measured serum ferritin at 12 months (Molavi
2014). Due to missing P values (baseline to end of study), SD
for change from baseline couldn’t be calculated. No significant
difference was observed between both groups at end of study (94
participants) (Analysis 6.5).
3. Measures of iron excretion (urine and faeces) over 24 hours
(mg/kg/day)
No data on iron excretion were available from the study.
4. Adverse events
No AEs were reported.
5. Participant satisfaction and adherence
No data on this outcome were available from the Molavi study;
however, no participant discontinued the study (94 participants)
(Analysis 6.6).
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6. Cost of intervention per year
No data on cost of intervention was available from the study.
7. Other additional outcomes
Haemoglobin at 12 months was slightly higher in participants
treated with deferoxamine alone (94 participants) (Analysis 6.7).
ALP was significantly higher in participants treated with both
deferasirox and deferoxamine (94 participants) (Molavi 2014) (
Analysis 6.8).
7. Transfusion-dependent thalassaemia: deferasirox in
combination with deferiprone compared to
deferiprone + deferoxamine
One study compared deferasirox and deferiprone to deferiprone
and deferoxamine (Elalfy 2015b).
Primary outcomes
1. Overall mortality measured at any point in time
Nodeaths were observed during the study (96 participants) (Elalfy
2015b) (Analysis 7.1).
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
The authors reported that “change in mean LVEF after one year
was not different between the two treatment groups (data not
shown).” (Elalfy 2015b). No quantitative data were available.
2. Measures of iron overload
a. Serum ferritin
One study measured serum ferritin at 12 months and reported
mean and SD values (Elalfy 2015b). Although not directly stated,
we considered the given P value to describe change from baseline
so we were able to calculate the mean change and SD. Serum
ferritin decreased in both groups, but no significant difference was
observed (96 participants) (Analysis 7.2).
b. Liver iron concentration (LIC)
LIC was measured by MRI R2* in the included study and mean
and SD values at end of study were reported (Elalfy 2015b). Al-
though not directly stated, we considered the given P value to
describe change from baseline, so we calculated the mean change
and SD. No significant difference was seen between both groups
(96 participants) (Analysis 7.3).
c. Myocardial iron concentration
Myocardial iron concentration was measured by T2* in the in-
cluded study and mean and SD values at end of study were re-
ported (Elalfy 2015b). Although not directly stated, we considered
the given P value to describe change from baseline, so we were able
to calculate the mean change and SD. No significant difference
was seen between the groups (96 participants) (Analysis 7.4).
3. Measures of iron excretion (urine and faeces) over 24 hours
(mg/kg/day)
No data on iron excretion were available from the included study
(Elalfy 2015b).
4. Adverse events
The number of participants with a SAE was equal in both groups
(96 participants) (Analysis 7.5). An acute cholecystitis was assessed
as a drug-related SAE in a participant receiving deferasirox and
deferiprone (96 participants) (Analysis 7.6). A SAE, classified as
unrelated to the drugs and which did not lead to death, was re-
ported in one participant who developed appendicitis while re-
ceiving deferiprone and deferoxamine (96 participants) (Analysis
7.7).
Mild-moderate neutropenia was observed in both groups, which
resolved with decreasing deferiprone dose (96 participants) (
Analysis 7.8). No cases of agranulocytosis were observed (96 par-
ticipants) (Analysis 7.8). Overall, drug-related AEs “were mostly
of mild to moderate severity” and common in both groups (96
participants) (Analysis 7.9). In the Elalfy study, agranulocytosis,
neutropenia, arthralgia, gastrointestinal problems, ALT (at least a
three-fold increase), serum creatinine (an increase of at least 33%)
above baseline on two consecutive occasions and skin rash were
assessed as drug-related with similar frequencies in both groups
(96 participants) (Elalfy 2015b) (Analysis 7.10).
Non-drug-related AEs were reported by 17 of 48 (35.41%) par-
ticipants in the deferasirox and deferiprone group versus 18 of 48
(37.5%) in the deferiprone and deferoxamine group (96 partici-
pants) (Analysis 7.11). Only the three most common non-drug-
related AEs were reported (infections, gastrointestinal disorders,
skin and subcutaneous tissue disorders) and no significant differ-
ences were observed (96 participants) (Analysis 7.12). Mild eleva-
tion of hepatic transaminases at the start of therapy were observed
in both groups, which returned to normal within the first two
months (96 participants) (Analysis 7.13). Initial gastrointestinal
manifestations also occurred in both groups and “were in form
of nausea and mild abdominal pain” (96 participants) (Analysis
7.14).
5. Participant satisfaction and adherence
Quality of life was measured by SF-36 in one study (Elalfy 2015b).
Data were not given, therefore mean and SD at end of study were
obtained through estimation from a figure, and SD for change
from baseline was calculated from given P values. No significant
differences were observed between both groups (96 participants)
(Analysis 7.15).
The definition of adherence in the Elalfy study was the actual dose
divided by the total prescribed dose (Elalfy 2015b). We calculated
missing SD from given P value. Adherence was significantly higher
in the deferasirox and deferiprone group, MD 0.15 (95% CI 0.06
to 0.24) (96 participants) (Analysis 7.16).
Overall, no participant discontinued the study (96 participants)
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(Analysis 7.17) and there were no SAEs necessitating discontinu-
ation or interruption of therapy in any of the groups (96 partici-
pants) (Analysis 7.18).
6. Cost of intervention per year
No data on cost of intervention were available from any study.
7. Other additional outcomes
No other additional outcomes were reported.
8. Non-transfusion-dependent thalassaemia:
deferasirox compared to placebo
One study evaluated people with non-transfusion-dependent tha-
lassaemia and compared deferasirox 5 mg/kg/day and deferasirox
10 mg/kg/day starting doses to matching placebos (Taher 2012).
Primary outcomes
1. Overall mortality measured at any point in time
No deaths occurred during the study in any treatment group dur-
ing one year of treatment (148participants) (Taher 2012) (Analysis
8.1).
Secondary outcomes
1. Reduced end-organ damage due to iron deposition
No data on end-organ damage were available from the study.
2. Measures of iron overload
a. Serum ferritin
Different types of data on change in serum ferritin were reported
in the journal publication and on clinicaltrials.gov. The journal
publication reports least squares mean (LSM), median and 95%
CI; the mean and SD are reported on clinicaltrials.gov. In the
journal publication, a LSM of -121 ng/mL (95% CI -203 to -38;
median -99 ng/mL) and a LSM of -222 ng/mL (95% CI -304
to -140; median -190 ng/mL) are given in the 5 and 10 mg/kg/
day subgroups, respectively. In the placebo group a LSM of 115
ng/mL (median 78 ng/mL) is reported, but due to missing SD
or 95% CI we were not able to include these data in our meta-
analysis.
The change in serum ferritin reported on clinicaltrials.gov was
significant in both the 5 and 10 mg/kg/day deferasirox subgroups
compared to placebo, with a MD of -259.10 (95% CI -377.35 to
-140.85) and -377.79 (95% CI -522.21 to -233.37) in the 5 and
10 mg/kg/day subgroups respectively (154 participants) (Analysis
8.2). The overall result was also significant, MD -306.74 (95%
CI -398.23 to -215.24). Only participants with both baseline and
post-baseline values were included in the analyses of the study.
b. Liver iron concentration (LIC)
In the Taher study, the primary efficacy end point was change in
LIC from baseline to 52 weeks (159 participants) (Taher 2012).
The authors used LSM and SEM when reporting data, so we cal-
culated SD to include the results in our meta-analysis. Regarding
both starting dose subgroups, decrease in LIC was significant in
both groups. For the 5 mg/kg/day group, MD -2.33 (95% CI
-4.00 to -0.66); for the 10mg/kg/day group the decreasewas larger,
MD -4.18 (95% CI -5.83 to -2.53) (Taher 2012) (Analysis 8.3).
Regarding the different types of thalassaemia, results, reported as
mean (SD), were only significant in favour of deferasirox in the
β-thalassaemia subgroups, with a larger decrease in the 10 mg/kg/
day group. Results for α-thalassaemia and HbE/β-thalassaemia
participants were not significant, but included participant popu-
lations were smaller than for the β-thalassemia subgroup. Com-
paring LIC regarding age of the participants, LIC decrease in the
subgroup of participants under 18 years of age with a deferasirox
starting dose of 5 mg/kg/day was the only of the four subgroups
without significant LIC decrease, but only 10 out of the 159 par-
ticipants were included (Analysis 8.4).
In the 5 mg/kg/day group, neither the decrease of≥ 3 mg Fe/g dry
weight in LIC, nor the reduction in Fe/g dry weight ≥ 30% were
significant compared to placebo. However, in the 10 mg/kg/day
group, significantly more participants had a LIC decrease of ≥ 3
mg Fe/g dry weight, RR 5.26 (95% CI 1.76 to 15.71) (83 partic-
ipants) (Analysis 8.5) and a reduction in Fe/g dry weight ≥ 30%,
RR 13.75 (95%CI 1.97 to 95.97) (83 participants) (Analysis 8.6).
When combined, both of these results were significant across dose
groups (Analysis 8.5; Analysis 8.6). Significantlymore participants
in both dose groups combined moved to a lower iron burden range
(166 participants), RR 3.35 (95% CI 1.62 to 6.91); for the 5 mg/
kg/day group, RR 3.39 (95%CI 1.10 to 10.45) and for the 10mg/
kg/day group, RR 3.31 (95% CI 1.28 to 8.55) (Analysis 8.7). No
significant difference was observed in the number of participants
in the 5 and 10 mg/kg/day subgroups who had LIC < 5 mg Fe/g
dry weight (166 participants) (Analysis 8.8); however, when these
data were combined the result was significant, RR 5.35 (95% CI
1.30 to 21.99) (Analysis 8.8).
c. Myocardial iron concentration
No data on myocardial iron concentration were available from the
study.
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3. Measures of iron excretion (urine and faeces) over 24
hours (mg/kg/day)
No data on iron excretion were available from the study.
4. Adverse events
An extensive data on SAEs and other AEs are available on
clinicaltrials.gov. We were not able to include these data in our
meta-analysis, because the data were not reported separately for
the core trial.
Six investigator-assessed drug-related SAEs were reported in four
participants receiving deferasirox (abdominal, pyrexia, hepatotox-
icity, cellulitis, pruritus, rash), no drug-related SAEs were reported
with placebo (166 participants), these results were not significant
(Analysis 8.9; Analysis 8.10).
No significant difference was found in the number of participants
experiencing at least one AE (166 participants) (Analysis 8.11)
and in the number of participants with mild, moderate or se-
vere AEs (166 participants) (Analysis 8.12; Analysis 8.13; Analysis
8.14). Neurosensory deafness was reported in a participant receiv-
ing placebo 10 mg/kg/day and proteinuria was reported in one
participant receiving deferasirox 5 mg/kg/day (166 participants)
(Analysis 8.15). No numbers are given, but the authors report
that “the overall number of AEs and SAEs reported before and
after dose increases was comparable within each treatment group.”
Comparisons of the number of participantswith notable abnormal
post-baseline laboratory results extracted from clinicaltrials.gov
(platelet count, neutrophil count, ALT, AST, serum creatinine, cre-
atinine clearance, urinary protein/creatinine ratio, low/high blood
pressure, low/high pulse rate), showed no significant differences
between both groups (166 participants) (Analysis 8.15).
Investigator-assessed drug-related AEs “were reported in 40
(24.1%) patients”, but no values for each treatment group sepa-
rately were given. Most common (at least three participants in to-
tal) investigator-assessed drug-related AEs were reported (nausea,
skin rash, diarrhoea, headache, upper abdominal pain, abdomina
pain), but no difference was seen between treatment groups (166
participants) (Analysis 8.16).
5. Participant satisfaction and adherence
No data on participant satisfaction were available from the study.
Adherence was defined as number of participants taking the
planned study dose in Taher study (Taher 2012). Adherence was
high, showing no difference between treatment groups (166 par-
ticipants) (Analysis 8.17).
Overall, no significant difference was observed in participants dis-
continuing the study (166 participants) (Analysis 8.18)
No significant difference was observed in the number of partic-
ipants who discontinued overall due to AEs (166 participants)
(Analysis 8.19): three participants discontinued in the deferasirox
5 mg/kg/day cohort (fractured pelvis, anaemia, increased urine
protein level), three participants in the deferasirox 10 mg/kg/day
subgroup (pregnancy (n = 2), rash and pruritus) and two partici-
pants in the placebo group (optic neuritis and severe anaemia).
No significant differences were observed in the number of partic-
ipants with dose increase (166 participants) (Analysis 8.20), dose
interruption (166 participants) (Analysis 8.21), dose reduction
(166 participants) (Analysis 8.22) and dose reduction due to AE
(166 participants) (Analysis 8.23).
A total of 46.4% of participants had a dose doubling after 24
weeks.
6. Cost of intervention per year
No data on cost of intervention were available from the study.
7. Other additional outcomes
Taher also reported no significant difference in change in haemo-
globin (144 participants) (Analysis 8.24). However, the study re-
ported a significant difference in transferrin saturation in the 5
mg/kg/day subgroup only, MD -7.16 (95% CI -12.15 to -1.37)
(70 participants) (Analysis 8.25) (Taher 2012).When dose groups
were combined, the difference was also significant, MD -7.10
(95% CI -11.71 to -2.50) (141 participants) (Analysis 8.25).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Deferasirox compared to deferiprone in people with transfusion-dependent thalassemia
Patient or population:people with transfusion-dependent thalassemia
Setting: outpat ient care
Intervention: deferasirox
Comparison: deferiprone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferiprone Risk with deferasirox
Mortality at any t ime
point
Study populat ion not est imable 146
(3 RCTs)
⊕©©©
VERY LOW 12
0 per 1.000 0 per 1.000
(0 to 0)
Responder analysis Not measured NA
Serum ferrit in (ng/ mL)
: mean change f rom
baseline and at end of
study
MD 229.99 ng/ mL
higher
(403.14 lower to 863.
11 higher)
- 83
(2 RCTs)
⊕©©©
VERY LOW 34
LIC (mg/ g) evaluated by
MRI R2* : mean change
f rom baseline
MD 0.8 mg/ g lower
(2.75 lower to 1.15
higher)
- 45
(1 RCT)
⊕©©©
VERY LOW 34
Satisfact ion Not measured NA
Adherence: discont inu-
at ions
Study populat ion RR 0.16
(0.01 to 2.99)
179
(3 RCTs)
⊕⊕©©
LOW 25
32 per 1.000 5 per 1.000
(0 to 95)
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Renal failure Study populat ion not est imable 38
(1 RCT)
⊕©©©
VERY LOW 16
0 per 1.000 0 per 1.000
(0 to 0)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; MRI: magnet ic resonance imaging; NA: not applicable RCT : randomised controlled trial; RR: risk
rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Very serious imprecision: only very few number of included part icipants.
2 Serious risk of bias: select ive report ing: Results f rom Elalf y 2015a for 60 part icipants not reported.
3 Serious risk of bias: no blinding assumed, select ive report ing: Results f rom Elalf y 2015a for 60 part icipants not reported.
4 Very serious imprecision: very wide conf idence interval including both relevant benef it as well as harm.
5 Serious imprecision: wide CIs including both benef it as well as harm.
6 Serious risk of bias: no blinding assumed.
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Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion-dependent thalassaemia
Patient or population: people with transfusion-dependent thalassaemia
Setting: outpat ient care
Intervention: deferasirox
Comparison: deferasirox and deferiprone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferasirox
and deferiprone
Risk with deferasirox
Mortality at any t ime
point
Not reported1 NA
Responder analysis Not measured1 NA
Serum ferrit in (ng/ mL) Not reported1 NA
LIC (mg Fe/ g dry
weight)
Not reported1 NA
Satisfact ion with treat-
ment
Not measured1 NA
Adherence Not reported1 NA
AE: serum creat inine in-
crease
Not measured1 NA
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; RCT : randomised controlled trial; RR: risk rat io.
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One RCT (40 part icipants) contributed to this comparison, but no relevant outcome data to this table are available (Kakkar
2014).
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Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion-dependent thalassaemia
Patient or population: people with transfusion-dependent thalassemia
Setting: outpat ient care
Intervention: deferasirox and deferiprone
Comparison: deferiprone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferasirox
and deferiprone
Risk with deferasirox
Mortality at any t ime
point
Not reported1 NA
Responder analysis Not measured1 NA
Serum ferrit in (ng/ mL) Not reported1 NA
LIC (mg Fe/ g dry
weight)
Not reported1 NA
Satisfact ion with treat-
ment
Not measured1 NA
Adherence Not reported1 NA
AE: Serum creat inine in-
crease
Not measured1 NA
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; RR: risk rat io.
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One RCT (40 part icipants) contributed to this comparison, but no relevant outcome data to this table are available (Kakkar
2014).
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Deferasirox and deferoxamine compared to deferoxamine in people with transfusion-dependent thalassemia
Patient or population: people with transfusion-dependent thalassemia
Setting:outpat ient care
Intervention: deferasirox and deferoxamine
Comparison: deferoxamine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferoxam-
ine
Risk with deferasirox
and deferoxamine
Mortality at any t ime
point
Study populat ion not est imable 94
(1 RCT)
⊕⊕©©
LOW 1
0 per 1.000 0 per 1.000
(0 to 0)
Responder analysis Not measured NA
Serum ferrit in (ng/ mL) -
mean at end of study
MD 87.84 ng/ mL higher
(612.23 lower to 787.
91 higher)
- 94
(1 RCT)
⊕©©©
VERY LOW 23
LIC Not measured NA
Satisfact ion with treat-
ment
Not measured NA
Adherence: Discont inu-
at ions
Study populat ion not est imable 94
(1 RCT)
⊕©©©
VERY LOW 12
0 per 1.000 0 per 1.000
(0 to 0)
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AE: serum creat inine in-
creased
Not reported NA Serum creat inine was
measured in Molavi
2014, but no results
were reported
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; NA: not applicable; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Very serious imprecision: only very few part icipants included.
2 Serious risk of bias: assumed lack of blinding.
3 Very serious imprecision: very wide conf idence interval including both benef it as well as harm.
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Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion-dependent thalassemia
Patient or population: people with transfusion-dependent thalassemia
Setting: outpat ient care
Intervention: deferasirox and deferiprone
Comparison: deferiprone and deferoxamine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with deferiprone
and deferoxamine
Risk with deferasirox
and deferiprone
Mortality at any t ime
point
Study populat ion not est imable 96
(1 RCT)
⊕⊕©©
LOW 1
‘‘All the included pa-
t ients cont inued t ill the
end of study with no pa-
t ients were lost follow-
up.’’ (Elalf y 2015b)
0 per 1.000 0 per 1.000
(0 to 0)
Responder analysis Not measured NA
Serum ferrit in (ng/ mL)
: mean change f rom
baseline
MD 315.9 ng/ mL lower
(1046.26 lower to 414.
46 higher)
- 96
(1 RCT)
⊕©©©
VERY LOW 23
LIC evaluated by MRI
R2* : mean change f rom
baseline
MD 0.62 mg/ g lower
(2.25 lower to 1.01
higher)
- 96
(1 RCT)
⊕⊕©©
LOW 24
Satisfact ion Not reported NA ‘‘Compared to baseline,
pat ient-reported sat is-
fact ion associated with
ICT was signif icant ly
higher in group B [DFX
and DFP] compared
to group A [DFP and
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DFO] (p<0.01)’’ (Elalf y
2015b)
Adherence: Discont inu-
at ions
Study populat ion not est imable 96
(1 RCT)
⊕©©©
VERY LOW 12
0 per 1.000 0 per 1.000
(0 to 0)
Drug-related AE: serum
creat inine increased (≥
33%) above baseline
in 2 consecut ive occa-
sions
Study populat ion RR 3.00
(0.32 to 27.83)
96
(1 RCT)
⊕©©©
VERY LOW 235
21 per 1.000 63 per 1.000
(7 to 580)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; MRI: magnet ic resonance imaging; NA: not applicable; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Very serious imprecision: very few part icipants included.
2 Serious risk of bias: no blinding, select ive report ing: no data for 18 months follow-up.
3 Very serious imprecision: very wide conf idence interval including both benef it as well as harm.
4 Serious imprecision: wide conf idence interval including both benef it as well as harm.
5 Serious indirectness: surrogate of creat inine used for pat ient-important outcome of kidney failure.
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Deferasirox compared to placebo in people with non- transfusion-dependent thalassemia
Patient or population: people with non-transfusion-dependent thalassemia
Setting: outpat ient care
Intervention: deferasirox
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with deferasirox
Mortality at any t ime
point
Study populat ion not est imable 148
(1 RCT)
⊕⊕⊕©
MODERATE 1
‘‘No deaths occurred
during the study in any
group’’ (Taher 2012)0 per 1.000 0 per 1.000
(0 to 0)
Responder analysis Not measured NA
Serum ferrit in (ng/ mL)
: mean change f rom
baseline
MD 306.74 ng/ mL
lower
(398.23 lower to 215.
24 lower)
- 154
(1 RCT)
⊕⊕⊕©
MODERATE 1
LIC (mg Fe/ g dry
weight) evaluated by
MRI R2: least squares
mean change f rom
baseline
MD 3.27 mg Fe/ g dry
weight lower
(4.44 lower to 2.09
lower)
- 159
(1 RCT)
⊕⊕⊕©
MODERATE 1
Satisfact ion with treat-
ment
Not measured NA
Adherence: Discont inu-
at ions
Study populat ion RR 1.32
(0.50 to 3.52)
166
(1 RCT)
⊕⊕©©
LOW 2
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89 per 1.000 118 per 1.000
(45 to 314)
AE: abnormal serum
creat inine (post-base-
line)
Study populat ion RR 3.59
(0.19 to 68.40)
166
(1 RCT)
⊕©©©
VERY LOW 23
0 per 1.000 0 per 1.000
(0 to 0)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
AE: adverse events; CI: conf idence interval; LIC: liver iron concentrat ion; MD: mean dif ference; NA: not applicable; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Serious imprecision: only few patients included.
2 Very serious imprecision: very wide conf idence interval, including both benef it as well as harm.
3 Serious indirectness: surrogate of creat inine used for pat ient-important outcome of kidney failure.
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D I S C U S S I O N
Summary of main results
In the two pharmacokinetic, dose-finding studies iron eliminating
efficacy could be shown. In conclusion, in our opinion efficacy
measures in these early studies were of limited value. However,
since they fulfilled the review’s inclusion criteria and were relevant
in particular for safety issues, we included them. They showed a
dose-response effect as expected, but conclusions regarding effi-
cacy when taken continuously were not really appropriate. In con-
clusion, pharmacodynamic efficacy and acceptable safety could be
confirmed justifying further clinical testing in phase II and phase
III studies based on an estimated equivalence ratio of deferasirox
to deferoxamine of approximately 1 mg: 2 mg.
A phase III study showed that depending on the actual dose
of deferasirox, sufficient efficacy could be achieved to lower
both serum ferritin level and liver iron concentration (LIC)
(measured by biopsy or superconducting quantum interference
device (SQUID)) in people with iron-overloaded thalassaemia
(Cappellini 2005b). In comparison to deferoxamine, at a ratio of
more than 2:1, deferoxamine showed a higher efficacy compared
to deferasirox; however, similar efficacy of deferasirox could be
achieved at a mean ratio of 1.8:1 of deferoxamine to deferasirox.
Also, of five smaller studies which didn’t consider the actual dose in
particular, two showed significantly reduced serum ferritin in par-
ticipants who received deferoxamine compared with deferasirox.
Pooling of all six studies showed a significant reduction in serum
ferritin favouring deferoxamine, mean difference (MD) 454.42
(95% confidence interval (CI) 337.13 to 571.71). One study
showed a significantly greater change in LIC measured by mag-
netic resonance imaging (MRI) in favour of deferoxamine, but no
significant difference was seen when pooled with a smaller study.
Adverse effects, particularly rare adverse effects, are difficult to
investigate in randomised clinical studies with a limited number
of participants and incomplete or inconsistent reporting. Accord-
ingly, with the exception of “increase in creatinine” (which may
also be a false-positive result due to the large number of differ-
ent types of adverse events reported and compared) no significant
differences in frequencies were observed between deferasirox and
deferoxamine. However, from the data it seems that gastrointesti-
nal problems are more common with deferasirox. Due to the low
number of included participants whowere investigated for adverse
events, estimation of rare adverse events (1 to 10 of 10,000 par-
ticipants) is not possible. Also, data on patient-relevant outcomes
such as mortality or end-organ damage are either sparse (low num-
ber of events for mortality) or too limited to adequately evaluate
the efficacy of deferasirox. Due to study duration of maximum
two years, long-term effects of deferasirox can not be judged.
Satisfaction with, and convenience of, deferasirox among those
who had previously received deferoxamine treatment was judged
significantly better resulting in higher willingness to continue
treatment; time lost from normal activities was also reported to be
less with deferasirox. The proportion of people who discontinued
treatment for any reason or who required dose interruptions or
adjustments was similar for both drugs.
Comparing deferasirox to deferiprone, only two small studies re-
ported markers of iron overload. Given the limited patient pop-
ulation, no difference was seen between either treatment. In one
study, significantly more participants experienced arthralgia in the
deferiprone group, but the validity of the data are limited because
the patient population was very small.
Four studies were identified including deferasirox as monotherapy
compared to combination therapy or as part of a combination
therapy. There was only one study for every comparison and a
patient population of 100 or less per study, so the data are very
limited. No significant differences were observed in any outcome,
except for adherence comparing deferasirox and deferiprone to
deferiprone and deferoxamine, which favoured the combination
of oral iron chelators, MD 0.15 (95% CI 0.06 to 0.24).
Treatment with deferasirox appears to reduce serum ferritin and
LIC significantly in people with non-transfusion-dependent tha-
lassaemia as reported in one study including 166 participants.
From the available safety data regarding overall number of par-
ticipants with AEs, similar frequencies were observed, but more
detailed and complete information on safety is needed. Results
should be confirmed in further studies of longer duration, where
patient-relevant outcomes, such as mortality or satisfaction, are
also considered. A total of 46.4% of participants had a dose dou-
bling after 24 weeks due to LIC being more than 7 mg Fe/g dry
weight and a LIC reduction less than 15% from baseline, which
reflects the importance of dose adjustments.
Overall completeness and applicability of
evidence
Given our comprehensive search strategy and contact with No-
vartis, we are confident that we have identified all relevant ran-
domised studies of deferasirox. However, evidence on deferasirox
for treatment of iron overload in people with thalassaemia is still
limited due to the limited number of randomised participants in-
cluded in studies comparing deferasirox to other iron chelators (n
= 1594) and themethodological limitations of most of the studies.
Also, pooling of data from different studies was only feasible for
a few outcomes, so that for most outcomes data from only one or
very few studies were available. Results from ongoing studies and
studies which have not been published in full so far will hopefully
add information regarding some of these outcomes in the near
future.
The applicability of our results is hampered by the use of surrogate
endpoints and the short duration of studies. Long-term studies
comparing deferasirox to placebo would be ethically unjustifiable,
given that the benefit and therefore also the necessity of iron chela-
tion therapy in people with thalassaemia requiring regular trans-
fusion, has been shown. Since the value of iron chelation therapy
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with deferoxamine in people with thalassaemia is well-established
(Fisher 2013a), change in surrogate parameters such as serum fer-
ritin or LIC would be acceptable to deduce changes in patient-rel-
evant endpoints such as mortality or end-organ damage for studies
comparing deferasirox to placebo. However, to adequately com-
pare the efficacy of two iron chelating drugs such as deferasirox and
deferoxamine, information on patient-relevant endpoints such as
mortality or end-organ damage should be available. In particular,
there is a lack of data from randomised studies regarding the re-
moval of cardiac iron and the prevention of cardiac complications.
Although long-term studies investigating these patient-important
endpoints would be important to adequately weigh benefits and
AEs of deferasirox compared to standard treatment with deferox-
amine, it must acknowledged that such studies take a long time to
conduct and are very cost-intensive. Therefore, it is not surprising
that the producers of deferasirox have no particular interest in un-
dertaking these types of studies after treatment has been approved
by the Food and Drug Administration (FDA) and the European
Medicines Agency (EMA).However, such studies are necessary for
a comprehensive evaluation of the effects of deferasirox as com-
pared to deferoxamine.
Furthermore, it has to be acknowledged that six included studies
were supported by the manufacturer of deferasirox.
Finally, the oral mode of application of deferasirox offers an im-
portant advantage of deferasirox over deferoxamine, which is of
high relevance to those with the disease (Taher 2010). Com-
paring the two oral iron chelators (deferasirox and deferiprone),
deferasirox allows for an easier application - once-daily com-
pared to three-times daily. Therefore, physicians prefer to pre-
scribe deferasirox. Nevertheless, data on adherence from ran-
domised controlled studies are still limited. One such study com-
paring deferasirox to deferoxamine showed no difference in ad-
herence (Pennell 2014), while a study comparing deferasirox and
deferiprone to deferiprone and deferoxamine showed a significant
higher adherence favouring the combination of oral iron chelators
(Elalfy 2015b). Whether this advantage will translate into better
long-term adherence and improved patient-relevant outcomes is
still to be shown (Trachtenberg 2011). Recently, the FDA and the
EMA have approved a new formulation of deferasirox (Chalmers
2016; EMA 2016; Novartis 2015). These tablets can be swallowed
with some water in a single step without dispersing in water, which
could further increase adherence. Results of studies investigating
this new formulation are not yet available, but may influence fu-
ture updates of this review, in particular regarding adherence and
safety compared to other iron chelators.
Quality of the evidence
The evidence on deferasirox for treating iron overload in thalas-
saemia is still limited.
The quality of included studies comparing deferasirox to defer-
oxamine in people with transfusion-dependent thalassaemia was
moderate to low, mainly due to a lack of blinding and selective re-
porting, the use of a surrogate marker instead of patient-important
outcomes and imprecision. For the comparison of deferasirox to
placebo in people with non-transfusion-dependent thalassaemia,
the quality of the evidence was moderate to very low based on only
one small study. For the other comparisons, quality of evidence
was low to very low, mainly due to the inclusion of even fewer
participants.
Potential biases in the review process
A very comprehensive search strategy was applied to identify all
potential studies and their reports. However, information on sev-
eral relevant outcome data prespecified in our protocol were not
reported. Several of these outcome measures are, however, impor-
tant tomake an informed and balanced decision onwhich chelator
to choose. Some of these outcome measures were most likely not
ascertained during the study, however, others could have well been
collected but not reported. Unfortunately, even after contacting
the primary investigators, to date we have not been able to obtain
any additional data.
We followed the rigorous methodology for systematic reviews out-
lined in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011), e.g. extracting data independently in dupli-
cate to minimize errors and reduce bias in the process of doing
this systematic review.
Agreements and disagreements with other
studies or reviews
Vanorden andHagemann published the first review on deferasirox
based on a systematic literature search in 2006 (Vanorden 2006).
Besides data from the phase III study (Cappellini 2005b), this
review includes evidence from phase I and phase II as well as
pharmacokinetic studies in both humans and non-humans. The
authorsmade no attempt to pool the data; so findings are presented
narratively (including observational data). The authors concluded
that their findings suggest that deferasirox is as safe and effective
as deferoxamine.
Lindsey and co-authors summarized the available data from five
phase I/II and the one phase III study in their systematic review
published in 2007 (Lindsey 2007). All six studies are critically dis-
cussed, but no pooling of data was performed and data are syn-
thesized qualitatively. Based on the only study looking at efficacy
as a primary endpoint (Cappellini 2006), the authors come to
the conclusion that the two agents have similar efficacy, although
overall the non-inferiority of deferasirox could not be shown by
the primary phase III study investigators. Tolerability is assessed
as good, even though deferasirox is associated with a higher in-
cidence of adverse effects. The authors conclude that long-term
efficacy and safety remain to be established.
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In 2009, McLeod and co-authors published a comprehensive
health technology assessment on deferasirox for secondary iron
overload in individuals with chronic anaemia, such as thalassaemia
and sickle cell disease (McLeod 2009). They identified 14 ran-
domised studies looking at various iron chelation regimens with
a high degree of heterogeneity between studies in terms of study
design and outcome reporting. Only three of these compared de-
ferasirox to deferoxamine, but data were not included in a meta-
analysis. Furthermore, eight economic evaluations were included
in their report. The authors conclude that it appears that there is
little difference between agents in terms of reducing serum ferritin.
The economic evaluations appear to demonstrate the cost-effec-
tiveness of deferasirox compared to deferoxamine. However, the
authors state that both their clinical and economic analyses were
restricted by the available evidence and should only be considered
exploratory.
CochraneReviews on the effects of deferasirox in peoplewith sickle
cell disease (Meerpohl 2014a) and myelodysplastic syndrome (
Meerpohl 2014) have been published; both conclude that data on
deferasirox in these groups of people are still limited and therefore
evidence is insufficient to recommend first-line use of deferasirox
in sickle cell disease ormyelodysplastic syndrome. Several narrative
reviews on deferasirox have also been published of late. These
have usually concluded that efficacy is given and the profile of
adverse events manageable and therefore acceptable (Cappellini
2008; Cappellini 2009; Porter 2009).
A clinical practice guideline by the Italian Society of Hematology
for the management of iron overload in thalassaemia major and
related disorders supports our findings and conclusions by rec-
ommending deferoxamine for children who start iron chelation
therapy before six years of age and in whom the goal of chelation
therapy is the prophylacticmaintenance of iron balance; while oral
chelators (such as deferasirox) should be considered investigational
and be used primarily within clinical trials or registries or for pa-
tients with poor adherence to, or experiencing AEs from deferox-
amine (Angelucci 2008). Due to the limited evidence, these rec-
ommendations were given a level D according to the Scottish In-
tercollegiate Guidelines Network (SIGN) grading system reflect-
ing consensus of the experts (SIGN 2008). This recommendation
is in line with the approval by the EMA as first-line only in people
with thalassemia major from six years of age (EMA 2016). In con-
trast, the FDA have already approved deferasirox in individuals
with thalassemia major aged two years of age and older and in
non-transfusion-dependent thalassemia individuals aged 10 years
and older with a LIC of at least 5 mg Fe/g dry weight and serum
ferritin over 300 µg/L (FDA 2013).
A systematic review published by Maggio in 2011 reviewed ran-
domised controlled studies for all three iron chelators used in
people with thalassaemia major (Maggio 2011). The authors in-
cluded two studies considering deferasirox (Cappellini 2005b;
Nisbet-Brown 2001). They did not pool data from the different
dosing subgroups, but analysed the comparisons separately and
found significantly lower increases in serum ferritin favouring de-
feroxamine compared to deferasirox 5 mg/day and 10 mg/day, sig-
nificantly higher decreases in the deferoxamine group compared
to deferasirox 20 mg/day and no significant difference in decrease
in the deferasirox 30 mg group versus deferoxamine.
Some additional data, including longer-term effects ondeferasirox,
were available from observational studies. However, these studies
were not systematically searched for nor critically evaluated within
this review. Also, due to a higher risk of bias and potential con-
founding, these types of data are not as well-suited for compari-
son of two interventions as are data from high quality randomised
studies.
It is important to note, however, that other more severe AEs have
been reported, such as: cytopenias; Fanconi syndrome and renal
failure (Grange 2010; Rafat 2009; Yew 2010); liver failure; and
gastrointestinal bleeding, which resulted in a boxed warning by
the FDA (FDA Boxed Warning 2010). These potential severe
AEs must be taken into consideration when prescribing or using
deferasirox.
Also, some studies have shown that higher doses of deferasirox
than those evaluated in the early included studies are often needed
to achieve adequate reduction of iron overload or prevent further
iron accumulation in heavily-transfused individuals (Chirnomas
2009; Taher 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Deferasirox offers an important treatment option for people with
thalassaemia and secondary iron overload. Based on the available
data, deferasirox does not seem to be superior to deferoxamine at
the usually recommended ratio of 1 mg of deferasirox to 2 mg
of deferoxamine. However, similar efficacy seems to be achievable
depending on the dose and ratio of deferasirox compared to de-
feroxamine. Whether this will result in similar efficacy and will
translate to similar benefits in the long term, as has been shown
for deferoxamine, needs to be confirmed. Data from randomised
controlled trials on rare toxicities and long-term safety are still lim-
ited. However, after a detailed discussion of the potential benefits
and risks, deferasirox could be offered as the first-line option to
individuals who show a strong preference for deferasirox, and may
be a reasonable treatment option for people showing an intoler-
ance or poor adherence to deferoxamine.
Implications for research
Although the efficacy of deferasirox to reduce iron overload has
been shown, data for a comprehensive comparison with the stan-
dard treatment of deferoxamine are still insufficient. Therefore,
patients should ideally be included in further, investigator-initi-
47Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ated clinical trials independent from the producer Novartis assess-
ing patient-relevant outcomes and long-term effects of deferasirox.
However, given its broad availability, it is unlikely that these stud-
ies will ever be conducted. In addition, assessment of rarer AEs, as
well as assessment of long-term adherence, in particular with the
new formulation, are important to pursue. Finally, it should be
ensured that relevant outcomes are measured in a consistent way
across studies to allow combination of data in a meta-analysis.
Since this review only included evidence from randomised studies
and additional evidence is available fromnon-randomised, uncon-
trolled studies, a systematic review also considering this observa-
tional evidence would most likely shed some additional light on
this topic. Taking into account that there is a third chelator, de-
feriprone, available and approved in some countries for treatment
of iron overload in people with thalassaemia, a network analysis
comparing these three interventions would seem useful in the fu-
ture, if more data are available.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cappellini 2005b
Methods Open-label, multinational, multicentre, randomised, phase III, non-inferiority study
Participants 586 β-thalassaemia individuals
Age (mean (SD)): DFX: 17 (9.47) years; DFO: 17.3 (9.96) years
Gender (male/female): DFX: 140/156 DFO: 142/148
Setting and country: 65 centres (mentioned in full text publication) in 12 countries:
Argentina, Belgium, Brazil, Canada, France, Germany, Greece, Italy, Tunisia, Turkey,
UK, USA
Inclusion criteria
• ≥ 2 years
• β-thalassaemia and chronic iron overload from blood transfusions
• LIC ≥ 2 mg/g dry weight
• ≥ 8 blood transfusions/year
• Female participants: required to use double-barrier contraception
Exclusion criteria
• ALT > 250 U/L during year prior to enrolment
• Chronic hepatitis B infection
• Active hepatitis C infection
• History of a positive HIV test
• Serum creatinine above the ULN
• Urinary protein/creatinine ratio > 0.5 mg/mg
• Nephrotic syndrome
• Uncontrolled systemic hypertension
• Prolonged corrected QT interval
• Systemic infection within the 10 days prior to entry
• GI conditions preventing absorption of oral medication
• Concomitant conditions preventing therapy with deferasirox or DFO
• History of ocular toxicity related to iron chelation therapy
• A poor response to DFO
• Noncompliance with prescribed therapy
Follow-up: 1 year
Interventions 2 groups
• DFX (n = 296): once-daily at the assigned dose as a suspension in water half an
hour prior to breakfast 7 days a week
Protocol assigned dose, mg/kg, Average daily dose, mg/kg/day (mean (SD)):
- LIC ≤ 3 mg Fe/g dry weight: 5; 6.2 (1.6)
- LIC > 3 mg Fe/g dry weight - 7 mg Fe/g dry weight: 10; 10.2 (1.2)
- LIC > 7 mg Fe/g dry weight - 14 mg Fe/g dry weight: 20; 19.4 (1.7)
- LIC > 14 mg Fe/g dry weight: 30; 28.2 (3.5)
• DFO (n = 290): Slow subcutaneous infusion using electronic infusion pumps
over 8 - 12 hours, 5 days a week
Protocol assigned dose, mg/kg, Average daily dose, mg/kg/day (mean (SD)):
- LIC ≤ 3 mg Fe/g dry weight: 20 - 30; 33.9 (9.9)
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Cappellini 2005b (Continued)
- LIC > 3 mg Fe/g dry weight - 7 mg Fe/g dry weight: 25 - 35; 36.7 (9.2)
- LIC > 7 mg Fe/g dry weight - 14 mg Fe/g dry weight: 35 - 50; 42.4 (6.6)
- LIC > 14 mg Fe/g dry weight: ≥ 50; 51.6 (5.8)
- Exceptions were permitted to the number of days of administration (ranged 3 - 7 days)
- DFO doses reported are normalized to administration for 5 days a week
Outcomes • Primary response criterion: maintenance or reduction of LIC:
Success criteria:
LIC at baseline (mg Fe/g dry weight): success, LIC value after 1 year (mg Fe/g dry weight)
; failure, LIC value after 1 year (mg Fe/g dry weight)
2 to less than 7: 1 to less than 7, less than 1 or at least 7
7 to less than 10: 1 to less than 7, less than 1 or at least 7
10 or more: decrease in LIC of at least 3, decrease in LIC below 3
• CBC/differential
• Electrolytes
• Liver function tests
• Trace element analysis
• Urinary protein/creatinine
• Serum ferritin
• Fe
• Transferrin
• ECGs
• Ophthalmologic and auditory examinations
• Individuals < 16 years of age: assessment of growth rate (growth velocity) and
sexual development
• LIC (liver biopsy or SQUID)
• Iron excretion-intake ratio
Furthermore, mortality, discontinuations, willingness to continue treatment, time lost
from normal activities due to treatment, satisfaction with treatment, dose adjustments
and dose interruptions, convenience and AEs were reported
Notes Funding and conflict of interests
Study was supported in part by research funding from Novartis Pharma to some of the
authors. Two authors have declared a financial interest in a company whose product was
studied in the present work. Several of the authors are employed by Novartis Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given with regard to sequence
generation.
“Randomisation was stratified by age
groups: 2 to younger than 12 years, 12
to younger than 18 years, and 18 years or
older. After randomization, patients were
assigned by the investigator to a dose de-
pendent on their baseline LIC according to
the algorithm noted in Table 2.”
61Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cappellini 2005b (Continued)
Allocation concealment (selection bias) Unclear risk No details given with regard to conceal-
ment of allocation.
“Randomisation was stratified by age
groups: 2 to younger than 12 years, 12
to younger than 18 years, and 18 years or
older. After randomisation, patients were
assigned by the investigator to a dose de-
pendent on their baseline LIC according to
the algorithm noted in Table 2.”
Blinding (performance bias and detection
bias)
All outcomes
High risk This was an open-label study.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No flowchart according to CONSORT
available.
586 individuals were randomised of which
29 discontinued and 4 died. The primary
efficacy population consists of 553 individ-
uals. However, it is stated that 541 partici-
pants completed one year of therapy. It re-
mains unclear, what happened to the re-
maining 12 participants
“Most patients completed 1 year of ther-
apy on this study: 541 (92.3%) of 586 un-
derwent both baseline and 1-year LIC as-
sessments. Discontinuationswere relatively
similar in the groups receiving deferasirox
(n = 17) and deferoxamine (n = 12).”
“The primary efficacy population in this
study consisted of 553 patients with LIC
evaluations at baseline and after 52 weeks
and those who discontinued due to safety
reasons (AE, abnormal laboratory value or
test procedure result, or iron overload-re-
lated death).”
Selective reporting (reporting bias) Unclear risk See also “Outcomes” in “Characteristics of
included studies” table Cappellini 2005b
above. Not all time points nor all pa-
rameters (secondary: e.g. trace elements)
reported. However, EOS primary results
are reported and secondary as outlined in
methods section. However, it remains un-
clear whether any others were measured
Other bias Low risk No other risk of bias detected.
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Chirico 2013
Methods Prospective study with randomised groups in the last 2 years of study period
Participants 72β-thalassaemia participants: 21non-transfusion-dependent thalassaemia participants,
51 transfusion-dependent thalassaemia participants
Randomised in the last 2 years of study: n = 37
Age (mean (SD)): DFO : 30.2 (7.3) years; DFP: 28.8 (8.9) years; DFX: 31.4 (7.4) years
Gender: not mentioned
Setting: Thalassaemia Unit, Department of Pediatrics, University of Messina
Country: Italy
Inclusion criteria: not mentioned
Exclusion criteria:
• βT minor
• Acute illness
• Severe renal and liver disease
• Heart failure or cardiomyopathy
• Endocrine complications (e.g. diabetes mellitus, thyroid dysfunction or assuming
hormonal therapy)
Follow-up: whole study: 8 years; randomised phase: 2 years
Interventions All participants received DFOmonotherapy for 4 years or until the appearance of thyre-
opathy. Afterwards, individuals with thyreopathy received DFO (20 - 40 mg/kg, 8 - 12
hours, 2 - 6 days/week) and DFP (daily oral administration 75 - 100 mg/kg/day in 3
divided doses). Individuals without thyreopathy continued with DFO. After the end of
2 years, participants with a new diagnosis of thyreopathy started combined chelation
therapy, whereas those without thyroid dysfunction were randomised in 3 arms for fur-
ther 2 years
• DFX (Exjade) (n = 12)
• DFP (n = 12)
• DFO (n = 13)
Only results of participants randomised to the 3 monotherapy groups in the last phase
of the study were included in this systematic review
All transfusion-dependent thalassaemia participants followed a standard treatment pro-
tocol and were regularly transfused with packed red cells every 3 weeks, with the aim of
maintaining pre-transfusion haemoglobin levels above 9 g/dL
Outcomes • Thyroid disease
• Serum ferritin
Furthermore, FT , FT , TSH,TGA,TPO, thyroid dysfunction (overt hypothyroidism:
low FT and/or FT , increased TSH levels; subclinical hypothyroidism: normal FT
, FT and increased TSH concentration (> 5 TSH IU/mL)); central hypothyroidism
(inappropriately low serum TSH concentration in the presence of subnormal serum T
and T concentrations), thyroid volumes, lipid profile, blood pressure and metabolic
parameters (in particular insulin resistance) were measured
Notes The authors declare that they have no conflict of interest.
The authors state that this research did not receive any specific grant from any funding
agency in the public, commercial or not-for-profit sector
Risk of bias
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Chirico 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “This latter group was randomised into
three arms, based on the type of iron chela-
tion [...]”
Not mentioned how random sequence was
generated.
Allocation concealment (selection bias) Unclear risk Not details given with regard to allocation
concealment.
Blinding (performance bias and detection
bias)
All outcomes
High risk “The patients, physicians, laboratory staff
and the epidemiologist who analysed the
data were not aware of the intervention of
each group”
No placebo treatment is mentioned, so
blinding of participants and physicians is
unlikely due to different administration
routes and frequencies of application
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results of all randomised participants at
end of study are reported
Selective reporting (reporting bias) High risk No results reported for TSH, FT , FT ,
but likely included in definition for thyroid
dysfunction
No results reported for TGA, TPO, thy-
roid volumes, insulin resistance, lipid pro-
file, blood pressure at the end of the ran-
domised phase
Other bias Unclear risk Baseline data for randomised patients not
reported apart from serum ferritin, age,
splenectomy rate and haemoglobin before
transfusion
Elalfy 2015a
Methods Randomised, prospective study.
Participants 180 people with β-thalassaemia major
Age: ≤ 18 years
Gender: not mentioned
Setting: regular attendants of the Hematology Clinic, Pediatric Hospital, Ain Shams
University
Country: Egypt
Inclusion criteria
• Moderately iron-overloaded people with β-thalassaemia major without clinical
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Elalfy 2015a (Continued)
symptoms of cardiac dysfunction
• Vitamin C deficiency
• Serum ferritin > 1000 - 2500 ng/mL
• Cardiac T2* > 10 ms calculated as geometric mean
• Ejection fraction > 56%
Exclusion criteria
• Insulin-dependent diabetes
• LVEF ≤ 56%
• Active hepatitis (serum transaminases > 5 times above ULN)
• Renal impairment (serum creatinine > 2 times ULN),
• Sepsis or active infection
• Participation in a previous investigational drug study within the 30 days
preceding screening
• Patients with a known allergy to DFX, DFP, and DFO
Follow up: 1 year
Interventions 3 groups:
• DFX (n = 60): 25 mg/kg/day
• DFO (n = 60): subcutaneous 40 mg/kg/day (5 days a week)
• DFP (n = 60): 75 mg/kg/day
- Each chelation group were further randomly divided into two subgroups according to
vitamin C supplementation (n = 30 in each group): Oral vitamin C in the morning 100
mg daily
- Previous chelation therapy was withdrawn for 2 weeks before randomisation
- Patients consumed a low-iron diet (11 - 15 mg of iron/day) and standard vitamin C
diet during the study
Outcomes • Serum ferritin
• LIC
• Cardiac MRI
• AEs
Furthermore: transfusion index, haemoglobin, iron, total iron binding capacity, trans-
ferrin saturation, vitamin C, compliance
Notes The authors declare that they have no conflict of interests.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Drug administration was according to a predeter-
mined schedule generated from random numbers in
a 1:1:1 manner based on a computer-generated ran-
domisation sequence maintained within the investi-
gational drug pharmacy[...]”
Allocation concealment (selection bias) Low risk “[...] with allocation concealment by opaque sequen-
tially numbered sealed envelope”
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Elalfy 2015a (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk No details given with regard to blinding. No placebo
treatment is mentioned. Due to different administra-
tion routes, blinding is not likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Five patients in DFO subgroup did not continue till
the end of study because of poor compliance [...]”
No ITT analysis performed, but proportion of miss-
ing outcome data was regarded as too low to have a
large impact on effect size
Selective reporting (reporting bias) High risk “The same improvement was found when each chela-
tion subgroup receiving vitamin C supplementation
was compared separately with the subgroup without
vitamin C (data not shown)”
Only summarized data for patients with vitamin C
supplementation versus patients without vitamin C
supplementation and data for all chelation groups
with vitamin C supplementation were reported
The outcome “occurrence of AE” is mentioned, but
only serious AE related to iron chelators are reported
Serum ferritin is reported as median and IQR, but no
reason for this reporting style is mentioned
Other bias Unclear risk Baseline data are not given for all treatment groups
Elalfy 2015b
Methods Interventional prospective randomised open-labelled study with blinded data manage-
ment and data analyses
Participants 96 people with β-thalassaemia major were randomised.
Age (mean (SD)): DFX + DFP : 14.05 (2.21), DFP + DFO: 15.25 (2.31)
Gender (male/female): 62/34
Setting: Thalassemia Centers of Ain Shams University, Egypt and Sultan Qaboos Uni-
versity Hospital, Oman
Countries: Egypt and Oman
Inclusion criteria
• β-transfusion-dependent thalassaemia
• Aged 10 - 18 years
• Serum ferritin > 2500 µg/L on maximum tolerated dose of a single iron chelator
with uptrend of serum ferritin over the last 12 months prior to the study
• Participants with LIC more than 7 mg/g by MRI R2* and mean cardiac T2* less
than 20 and more than 6 ms calculated as geometric mean without clinical symptoms
of cardiac dysfunction (shortness of breath at rest of exertion, orthopnoea, exercise
intolerance, lower extremity edema, arrhythmias). Adequacy of prior chelation was
defined as taking > 75% of the calculated dose/month on maximum tolerated dose
with upward ferritin trend. For DFX, this should be 40 mg/kg/day, for DFP 100 mg/
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Elalfy 2015b (Continued)
kg/day and for DFO at least 40 - 50 mg/kg.
Exclusion criteria
• History of agranulocytosis
• Clinically significant GI or renal disease
• Clinical cardiac disease, or with LEVF < 50% on baseline echocardiography
• Evidence of active hepatitis
• Serum transaminase > 3 times above ULN
• Renal impairment (serum creatinine > ULN)
• Participation in a previous investigational drug study within the 30 d preceding
screening
• Individuals with a known allergy to DFX, DFP and DFO
Follow-up: 1 year
Interventions 2 groups:
• DFX + DFP (n = 48): DFP 75 mg/kg/day, divided into 2 doses taken orally at 8
a.m. and 3 p.m. combined with DFX 30 mg/kg/day taken orally at 10 p.m. for 7 days
a week
• DFP + DFO (n = 48): DFP 75 mg/kg/day divided into 2 doses taken orally at 8
a.m. and 3 p.m, for 7 days (with 6 - 8 hour interval between the 2 doses) combined
with DFO 40 mg/kg/day by subcutaneous infusion over 10 hours starting at 10 p.m.
for 6 days a week
- Chelation therapy was withdrawn for 2 weeks before randomisation
- The patients consumed a low-iron diet (11 - 15 mg of iron per day) during the study
- The transfusion regimen aimed to maintain the patients pre-transfusion haemoglobin
≥ 8.0 g/dL by receiving approximately 15 mL/kg packed red blood cells every 3 - 4 week
Outcomes • Serum ferritin
• LIC
• Cardiac MRI
• SAE
• AE
• Adherence
• Satisfaction
• QoL
• Self-reported adherence
• Proportion of participants who never thought about stopping iron-chelating
therapy
Notes The authors state that they have nothing to declare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomisation sequencewas based on
a computer randomised list in permuted
blocks of 10 with a 1:1 ratio, generated at
both University of Ain Shams and Sultan
Qaboos”
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Elalfy 2015b (Continued)
Allocation concealment (selection bias) Low risk “To ensure no allocation bias, treatment
group was assigned by telephone contact
from the coordinating centre inAinShams”
Blinding (performance bias and detection
bias)
All outcomes
High risk “[...] open-labelled study with blinded data
management and data analyses”
High risk of bias in particular of perfor-
mance bias.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “ [...] all the included patients continued
till the end of study with no patients were
lost follow-up”
Selective reporting (reporting bias) High risk Patient-reported satisfaction, percentage of
patient’s with self reported adherence, pro-
portion of patients who never thought
about stopping iron-chelating therapy and
18-months-follow-up results were reported
incompletely so that they cannot be entered
in a meta-analysis
Serumcreatinine, liver function, audiomet-
ric and ophthalmological assessment were
conducted as described in a conference ab-
stract, but no or only incomplete results are
published
Although not pre-defined as an outcome,
the authors describe that “change in mean
LVEF after 1 yr was not different between
the two treatment groups (data not shown)
.”
On clinicaltrials.gov, only change in serum
ferritin and the number of patients devel-
oping adverse reactions are predefined as
outcomes
Other bias Low risk No other bias detected.
Galanello 1999
Methods 2-period, randomised, double-blind, placebo-controlled, sequential parallel-group de-
sign
Participants 25 people with transfusion-dependent β-thalassaemia were randomised
Age (mean (SD)): 21.6 (3.3) years
Gender (male/female): 25/0
Setting and country: 2 centers in Italy
Country: Italy
Inclusion criteria:
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Galanello 1999 (Continued)
• White males
• Age ≥ 18 years
• Transfusion-dependent β-thalassaemia
• Participants had serum ferritin values between ≥ 1500 ng/mL and ≤ 5000 ng/
mL, as well as post-transfusion haemoglobin levels of at least 13 ± 0.5 g/ dL
• All patients had previously been treated with a mean daily dose of 20 to 50 mg/
kg/day DFO for at least 4 weeks before screening.
Exclusion criteria:
• History of systemic reactions to treatment with DFO
• History of systemic disease
• Any medical condition that might have significantly altered the absorption,
distribution, metabolism, or excretion of the study drug
Follow-up: safety: Up to 10 days post dose
Interventions “Following a 16-day run-in period, 24 patients were allocated to one of three study
groups, with each group consisting of 8 patients. Each group was administered two single
oral doses of ICL670 at an interval of at least 7 weeks, first a lower dose and later a
higher dose. Group 1 received 2.5 and 20 mg/kg, group 2 received 5 and 40 mg/kg, and
group 3 received 10 and 80 mg/kg ICL670, in all cases given as an oral suspension of
100 mL prepared from dispersible tablets. Before proceeding to a higher dose, the safety
and tolerability of the preceding dose had to be assessed as satisfactory. In each treatment
period, 2 of 8 patients received placebo in such a way that a given patient did not receive
placebo more than once. Patients went back to their usual deferoxamine therapy and
transfusion scheme in the interval between study periods.”
Outcomes • Urinary iron excretion
• Serum iron
• Transferrin
• Safety assessment: physical examination, vital signs, ECG, audiometry, clinical
laboratory evaluations, and AE monitoring.
• Safety laboratory evaluations: hematology (including transferrin and serum iron),
biochemistry (including routine renal and liver function parameters, zinc, copper, and
vitamin C), special kidney function parameters (α-glutathione-S-transferase, N-acetyl-
β-Dglucosaminidase, β2-microglobulin, and retinol-binding protein), urinalysis
Notes Novartis involved in trial. No details given and no information available with regard to
potential conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given with regard to sequence
generation. From information given in pa-
per, unclear, whether randomisation took
place both in group assignment and in al-
locating patients to placebo. Author con-
firmed that randomisation was used to al-
locate placebo
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Galanello 1999 (Continued)
“Randomization was used to assign both
drug (all treatment groups) and placebo.
Hope to have clarified.”
Allocation concealment (selection bias) Unclear risk No details given with regards to conceal-
ment of allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The study employed a two-period,
randomised, double-blind, placebo-con-
trolled, sequential parallel group design.”
However, no definition of double-blind.
Unclear whether, e.g. outcome assessors
and data analysts were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not applicable. Data from all participants
are presented.
Selective reporting (reporting bias) Unclear risk Only general information with regard to
safety issues. No clear-cut comparison of
placebo vs verum groups. Unclear, whether
other parameters were evaluated than those
reported
Other bias Low risk No other risk of bias detected.
Habibian 2014
Methods Randomised clinical study
Participants 30 people with thalassaemia major
Age: not mentioned
Gender: not mentioned
Setting: Bahonar hospital of Karaj
Country: Iran
Inclusion criteria: not mentioned
Exclusion criteria: not mentioned
Follow-up: 1 year
Interventions 2 groups:
• DFX
• DFO
Outcomes Serum ferritin
Notes The study was only reported in a conference abstract
Risk of bias
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Habibian 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In this randomized clinical trial [...]”
Notmentioned how random sequence generation was gen-
erated.
Allocation concealment (selection bias) Unclear risk No details given with regard to concealment of allocation.
Blinding (performance bias and detection
bias)
All outcomes
High risk No details given with regard to blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported how many patients reached end of study.
Selective reporting (reporting bias) High risk No results were reported.
Other bias Unclear risk No baseline characteristics were reported.
Hassan 2016
Methods Prospective randomised study
Participants 60 β-thalassemia major participants
Age (mean (SD)): DFX group: 8.9 (2.2), DFO group: 9.7 (1.9)
Gender: 19 male, 41 female
Setting: Out-patient paediatric hematology clinic of Al-Hussein University Hospital, Al-
Azhar University, Cairo
Country: Egypt
Inclusion criteria:
• ≥ 6 years
• Serum ferritin > 1500 µg/L
• Irregular subcutaneous DFO chelation therapy
Exclusion criteria:
• Serum creatinine above the upper age-related normal range
• Significant proteinuria (urinary protein/creatinine ratio > 1.0 in a non-first-void
urine sample at baseline)
• Elevated ALT more than 3-fold of the ULN
• GI diseases,
• Clinically relevant auditory or ocular toxicity (or both) related to iron chelation
therapy
• Cardiac disease
• Serious AEs with DFO or DFX
• Absolute neutrophilic count < 1500/mm³
• Platelet count < 100,000/mm³
Follow-up: 1 year
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Hassan 2016 (Continued)
Interventions Two groups:
• DFX (n = 30): Orally single daily dose of 20 - 40 mg/kg/day on an empty
stomach after dissolution in water, apple juice, or orange juice; Starting dose of DFX
was individualized based on the frequency of blood transfusions
• DFO (n = 30): 20 - 50 mg/kg/day via subcutaneous infusion over 8 - 10 hours, 5
days per week
Outcomes • Serum ferritin < 1500 µg/L
• Safety
Furthermore, serum ferritin, ALT, AST, blood urea, serum creatinine, neutrophilic and
platelet counts and some AEs were reported
Notes The authors state that there is no conflict of interest to be declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[...] the patients were randomized in a 1:1 ratio based
on permuted blocks [...]”
Not mentioned how random sequence generation was
generated.
Allocation concealment (selection bias) Unclear risk No details given with regard to concealment of alloca-
tion.
Blinding (performance bias and detection
bias)
All outcomes
High risk No details given with regard to blinding.
Due to different administration routes, blinding is not
likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk “[...] no discontinuation of drugs or drop-out of follow-
up occurred.”
Selective reporting (reporting bias) Low risk No protocol available. All predefined outcomes in the
method section were reported
Other bias Low risk No other bias detected.
Kakkar 2014
Methods Randomised controlled study.
Participants 40 thalassaemia major participants
Age: 5 - 18 years
Gender: not mentioned
Setting: unclear
Country: unclear
Inclusion criteria: not mentioned
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Kakkar 2014 (Continued)
Exclusion criteria: not mentioned
Follow-up: not mentioned
Interventions Three groups:
• DFP (n = 10): 75 - 100 mg/kg/day
• DFX (n = 10): 30 - 40 mg/kg/day
• Both drugs administered sequentially every alternate week (n = 20)
Outcomes • Cardiac MRI T2*
• Liver MRI T2*
• Serum ferritin
• CBC
• Liver enzymes
• Renal function tests
Notes The study was only reported in a conference abstract.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[...] were randomised to three groups [...]”
Not mentioned how random sequence generation was
generated.
Allocation concealment (selection bias) Unclear risk No details given with regard to concealment of alloca-
tion.
Blinding (performance bias and detection
bias)
All outcomes
High risk No placebo treatment mentioned. High risk of bias in
particular of performance bias and outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported how many patients reached end of study.
Selective reporting (reporting bias) High risk Regarding cardiac MRI T2*, only baseline data and P
value for DFP vs DFP+DFX at the end of the study
was reported. For liver MRI T2* it is unclear whether
values given are baseline or end of study data. Missing
data for serum ferritin. CBC, liver enzymes and renal
function tests. Only untoward side-effects reported and
only for group receiving combination therapy
Other bias Unclear risk No baseline data reported.
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Molavi 2013
Methods Randomised controlled open-label study.
Participants 138 patients with β-thalassemia major (n = 122) and thalassaemia intermedia (n = 16)
Age (mean (SD)): 13.59 (6.81) (range: 4 - 27 years)
Gender (male/female): 62/76
Setting: Bandar Abbas Pediatric Hematology Clinic
Country: Iran
Inclusion criteria
• major/intermedia thalassaemia
• > 2 years
• Serum ferritin > 1000 ng/mL
• Normal creatinine
• Acceptable CBC
• Negative PCR in terms of HCV, negative HBV and HIV
• Absence of heart disease and cardiac drugs
• EF> 55%
• Absence of proteinuria
Exclusion criteria
• Serum creatinine increased by more than 33% compared to baseline
• Vision and hearing problems
• Hyperemesis
• Lack of response to anti-nausea medication and fluids therapy
• Severe and rapidly progressive skin rash
• Increase in liver enzymes more than 5 times normal
• Platelets < 150 000
• Neutrophils < 1500
Follow-up: 8 months
Interventions 2 groups:
• DFX (n = 69): 20 mg/kg/day oral, once a day on an empty stomach at least half
an hour before a meal
• DFO (n = 69): 40 - 50 mg/kg subcutaneous for 6 nights a week
Outcomes • CBC
• ALT, AST
• Ferritin
• Creatinine
• Urinalysis
Furthermore, patients were visited weekly on the base of drug tolerance and side effects
Notes No funding or conflict of interest mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were assigned randomly in two
groups”
No details given with regard to sequence
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generation.
Allocation concealment (selection bias) Unclear risk No details given with regard to concealment
of allocation.
Blinding (performance bias and detection
bias)
All outcomes
High risk No placebo treatment mentioned. Due to
different administration routes, blinding is
not likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although number of patients who reached
end of study was not clearly stated, we con-
cluded from given means, SDs and P val-
ues, that 69 participants were included in
the results
Selective reporting (reporting bias) High risk ALT, AST, creatinine evaluated at EOS, but
only baseline values given
Only ferritin level, haemoglobin level and
drug side effects predefined as outcomes on
clinicaltrials.gov
Exclusion criteriawere stated as, amongoth-
ers, “vision and hearing problems”, “severe
skin rash”: implies that AEs were known for
DFX/DFO and these data were collected;
however they were not reported;
Only AEs reported: leukopenia, thrombo-
cytopenia, although patients were visited
weekly for drug tolerance and side effects
Other bias Low risk No other bias detected.
Molavi 2014
Methods Randomised clinical study.
Participants 100 children with thalassaemia major were selected, 94 participants entered study
Age (mean (SD)):12.23 (4.09) years (range: 2 - 15 years)
Gender (male/female): 44/48
Setting: Thalassemia medical centre of Bandar Abbas
Country: Iran
Inclusion criteria:
• Age: 2 - 15 years
• Serum ferritin > 2000 ng/mL despite the treatment with DFO (50 mg/kg 3 times
a week)
Exclusion criteria: not mentioned
Follow-up: 12 months
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Molavi 2014 (Continued)
Interventions Two groups:
• DFO (n = 48): 50 mg/kg transfused 3 times a week
• DFO and DFX (n = 46): DFX 20-40 mg/kg (in case there was no desirable
response, the dosage was altered to 20 mg/kg, and when no consequences were
observed, it was increased to 40 mg/kg)
Outcomes • Serum ferritin
• Neutrophil, ALT, AST, ALP
• Creatinine
• Hemoglobin
Notes Conflict of interest not mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly and in the order of visiting the centre, they
were divided in two 50-member groups”
No details given on how random sequence was generated.
Allocation concealment (selection bias) Unclear risk No details mentioned with regard to concealment of allo-
cation
Blinding (performance bias and detection
bias)
All outcomes
High risk No placebo treatment in the Desferal monotherapy group
is mentioned, so blinding is not likely in particular of
performance bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk It remains unclear wether six patients were excluded due
to exclusion criteria before or after randomisation; small
number doesn’t seem to affect results
Selective reporting (reporting bias) High risk Level of creatinine was measured, but results were not re-
ported
Other bias Low risk No other bias detected.
Nisbet-Brown 2001
Methods Randomised, double-blind, placebo-controlled dose-escalation study
Participants 24 participants with transfusion-dependent β-thalassaemia (23 analysed, 3 replacements
for participants who were withdrawn for serious AEs during the study)
Age (median (range): placebo: 32 (22 - 38) years; 10 mg/kg DFX: 28 (20 - 39) years; 20
mg/kg DFX: 24 (18 - 38); 40 mg DFX: 27 (19 - 34)
Gender (male/female): 11/12
Setting: Children’sHospital, Boston; WeillMedical College, NewYork; Toronto General
Hospital, Toronto
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Nisbet-Brown 2001 (Continued)
Country: USA (2 centres) and Canda (1 centre)
Participant characteristics:
• Transfusion-dependent β-thalassaemia
• ≥ 16 years
• Serum ferritin values:1000 - 8000 ng/mL
• Liver biopsies done in the previous 3 months with ≥ 3.5 mg Fe/g dry weight
• All participants required treatment with DFO at 20 mg/kg/day (mean daily dose)
for at least 4 weeks before screening and a post transfusion haemoglobin concentration
of at least 130 g/L
Follow-up: 12 days
Interventions Four groups:
• DFX (n = 5): 10 mg/kg
• DFX (n = 6): 20 mg/kg
• DFX (n = 7): 40 mg/kg
• Placebo (n = 5)
Outcomes • Dietary, urine and faecal iron measured by atomic absorption spectrometry
• Net faecal iron excretion calculated by individual iron content in faeces minus
individual iron content in the diet (the net iron excretion for each participant in mg Fe
kg-1 day-1 was derived from the sum of the daily measurements of net faecal iron
excretion and urinary iron excretion)
• UIBC calculated from serum iron concentration and total iron binding capacity
Notes Conflict of interest and funding:
Novartis was involved in design and monitoring of the study.Study was financial sup-
ported by Novartis Pharmaceuticals Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details of sequence generation process not
stated.
“The randomisation sequence was gener-
ated by Novartis Pharmaceuticals and de-
livered to the research pharmacy in dupli-
cate sealed envelopes.”
Allocation concealment (selection bias) Unclear risk Sealed envelopes were used. However, un-
clear whether opaque and numbered
“The randomisation sequence was gener-
ated by Novartis Pharmaceuticals and de-
livered to the research pharmacy in dupli-
cate sealed envelopes.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk This was a placebo-controlled study, in
which investigators and those responsible
for administering study drug were blinded
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Nisbet-Brown 2001 (Continued)
with regard to treatment allocation. How-
ever, it remains unclear whether outcome
assessors and data analysts were blinded as
well
“The investigators and those responsible
for administering study drug were unaware
of treatment allocation.”
“Placebo and ICL670 were prepared as dis-
persible tablets with standard excipients.
Tablets were suspended in water, and pa-
tients ingested the drug or placebo on an
empty stomach.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Therefore, all patients who began either
placebo or drug were included in the data
analysis, whether they completed the 12-
day course or withdrew prematurely.”
Selective reporting (reporting bias) Unclear risk “We did clinical, laboratory, and other sa-
fety assessments regularly throughout the
study.”
However, only a limited amount of data are
presented in the publication
Other bias Low risk No other bias detected.
Peng 2013
Methods Randomised controlled study.
Participants 26 individuals were recruited, who were diagnosed as β-severe thalassaemia by gene
screening, 2 met exclusion criteria
24 participants were randomised
Gender: 13 male, 11 female
Age (mean (SD) (range)): (14 (3) (11 - 26)) years
Setting: First Affiliated Hospital, Guangxi Medical University, Nanning
Country: China
Inclusion criteria:
• Age ≥ 10 years
• History of 50 unit red blood cell transfusion (1 unit = 200 mL red blood cell) at
least
• Receiving red blood cell transfusion (≥ 10 unit per year)
Exclusion criteria:
• T2∗ ≥ 6.3 ms at first MRI screening or LIC ≤ 2 mg/g (1 mg/g = 17.9 mmoL/kg)
• Dysfunction of liver and kidney
• Contraindication of MR screening or disagreement doing the screening
Follow up: 12 months
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Interventions Two groups:
• DFX (n = 12): 40 mg/kg daily before breakfast
• DFO (n = 12): 50 mg/kg, diluted by 10% solution, subcutaneous injection 8 - 12
hours continuously per day, at least 5 days every week
- Parameters of the body of patient, LIC, serum ferritin, serum creatinine, liver function
and toxicity of the drugs are regarded as standards to adjust the dose or discontinue the
therapy
- Meanwhile, the patients still receive the former transfusion program (red blood cell
transfusion ≥ 10 units per year) to maintain the haemoglobin > 90 g/L
- 5-day washout period without chelation therapz before treatment
Outcomes • Serum ferritin
• Liver R2
∗
• Severity of iron deposition in liver
Notes Study funding sources: National Natural Science Foundation of China, the Natural
Science Foundation of Guangxi, China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[...] 24 iron-overloaded patients were randomly di-
vided into 2 groups [...]”
No details given with regard to sequence generation.
Allocation concealment (selection bias) Unclear risk No details given with regard to concealment of alloca-
tion.
Blinding (performance bias and detection
bias)
All outcomes
High risk No details given with regard to blinding.
Due to different administration routes, blinding is not
likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no missing outcome data.
Selective reporting (reporting bias) High risk Side effects were not reported.
Other bias Low risk No other bias detected.
Pennell 2014
Methods Prospective, multinational, randomised, open-label, parallel-group, phase 2 study; Non-
inferiority study
Participants 197 participants were randomised
160 participants completed one year of treatment
Age (mean (SD)): 19.8 (6.4) years (range: 10 - 40 years)
79Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pennell 2014 (Continued)
Gender (male/female): 115/82
Setting and countries: 22 centres across 11 countries
Inclusion criteria:
• People with β-thalassaemia major, Diamond-Blackfan anaemia, low/intermediate
1 myelodysplastic syndromes, or sideroblastic anaemia
• Aged ≥ 10 years
• Myocardial T2* 6 to 20 ms without clinical symptoms of cardiac dysfunction
(shortness of breath at rest or exertion, orthopnoea, exercise intolerance, lower-
extremity edema, arrhythmias)
• LVEF ≥ 56%,
• R2 magnetic resonance imaging LIC ≥ 3 mg Fe/g dry weight
• Lifetime history of ≥ 50 U red blood cell transfusions
• Receiving ≥ 10 U/y of red blood cell transfusion
• Only people with β-thalassaemia major fulfilled the inclusion criteria and were
enrolled in the study
Exclusion criteria:
• Serum creatinine above the ULN
• Significant proteinuria (urinary protein/creatinine ratio ≥ 1.0 mg/mg in a non-
first-void urine sample at baseline)
• ALT > 5 times the ULN only if their LIC was < 10 mg Fe/g dry weight
• Considerable impaired GI function or GI disease
• History of clinically relevant ocular and/or auditory toxicity related to iron
chelation therapy
• History of HIV seropositivity or malignancy within the past 5 years
Follow-up: 12 months
Interventions Two groups:
• DFX (n = 96): Once-daily starting dose was 20 mg/kg per day for 2 weeks,
followed by 30 mg/kg per day for 1 week, and then continued with 40 mg/kg per day
• DFO (n = 91): 50 to 60 mg/kg per day via subcutaneous infusion over 8 to 12
hours, 5 to 7 days a week; dose adjustment recommendations were provided based on
continuous assessment of efficacy and safety markers
Outcomes • Ratio of geometric mean myocardial T2* with DFX divided by the ratio of
geometric mean for DFO
• LVEF
• LIC
• Serum ferritin
Furthermore, safety, compliance, dose interruptions/reductions and laboratory parame-
ters (serum creatinine, blood creatinine, ALT) were measured
Notes Study was sponsored by Novartis Pharma AG. Novartis Pharma AG was involved in
design of the study, conducted the statistical analysis and paid a medical writer who
assisted with writing the article. Some of the authors received research grant funding,
honoraria or lecture fees from Novartis Pharmaceuticals and/or other pharmaceutical
companies
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[...]patients were randomised in a 1:1 ratio
[...]”
“Randomization was based on permuted
blocks; stratification by centre was not con-
ducted.”
Allocation concealment (selection bias) Unclear risk No details given with regard to conceal-
ment of allocation.
Blinding (performance bias and detection
bias)
All outcomes
High risk “Core laboratories were blinded to treat-
ment allocation.”
“In order to eliminate potential unrecog-
nised biases, the core clinical trial team was
blinded to the treatment assignment prior
to the database lock for the primary analy-
sis.”
“Open-label trial”
No placebo treatment mentioned. Due to
different administration routes, blinding is
not likely in particular of performance bias
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT was done regarding myocardial T2*,
but the number of included patients (n=
180) was lower than the number of ran-
domised patients (n=197)
Apart from that, per-protocol analysis was
done for the other outcomes
Selective reporting (reporting bias) High risk Only most common AE (≥ 5%) and drug
related AE ≥ 2 participants were reported
Other bias Low risk No other bias detected.
Piga 2002
Methods Open label, randomised, multicenter, phase II study.
Participants 71 people with thalassaemia and transfusional iron overload: 69 people with β-tha-
lassemia major, 2 people with β-thalassemia intermedia
Age mean (range): DFX 10 mg/kg/day: 23.7 years (17 - 33 years); DFX 20 mg/kg/day:
25.6 years (19 - 50 years); DFO: 22.7 (18 - 29 years)
Gender (male/female): 26/45
Setting and country: 4 centres in Italy
Inclusion criteria:
• Should have been regularly transfused
• Should have received a mean daily dose of DFO ≥ 30 mg/kg for 5 days/week for
81Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Piga 2002 (Continued)
at least 4 weeks prior to entering the screening period
• Serum ferritin between 2000 - 8000 ng/mL on at least two evaluations in the last
12 months or
• LIC of 5 - 15 mg Fe/g dry weight measured in the last 12 months by SQUID
• Average post-transfusion haemoglobin level between 10.5 - 13.5 g/dL during last
12 months
Exclusion criteria:
• AST or ALT > 250 U/L
• Creatinine clearance < 80 mL/minute
• People with hypertension
• People with any degree of A-V block, clinically relevant QT prolongation
• Treatment with digoxin or any other drug that could induce prolongation of A-V
conduction
• People with diagnosis of cataract or a previous history of clinically relevant ocular
toxicity related to iron chelation
Follow-up: 48 weeks
Interventions 3 groups:
• DFX (n = 24): 10 mg/kg once-daily using 250 mg tables which were divisible into
four parts. The correct number of tablets was dispersed in a glass of non-carbonated
mineral water, stirred and ingested 30 minutes before breakfast
• DFX (n = 24): 20 mg/kg once daily using 250 mg tables which were divisible into
four parts. The correct number of tablets was dispersed in a glass of non-carbonated
mineral water, stirred and ingested 30 minutes before breakfast
• DFO (n = 23): 40 mg/kg on 5 consecutive days per week. Doses were prepared as
a 10% solution using commercially available vials of 500 or 2000 mg dry powder.
Subcutaneous infusion was performed using a pump over 8 - 12 hours.
-During the 14-day run-in period, eligible patients had their usualDFO therapy adjusted
to 40 mg/kg given on 5 consecutive days each week
- The study protocol allowed for dose adjustment within the range of 5 - 40 mg/kg/day
in the DFX groups and 20 - 50 mg/kg in the DFO group
- Depending on response, assessed primarily using the change in LIC at 3 consecutive
determinations, dose increases or decreases were made by ±5 or ±10 mg/kg in the DFX
groups and by ± 10 mg/kg in the DFO group
- Dose reductions were performed if the decrease in LIC was extrapolated to fall below
2 mg Fe/g dry weight within the next 12 weeks and dose increases were prescribed if an
increasing trend in LIC was noted
- Dose adjustments were decided on a case-by-case basis in joint consultation between
the Study Monitoring Committee and the sponsor
- On day -5, participants were admitted to the study site to receive a blood transfusion
to achieve a target haemoglobin level of≥ 13g/dL prior to commencing study treatment
followed by a DFO washout period of 5 days
Outcomes • Mortality
• LIC (SQUID)
• Serum ferritin
• Serum iron
• Serum transferrin
• Transferrin saturation
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• Blood indices
• Liver and renal function
• Serum electrolytes
• Copper and zinc
• Second void urine samples with measurement of N-acetyl-beta-glucosaminidase
and beta2-miroglobulin
• Ophthalmological examination including slit lamp examination of the lens and
retinal fundoscopy
• Audiometry, ECG and liver ultrasonography
Notes Study was supported by Novartis Pharma AG. Some of the authors are employed by
Novartis Pharma or received lecture fees from the manufacturer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a
validated system that generates an auto-
mated random assignment of numbers to
treatment groups.”
We expect that using this system resulted
in an adequate sequence generation
Allocation concealment (selection bias) Unclear risk “Randomization was performed using a
validated system that generates an auto-
mated random assignment of numbers to
treatment groups.”
No information is given with regard to al-
location concealment
Blinding (performance bias and detection
bias)
All outcomes
High risk It is classified as an open-label study. There
is no mentioning of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants are included in safety anal-
ysis (primary objective). Few patients only
are not included in efficacy analysis (sec-
ondary objective)
Selective reporting (reporting bias) Unclear risk “Laboratory tests, including evaluation of
blood indices, liver and renal function,
serum electrolytes, copper and zinc, were
performed at baseline and at 2-weekly in-
tervals throughout the study. All labora-
tory parameters were measured at a cen-
tral laboratory (EXACTA Clinical Trials
Services, Verona, Italy). Second void urine
samples were collected for measurement of
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N-acetyl-b-glucosaminidase and an aliquot
of urine was alkalinized for measurement
of b-2 microglobulin. An ophthalmology
examination, including a slit lamp exami-
nation of the lens and retinal fundoscopy,
was performed every 2 weeks. Audiometry,
ECG and liver ultrasonography were car-
ried out every 3 months. Adverse events
were recorded at each study visit and the
severity of each adverse event was graded as
mild, moderate or severe. A serious adverse
event was defined as a medically significant
event that was either fatal or life threat-
ening, required surgical intervention, pro-
longed hospitalization or resulted in persis-
tent disability. All adverse events and seri-
ous adverse events were assessed by the in-
vestigator for a possible relationship to the
study drug. Adverse events were ranked ac-
cording to incidence in the deferasirox 20
mg/kg/day treatment group.”
“All biomagnetic liver susceptometry eval-
uations were performed at the Ospedale
Regina Margherita, University of Turin,
Italy. LIC was determined at screening and
then every 12 weeks during treatment and
at the endof the study......During the study,
markers of ironmetabolism (serum ferritin,
serum iron, serum transferrin and transfer-
rin saturation) were analyzed by a central
laboratory (EXACTA Clinical Trials Ser-
vices, Verona, Italy). The transferrin satu-
ration was calculated from the serum iron
and the transferrin concentrations. Urinary
iron excretion was determined in 24-hour
urine collections in ten patients taking de-
ferasirox (five in each dose group) who
also underwent blood sampling for phar-
macokinetic analyses. Urinary iron excre-
tion wasmeasured using atomic absorption
spectrometry.”
Only selected parameters at selected time
points are reported
Other bias Low risk No other bias detected.
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Sanjeeva 2015
Methods Prospective randomised comparative study.
Participants 41 participants were randomised
38 participants reached end of study
Age (mean (SD)): DFX (n = 19): 5.23 (2.76) years; DFP (n = 19): 7.26 (2.42) years
Gender (male/female): 22/16
Setting: Thalassemia day care centre of IndiraGandhi Institute of child health, Bengaluru
Country: India
Inclusion criteria
• Thalassemia diagnosis and regular blood transfusion
• Serum ferritin > 1000 ng/mL
• No chelation therapy
Exclusion criteria
• Already on chelation therapy
• Chronic liver or renal disease
Follow-up: 12 months
Interventions 2 groups:
• DFX (n = 19): dose of 20 mg/kg/day, once a day
• DFP (n = 22): 75 mg/kg/day in 3 divided doses
Outcomes • Serum ferritin
• WBC
• Platelet count
• Blood urea
• Serum creatinine
• Serum enzymes (AST, ALT)
• Side effects
Notes No funding or conflict of interest mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “These children were randomly divided
into two groups as group 1 and group 2 by
computer generated randomisation.”
Allocation concealment (selection bias) Unclear risk No details mentioned with regard to con-
cealment of allocation
Blinding (performance bias and detection
bias)
All outcomes
High risk No details given with regard to blinding.
Due to different application frequencies,
blinding is not likely, in particular regard-
ing performance bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 dropouts due to AEs in deferiprone
group, per protocol analysis
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Selective reporting (reporting bias) High risk Measurements other than serum ferritin
and AEs only given for 9 months (and only
in the thesis document), but not for end
of study (unsure whether not measured or
not reported), although the author report
measurements every 3 months
In the thesis document, fundoscopy,
growth harm and hearing were part of the
evaluation sheet at 12-month follow-up,
but no results were reported
Other bias Low risk No other bias detected.
Taher 2012
Methods Multinational, prospective, randomised, double-blind, placebo-controlled phase 2 study
Participants 166 participants were randomised.
95 non-transfusion-dependent β-thalassaemia, 22 α-thalassaemia, 49 HbE/β-thalas-
saemia
148 participants completed 1 year of the study.
Inclusion criteria
• ≥ 10 years of age with
• Non-transfusion-dependent β-thalassaemia
• Iron overload (R2-MRI-measured LIC ≥ 5 mg Fe/g dry weight)
• Serum ferritin > 300 ng/mL at screening based on 2 consecutive values ≥ 14 days
apart were eligible
• Participants were required to have not received transfusions within 6 months or
chelation therapy within 1 month before study entry
Exclusion criteria
• People with previous exposure to DFX
• Anticipated regular transfusions; unplanned transfusions during the study were
allowed
• HbS variants of thalassaemia syndromes
• Active hepatitis B (positive hepatitis B surface antigen with negative hepatitis B
surface Ab) or hepatitis C (positive hepatitis C virus Ab and detectable hepatitis C virus
RNA with alanine aminotransferase [ALT] above the normal range)
• Cirrhosis
• Levels of ALT > 5 x ULN
• Serum creatinine > ULN or creatinine clearance ≤ 60 mL/min on 2
measurements
• Significant proteinuria (urine protein/urine creatinine ratio > 1.0 mg/mg) on 2
measurements
Follow-up: 1 year
Interventions 4 groups:
• DFX (n = 55): 5 mg/kg/day
• DFX (n = 55): 10 mg/kg/day
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• Placebo (n = 28): 5 mg/kg/day
• Placebo (n = 28): 10 mg/kg/day
- Doses were doubled at 24 weeks for patients with LIC > 7 mg Fe/g dry weight and LIC
reduction < 15% from baseline
- Dose adjustment recommendations were also provided based on continuous safety
assessments
- If serum ferritin was <100 ng/mL or LIC was <3 mg Fe/g dry weight at any visit,
treatment was to be suspended until LIC increased to≥ 5 mg Fe/g dry weight and serum
ferritin to > 300 ng/m
Outcomes • LIC
• Number and proportion of patients with a LIC decrease of ≥ 3 mg Fe/g dry
weight, those with ≥ 30% reduction in LIC, and those with LIC ≤ 7, ≤ 5, and ≤ 3
mg Fe/g dry weight
• Serum ferritin
• Correlation of serum ferritin and LIC
• AEs
• Serious AEs
• Adherence
Notes Study was sponsored by Novartis Pharma AG. Novartis was involved in design and
statistical analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[...] patients were block randomised [...]”.
No details given on how random sequence
was generated.
Allocation concealment (selection bias) Low risk “[...] patients were block randomised using
an interactive voice response system. Af-
ter confirming that the patient fulfilled the
inclusion/exclusion criteria, the investiga-
tor contacted the interactive voice response
system to obtain a randomisation number
linking the patient to a treatment arm.”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Because blinding of dose was not possible,
blinding was only applied to the treatment
received. All persons were blinded to the
treatment from the time of randomisation
until database lock.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition was 12.7%, 10.9% and 8.9% for
theDFX5mg,DFX10mgand the placebo
group, respectively
In the journal publication, the authors state
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that “efficacy was assessed for the full anal-
ysis set (all randomised patients).[...] If
there was no LIC measurement available
at week 52, the last available post-baseline
LIC measurement was carried forward.”
Number of participants analysed on clini-
caltrials.gov doesn’t include all randomised
patients for continuous outcomes
Selective reporting (reporting bias) High risk Extensive data set available on ClinicalTri-
als.gov (along with prespecified protocol),
but AEs and SAEs were not reported sepa-
rately for the core phase
In the journal publication AEs and drug-
related AEs were not reported completely
Other bias Low risk No other bias detected.
AE: adverse event
ALP: alkaline phosphatase
ALT: alanine aminotransferase
AST: aspartate aminotransferase
A-V: atrio-ventricular
CBC: complete blood count
CONSORT: consolidated standards of reporting trials
DFO: deferoxamine
DFP: deferiprone
DFX: deferasirox
ECG: electrocardiogram
EF: ejection fraction
EOS: eosinophil count
Fe: iron
FT : serum-free triiodothyronine
FT : serum-free thyroxine
GI: gastrointestinal
HBV: hepatitis B virus
ITT: intention-to-treat
LVEF: left ventricular ejection fraction
LIC: liver iron concentration
MRI: magnetic resonance imaging
QoL: quality of life
PCR: polymerase chain reaction
RBCs: red blood cells
RNA: ribonucleic acid
SD: standard deviation
SQUID: superconducting quantum interference device
TGA: antithyroglobulin
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TSH: thyroid-stimulating hormone
TPO: antithyroid peroxidase
UIBC: unsaturated iron binding capacity
ULN: upper limit of normal
WBC: white blood count
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Economou 2010 Not randomised. Two-arm observational study.
EPIC 2008 Not randomised, no comparison group. Single-arm observational study
Erdogan 2013 Not randomised. Two-arm observational study.
ESCALATOR 2005 Not randomised, no comparison group. Single-arm observational study
Fernandes 2013 Randomised, evaluating amlodipine added to standard iron chelation therapy
Gao 2011 Not randomised. Study comparing different doses of DFX and DFX to deferiprone and DFO
Garadah 2011 Not randomised. Single-arm interventional study.
Genc 2015 Not randomised. Three-arm observational study.
Gomber 2016 Not randomised. No adequate random sequence generation.
Grady 2012 Non-randomised. Single-arm interventional study.
Hagag 2013 Randomised. Evaluating silymarin versus placebo added to DFX
Hesham 2014 Not randomised. Case-control study.
Inati 2011 Randomised controlled study on people with thalassaemia having undergone curative hematopoietic stem
cell transplantation
Kallistheni 2012 Not randomised. Two-arm interventional study.
Karakukcu 2012 Not randomised. Three-arm observational study.
Keikhaei 2011 Not randomised. Two single-arm interventional studies.
Lu 2015 Randomised. Pharmacokinetic study with a very small population (n = 8)
Medrano Engay 2013 Randomised. No individuals with thalassaemia included.
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Ozturk 2015 Not randomised. Three-arm observational study.
Pakakasama 2011 Randomised controlled study on people with thalassaemia having undergone curative hematopoietic stem
cell transplantation
Pepe 2010 Study not randomised. Three-arm observational study.
Pepe 2011 Study not randomised. Two-arm observational study.
Pileri 2014 Randomised. No individuals with thalassaemia included.
Song 2014 Randomised. Pharmacokinetic study with a very small population (n = 8)
Torcharus 2011 Not randomised. Three-arm observational study.
Walter 2012 Not randomised. Single-arm interventional study.
DFO: deferoxamine
DFX: deferasirox
Characteristics of studies awaiting assessment [ordered by study ID]
Ansari 2015
Methods Unclear, if study was randomised.
Participants 108 people with thalassemia major
Age: > 10 years
Inclusion criteria
• Iron overload in cardiac T2* MRI assay
Interventions 3 groups:
• DFX
• DFO
• DFO + DFP
Outcomes • Myocardial iron (T2* MRI)
• Liver T2*
• AEs
Notes Author was contacted.
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EUCTR2010-023217-61-GB
Methods A phase IV, open-label, partial cross-over partial parallel, randomised, multi-centre study
Participants Target sample size: 64
Inclusion criteria
• ≥ 18 years
• Ability to provide informed consent
• Ability to meet all study requirements
• Adequate renal function (e.g. creatinine clearance = 60 mL/min)
• Willingness to stop other iron chelation therapy
• No known allergies to the drug
• Not pregnant or breastfeeding and willing to use effective contraception
For non-naive cohort
• Transfusional iron overload as defined by a minimum of 20 lifetime transfusion episodes
• Transfusional iron loading with ferritin levels > 500 mcg/L and/or LIC > 3 mg of iron/g dry weight (as
previously demonstrated by liver biopsy or MRI prior to the study)
• Established on deferasirox therapy for at least 1 year
• GI side effects believed to be related to their therapy as suggested by at least one of the following: - The
temporal relationship of GI side effects occurrence with the administration of deferasirox.
Exclusion criteria
• People with GI symptoms assumed or known not to be caused by DFX
• People who are treated for any condition with aspirin daily, those under chronic steroid therapy and those on
anticoagulant therapy that could all lead to potential GI symptoms/bleeding
• Presence of GI disease that may significantly alter the absorption of deferasirox (e.g. ulcerative diseases,
uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, GI or rectal bleeding)
• History of GI surgery (except appendicitis and cholecystectomy) e.g. stomach/bowel surgery or awaiting
elective surgery in the next 2 months
• Undergoing acute medical intervention or hospitalisation
• Psychiatric illness (schizophrenia, major depression) which may interfere with study requirements
• Any other medical condition that, in the opinion of the site investigator would interfere with completing the
study (visual problems or cognitive impairment)
• Platelet count less than 100,000
• Currently on treatment for hepatitis C
• Patients with severe iron loading in the heart (T2* less than 10 ms)
• Patients with severe total body iron load (LIC over 30 mg/g dry weight)
• Patients who have historical evidence of severe iron loading in the heart
• Women of child-bearing potential who are planning a pregnancy, pregnant, lactating and unwilling to use
effective means of contraception
• Inadequate renal function (e.g. creatinine clearance < 60 mL/min)
• Patients unwilling to stop using other iron chelation therapy for the study duration
• Known allergy to the drug
• Patients on aluminium containing antacid preparations
• Patients who are on vitamin C at doses higher than 200 mg/day
• Patients receiving or having received any investigational drug within 30 days prior to study enrolment
• Patients unable to understand oral or written English
Interventions Once daily oral DFX (dispersible tablet), when administered before or after food in people with transfusional
haemosiderosis
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Outcomes Primary outcome
• Between-treatment arm-difference of the mean individual change of GIQLI (follow-up minus baseline) in the
non-naive cohort (patients on established deferasirox therapy)
Secondary outcomes
• Difference between mean follow-up (1 month and 2 months) vs baseline changes of GIQLI per arm in naive
cohort
• Difference of the mean GSRS score changes in both arms of the established cohort and the naive cohort
• Difference of the mean SF-36 score changes in both arms of the established cohort and the naive cohort
• Arm difference of geometric mean steady state Cmin at visit 3 and visit 4 in the cross-over group
• Arm difference of geometric mean AUC and Cmax at visit 3 and visit 4 in cross-over group
• Arm difference of geometric mean steady-state Cmin at Visit 3 for all patients (after 1 month of treatment)
• Effect of food on systemic exposure of deferasirox as assessed by pharmacokinetics approach. Pooled
pharmacokinetic data from all arms will be analysed with a population pharmacokinetic model and appropriate
covariates will be examined for clinical and statistical relevance
Notes Date of first enrolment: 27/01/2012
Date of the global end of the study: 16/07/2012
Sponsor: University College London
Recruitment status: Not Recruiting
In the EU Clinical Trials Register, a premature end of the study is reported. As of now, no data have been published
Author was contacted
Hagag 2015
Methods Unclear, if study was randomised.
Participants 120 people with β-thalassemia major were included.
Age (mean (SD)): 5.43 (1.37) (range 4 - 7) years
Gender: 68 males, 52 females
Setting: Hematology Unit, Pediatric Department, Tanta University Hospital
Country: Egypt
Inclusion criteria
“Children with beta thalassaemia major with serum ferritin levels of more than 1000 ng/mL who had not received
iron chelation before this study and maintained on regular use of chelation during this study.”
Exclusion criteria
“Children with thalassaemia with serum ferritin level less than 1000 ng/mL. Children with thalassaemia with hepatitis
A, B or C.”
Follow-up: 6 months
Interventions Group A: “30 patients were treated with 8 hours intravenous infusion of Desferrioxamine, 40 mg/kg/day, 6 days per
week for 6 months.”
Group B: “ 30 patients were treated with subcutaneous infusion of Desferrioxamine, 40 mg/kg/day, 6 days per week
8 hours per day at night using Desferal pump for 6 months.”
Group C: “ 30 patients were treated with oral Deferiprone 75 mg/kg/day in three divided doses daily for 6 months.”
Group D: “ 30 patients were treated with oral Deferasirox 30 mg/kg/day in single daily dose on empty stomach for
6 months.”
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Outcomes • Serum ferritin
• Serum TIBC
• White blood cells
• Neutrophils
• Platelets count
• Liver enzymes
• Creatinine
• Blood urea
• Kidney function
Notes Author was contacted.
IRCT201110087677N1
Methods Comparative study of incidence of lens opacity between Osferal and Deferoxamine in thalassaemia major
Participants 50 people with thalassaemia major
Inclusion criteria:
- children with thalassaemia major
- being candidate for chelator therapy because of iron overload
Exclusion criteria:
- diabetes mellitus and rheumatologic diseases
- any lens disease or chelator therapy before the study
Follow-up: 12 months
Interventions “Then the patients will be divided into two 25 membered groups, and each group will receive one of the chelators
randomly.”
“Intervention:In this group, 25 patients are put on a new Iranian drug Osferal, and then it’s side effect that is ”lens
opacity“, will be compared with that of the control group.”
“Control:Based on the present policy, 25 patients who receive Deferoxamine and have a known percent of ”lens
opacity“, are considered as the control group.”
Outcomes Lens opacity
Notes Expected recruitment start date: 2010-12-22
Expected recruitment end date: 2011-12-22
Author was contacted
Kakkar 2015
Methods Prospective randomised study.
Participants Size of study population: not mentioned
Setting: Thalassemia ward of Department of Pediatrics, Dayanand Medical College and Hospital, Ludhiana
Country: India
Inclusion and exclusion criteria: not mentioned
Follow-up: not mentioned
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Interventions 2 groups:
• DFX: 40 - 50 mg/kg/day in once daily doses
• DFX: 40 - 50 mg/kg/day in 2 divided doses
Outcomes • Serum ferritin
• Cardiac MRI T2*
• Liver MRI T2*
• LVEF
• Safety profile in terms of gastrointestinal side effects, rash and change in serum creatinine values, SGPT and
GFR
Notes The study was only reported in a conference abstract.
Author was contacted.
NCT02198508
Methods Randomised, open-label, single-centre, cross-over study.
Participants Target sample size: 13
Inclusion criteria
• 18 years of age or older
• Serum ferritin greater than 2000 ng/mL
• Serum creatinine within normal range for a measuring laboratory
• Platelet count exceeding 140000/mm³
• Body weight at least 40 kg
• None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious,
pulmonary or cardiovascular disease
Exclusion criteria
• HIV positive, history of immunologic hypersensitivity to any medication
• Women pregnant or breastfeeding
• Drug or alcohol abuse
• Patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or
less than one bowel movement every other day)
• Receiving warfarin, digoxin, or anti-arrhythmic or anti-seizure medication
Interventions Experimental: combination treatment: DFX and DFP
Active comparator: DFX
Active comparator: DFP
Outcomes Primary outcome:
• Iron excretion from urine and faeces by flame atomic absorption spectroscopy [time frame: 25 days]
Secondary outcome:
• Drug concentration in plasma by pharmacokinetics analysis [time frame: 25 days]
Notes Primary completion date: July 2008
Recruitment status: completed
Author was contacted
94Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
AE: adverse event
AUC: area under the curve
Cmax: maximum or peak concentration (of a drug observed after its administration)
Cmin: minimum concentration (of a drug observed after its administration)
DFO: deferoxamine
DFP: deferiprone
DFX: deferasirox
EU: European Union
GFR: glomerular filtration rate
GIQLI: Gastrointestinal Quality of Life Index
GI: gastrointestinal
GSRS: Gastrointestinal Symptom Rating Scale
LIC: liver iron concentration
LVEF: left ventricular ejection fraction
MRI: magnetic resonance imaging
SD: standard deviation
SGPT: serum glutamic-pyruvic transaminase
TIBC: total iron building capacity
Characteristics of ongoing studies [ordered by study ID]
Cutino 2009
Trial name or title Sequential DFX-DFP versus DFX or DFP multicentre randomised study
Methods Randomised, parallel-group, open study.
Participants Planned number of participants to be included in the member state: 363
Inclusion criteria:
• Male and female
• Age > 12 and < 50 years old
• Diagnosis of β-thalassemia major
• Seric ferritin concentration > 1000 µg/L
Exclusion criteria:
• Diagnosis other than β-thalassemia major
• Participants with renal failure (creatinine clearance < 60 mL/min)
• ALT/AST > 300 U/L
• Severe cardiomyopathy
• Individuals with previous significant ocular toxicity related to iron chelating drugs
• Individuals with previous significant idiosyncratic reaction or severe toxicity to previous therapy with
DFP or DFX
• Platelets < 100.000/mmc
• Leukocytes < 300/mm
• Severe liver insufficiency (Child-Pugh Score C)
Interventions Experimental: sequential DFX-DFP
Comparator 1: DFX
Comparator 2: DFP
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Outcomes Primary outcome measure:
• Chelating efficacy assessment of sequential therapy DFX-DFP versus DFX or DFP alone
Secondary outcome measures:
• To assess in the sequential deferasirox-deferiprone treated group a reduction at least in 50% of cases of
creatininemia significant increase (> 33%) compared to the deferasirox alone group
• To assess in the sequential DFX-DFP group a reduction at least in 70% of cases of neutropenia
compared to the DFP alone group
• To assess, using MRI, in a subgroup, the possible organ-specific (heart, liver, pancreas) iron overload
variation during therapy
Starting date Date of first enrolment: 27/01/2010
Contact information N/A
Sponsor: FONDAZIONE FRANCO E PIERA CUTINO
Notes Initial estimate of the duration of the study: 5 years
DEEP-2 2012
Trial name or title Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients
Methods Multicentre, randomised, open label, non-inferiority active-controlled study
Participants Estimated enrolment: 344
Inclusion criteria;
• People of both genders aged from 1 month up to less than 18 years at the time of enrolment
• People affected by any hereditary haemoglobinopathy requiring chronic transfusion therapy and
chelation, including but not limited to thalassaemia syndromes and sickle cell disease
• People on current treatment with DFO or DFX or DFP in a chronic transfusion program receiving at
least 150 mL/kg/year of packed red blood cells (corresponding approximately to 12 transfusions)
• For participants naive to chelation treatment: participants that have received at least 150 mL/kg of
packed red blood cells (corresponding to approximately 12 transfusions) in a chronic transfusion program
and with serum ferritin levels≥ 800 ng/mL
• For participants aged from 1 month to less than 6 years: known intolerance or contraindication to
DFO;
• Written informed consent and participant’s informed assent, relating to his/her comprehension
abilities and level of maturity
Exclusion criteria:
• Participants with known intolerance or contraindication to either DFP or DFX
• Participants receiving DFX at a dose > 40 mg/kg/day or DFP at a dose > 100 mg/kg/day at screening
• Platelet count < 100.000/mm³ during the run-in phase
• Absolute neutrophils count < 1.500/mm³ during the run-in phase
• Hb levels lower than 8 g/dL during the run-in phase
• Evidence of abnormal liver function
• Iron overload from causes other than transfusional haemosiderosis
• Severe heart dysfunction secondary to iron overload
• Serum creatinine level > ULN for age during the run-in phase
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• History of significant medical or psychiatric disorder
• The patient has received another investigational drug within 30 days prior to this study
• Fever and other signs/symptoms of infection in the 10 days before baseline assessment
• Concomitant use of trivalent cation-dependent medicinal products such as aluminium-based antacids
• Positive test for β-HCG
Interventions Experimental: DFP oral solution
Comparator: DFX
Outcomes Primary outcome measure
• Percentage of successfully chelated participants assessed by serum ferritin levels (all participants) and
cardiac MRI T2* (participants above 10 years of age able to have an MRI scan without sedation)
Secondary outcome measures
• LlC as measured by MRI in participants able to undergo MRI scan without sedation
• Safety and tolerability assessments
• QoL
Starting date Date of first enrolment: 29/11/2012
Contact information Direzione Scientifica
via Luigi Porta, 14
27100 Pavia
Italy
Arianna Gambino, M.Sc.
phone: +39.0382.25075
email: deep.2@deep-project.net / agambino@cvbf.net
Notes Estimated study completion date: December 2014
Estimated primary completion date:December 2014 (Final data collection date for primary outcomemeasure)
NCT02125877
Trial name or title Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Methods A randomised, open-label, multicentre, 2-arm, phase II study
Participants Enrollment: 168
Inclusion criteria:
• Males and females aged ≥ 10 years
• Individuals with transfusion-dependent thalassaemia and iron overload, requiring DFX dispersible
tablets at doses of ≥ 30 mg/kg/day as per the investigator’s decision OR those with very low, low or
intermediate risk of myelodysplastic syndrome and iron overload, requiring DFX dispersible tablets at doses
of ≥ 20 mg/kg/day as per the investigator’s decision
• History of transfusion of at least 20 PRBC units and anticipated to be transfused with at least 8 units
of PRBCs annually during the study
• Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will
be used for eligibility criteria)
Exclusion criteria:
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• Creatinine clearance below the contraindication limit in the locally approved prescribing information.
Creatinine clearance will be estimated from serum creatinine at screening Visit 1 and screening Visit 2 and
the mean value will be used for eligibility criteria
• Serum creatinine > 1.5 x ULN at screening measured at screening Visit 1 and screening Visit 2 (the
mean value will be used for eligibility criteria)
• ALT (SGPT) > 5xULN, unless LIC confirmed as >10 mg Fe/dry weight within 6 months prior to
screening visit 1
• Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first
void urine sample at screening Visit 1 or screening Visit 2
• People with significant impaired GI function or GI disease that may significantly alter the absorption
of oral deferasirox (e.g. ulcerative diseases uncontrolled nausea, vomiting, diarrhoea, malabsorption
syndrome, or small bowel resection)
• Liver disease with severity of Child-Pugh Class B or C
Interventions Experimental: DFX film-coated tablet
Active comparator: DFX dispersible tablet
Outcomes Primary outcome
• Overall safety [Time Frame: Screening visit thru post-treatment period - 30 weeks]
Secondary outcome
• Frequency of selected GI AEs (GI AEs) [time frame: on-treatment period (Day 1 - safety follow-up) -
28 weeks]
• Pharmacokinetic parameters [Time frame: week 1, 3, 13 and 21]
• Domain scores of treatment satisfaction and palatability over time [time frame: Week 2, 3, 13 and end
of treatment (week 24 or within 7 days of last dose)]
• Weekly average of daily scores of GI diary [Time frame: weekly (screening thru end of treatment visit) -
26 weeks]
• Relative consumed film-coated tablet/dispersible tablet counts. Participant-reported medication
consumption [Time frame: daily (day 1/visit 3 - last visit) 24 weeks]
Starting date July 2014
Contact information Sponsor: Novartis Pharmaceuticals
Notes Estimated study completion date: February 2016
Estimated primary completion date: February 2016 (Final data collection date for primary outcome measure)
NCT02435212
Trial name or title Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation
(Granules) in Pediatric Patients (2 - < 18 years old) With Iron Overload
Methods Randomised, open-label, multicentre, 2-arm, phase II study. Randomisation will be stratified by age groups
(2 to < 10 years, 10 to < 18 years). The study treatment duration will be 48 weeks
Participants Target sample size:120
Inclusion criteria:
• Written informed consent/assent before any study-specific procedures. Consent will be obtained from
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parent(s) or legal guardians. Investigators will also obtain assent of participants according to local guidelines
• Iron chelation therapy naive male and female children and adolescents aged ≥ 2 and < 18 years
• Any transfusion-dependent anaemia associated with iron overload requiring iron chelation therapy and
with a history of transfusion of at least 20 PRBC units and a treatment goal to reduce iron burden
• Serum ferritin > 1000 ng/mL, measured at screening visit 1 and screening visit 2 (the mean value will
be used for eligibility criteria)
Exclusion criteria:
• Creatinine clearance below the contraindication limit in the locally approved prescribing information.
Creatinine clearance will be estimated from serum creatinine (using the Schwartz formula) at screening Visit
1 and screening visit 2 and the mean value will be used for eligibility criteria
• Serum creatinine > 1.5 x ULN at screening measured at screening visit 1 and screening visit 2 (the
mean value will be used for eligibility criteria)
• ALT > 5 x ULN, unless LIC within 6 months is > 10 mg Fe/dry weight
• Prior iron chelation therapy
• Liver disease with severity of Child-Pugh class B or C
• Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first
void urine sample at screening visit 1 or screening visit 2
• Patients with significant impaired GI function or GI disease that may significantly alter the absorption
of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption
syndrome, or small bowel resection)
Other protocol-defined inclusion/exclusion may apply
Interventions Experimental: DFX granule formulation
Active comparator: DFX dispersible tablet formulation
Outcomes Primary outcomes:
• Change in serum ferritin [Time frame: baseline, 48 weeks]
• Compliance (using stick/pack tablet count) [Time frame: 48 weeks]
Secondary outcomes:
• Domain scores of treatment satisfaction and palatability over time [time frame: 48 weeks]
• Frequency of AEs as a measure of overall safety [Time frame: baseline, 48 weeks]
• Pharmacokinetic parameters including clearance and volume of distribution in all participants
(AUClast, AUCinf, AUCtau, Cmax, Tmax and R) [Time frame: Week 1, Week 5]
• Pre-dose DFX concentrations in all participants [time frame: at weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33,
37, 41 and 45]
• Rate of dosing instructions deviations (’Compliance’, using a questionnaire) [Time Frame: 48 weeks]
• Severity of AEs as a measure of overall safety [Time frame: baseline, 48 weeks]
Starting date September 2015
Contact information Novartis Pharmaceuticals 1-888-669-6682
Notes Estimated study completion date: August 2017
Estimated primary completion date: August 2017 (Final data collection for primary outcome measure)
Information given in table according to www.clinicaltrials.gov or http://apps.who.int/trialsearch/ or http://www.irct.ir/. Data were
extracted in October 2015.
AEs: adverse events
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ALT: alanine aminotransferase
AST: aspartate transaminase
AUCinf: area under the concentration-time curve extrapolated to time infinity
AUClast: area under the curve up to the last measurable concentration
AUCtau: area under the plasma concentration-time curve during the dosing interval
Cmax: maximum or peak concentration (of a drug observed after its administration)
CMR: cardiovascular magnetic resonance
DFO: deferoxamine
DFP: deferiprone
DFX: deferasirox
GI: gastrointestinal
HCG: human chorionic gonadotropin
LIC: liver iron concentration
LVEF: left ventricular ejection fraction
MRI: magnetic resonance imaging
PRBC: packed red blood cells
QoL: quality of life
SD: standard deviation
SGPT: serum glutamic-pyruvic transaminase
Tmax: amount of time that a drug is present at the maximum concentration in serum
ULN: upper limit of normal
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D A T A A N D A N A L Y S E S
Comparison 1. Transfusion-dependent thalassemia: deferasirox vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 2 47 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Eye disorders - retinal
infarct
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 GI disorders - abdominal
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 GI disorders - diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 GI disorders - nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Investigations - extended
QT interval, hypocalcaemia,
hypoparathyroidism
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Skin and subcutaneous
tissue disorders - rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Discontinuations due to serious
AEs
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 8 1170 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.09, 2.63]
1.1 At 8 months 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 48 weeks (deferasirox
10 mg/kg/day)
1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 At 48 weeks (deferasirox
20 mg/kg/day )
1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 At 1 year 5 942 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.09, 2.63]
1.5 At 2 years 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 LVEF (%): least squares mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 LVEF (# participants affected) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Improvement from
abnormal LVEF to normal
range
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Decrease from normal
LVEF to below LLN
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Incidence of thyroid disease at
end of study
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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5 ALT (# participants affected):
improvement from abnormal
to normal range
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 ALT (U/L) at end of study 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 AST (U/L) at end of study 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Serum creatinine (mg/dL) at end
of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Blood urea (mg/dL): mean at
end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Serum ferritin (ng/mL): mean
change from baseline and at
end of study
6 1002 Mean Difference (IV, Fixed, 95% CI) 454.42 [337.13,
571.71]
10.1 Less than 3 mg Fe/g dw
(median 5 mg deferasirox /
30mg deferoxamine)
1 28 Mean Difference (IV, Fixed, 95% CI) 978.0 [544.71,
1411.29]
10.2 More than 3 to 7 mg Fe/
g dw (10/35)
1 150 Mean Difference (IV, Fixed, 95% CI) 801.0 [572.53,
1029.47]
10.3 More than 7 mg Fe/g dw
(20/41)
1 169 Mean Difference (IV, Fixed, 95% CI) 328.0 [124.94, 531.
06]
10.4 More than 14 mg Fe/g
dw (30/51)
1 216 Mean Difference (IV, Fixed, 95% CI) 77.0 [-303.18, 457.
18]
10.5 Any iron overload 5 439 Mean Difference (IV, Fixed, 95% CI) 234.25 [-8.02, 476.
52]
11 Sensitivity analysis: serum
ferritin (ng/mL): mean change
from baseline
2 701 Mean Difference (IV, Fixed, 95% CI) 418.94 [297.23,
540.65]
11.1 Less than 3 mg Fe/g dw
(median 5 mg deferasirox / 30
mg deferoxamine)
1 28 Mean Difference (IV, Fixed, 95% CI) 978.0 [544.71,
1411.29]
11.2 More than 3 to 7 mg Fe/
g dw (10/35)
1 150 Mean Difference (IV, Fixed, 95% CI) 801.0 [572.53,
1029.47]
11.3 More than 7 mg Fe/g dw
(20/41)
1 169 Mean Difference (IV, Fixed, 95% CI) 328.0 [124.94, 531.
06]
11.4 More than 14 mg Fe/g
dw (30/51)
1 216 Mean Difference (IV, Fixed, 95% CI) 77.0 [-303.18, 457.
18]
11.5 Any iron overload 1 138 Mean Difference (IV, Fixed, 95% CI) -64.16 [-354.62,
226.30]
12 Liver R2* (Hz): mean change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 LIC (mg/g) evaluated by MRI
(R2/R2*): mean change from
baseline
2 217 Mean Difference (IV, Fixed, 95% CI) 0.36 [-1.01, 1.72]
14 LIC (mg Fe/g dw) evaluated
by biopsy or SQUID: mean
change from baseline
1 541 Mean Difference (IV, Fixed, 95% CI) 2.37 [1.68, 3.07]
14.1 LIC 3 mg Fe/g dw or less
(5/30)
1 28 Mean Difference (IV, Fixed, 95% CI) 4.3 [2.30, 6.30]
14.2 LIC more than 3 mg to
7 mg (10/35) Fe/g dw
1 143 Mean Difference (IV, Fixed, 95% CI) 3.80 [2.74, 4.86]
14.3 LIC more than 7 mg to
14 mg Fe/g dw (20/41)
1 164 Mean Difference (IV, Fixed, 95% CI) 1.5 [0.28, 2.72]
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14.4 LIC more than 14 mg
Fe/g dw (30/51)
1 206 Mean Difference (IV, Fixed, 95% CI) -2.5 [-4.55, -0.45]
15 Responder analysis I
(responder: fall in LIC > 10%)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15.1 Response at 48 weeks
(deferasirox 10 mg/kg/day)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Response at 48 weeks
(deferasirox 20 mg/kg/day)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Responder analysis II
(responder: LIC 1 to < 7 mg
Fe/g dw)
1 553 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.69, 0.92]
16.1 Response at 1 year (LIC
below 7 mg Fe/g dw)
1 172 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.37, 0.64]
16.2 Response at 1 year (LIC
at least 7 mg Fe/g dw)
1 381 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.18]
17 Myocardial T2* (ms): mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18 Myocardial iron concentration
derived from T2* value (mg
Fe/g dw): change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 All participants 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Participants with T2*
<10 ms
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 Participants with T2*
≥10 ms
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Myocardial T2* (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
19.1 Normalization 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 Improvement (from 6 - <
10 ms to 10 - ≤ 20 ms)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.3 Worsening (from 10- ≤
20 ms to 6 - < 10 ms)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Iron excretion-intake ratio 1 541 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.24, -0.12]
20.1 Less than 3 mg Fe/g dw
(median 5 mg deferasirox / 30
mg deferoxamine)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.54, -0.20]
20.2 More than 3 to 7 mg Fe/
g dw (10/35)
1 143 Mean Difference (IV, Fixed, 95% CI) -0.31 [-0.41, -0.21]
20.3 More than 7 mg Fe/g dw
(20/41)
1 164 Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.21, -0.01]
20.4 More than 14 mg Fe/g
dw (30/51)
1 206 Mean Difference (IV, Fixed, 95% CI) 0.23 [0.05, 0.41]
21 Any serious AEs (# participants
affected)
2 773 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.42, 1.86]
22 Serious AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
22.1 Cardiac disorders -
arrhythmia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.2 Endocrine disorders -
hypogonadism
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.3 GI disorders abdominal
abscess
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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22.4 GI disorders amoebiasis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.5 GI disorders -
appendicitis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.6 GI disorders - colitis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.7 GI disorders - diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.8 GI disorders - gastric
haemorrhage
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.9 GI disorders -
gastroenteritis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.10 GI disorders - ileus 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.11 GI disorders - upper
abdominal pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.12 GI disorders - vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.13 GI disorders - GI
infection
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.14 General disorders and
administration site conditions -
pyrexia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.15 General disorders and
administration site conditions -
local swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.16 Hepatobiliary disorders
- liver abscess
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.17 Hepatobiliary disorders
- cholelithiasis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.18 Immune system
disorders - face oedema
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.19 Infections and
infestations - herpes zoster
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.20 Infections and
infestations - tooth infection
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.21 Infections and
infestations - urinary tract
infection
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.22 Injury, poisoning and
procedural complications -
oesophageal rupture
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.23 Injury, poisoning and
procedural complications -
haemosiderosis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.24 Injury, poisoning and
procedural complications - iron
overload
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.25 Metabolism and
nutrition disorders -
hyperglycaemia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.26 Musculoskeletal and
connective tissue disorders -
back pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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22.27 Musculoskeletal and
connective tissue disorders -
pain in jaw
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.28 Nervous system
disorders - grand mal
convulsion
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.29 Nervous system
disorders - meningitis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.30 Respiratory, thoracic
and mediastinal disorders -
acute tonsilitis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Any AE (# participants
affected)
2 258 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.83, 1.08]
24 AEs 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24.1 Blood and lymphatic
system disorder -
agranulocytosis
2 657 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.2 Blood and lymphatic
system disorder - leukopenia
1 138 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.37, 133.02]
24.3 Blood and lymphatic
system disorder - neutropenia
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.4 Blood and lymphatic
system disorder -
thrombocytopenia
2 209 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.46, 34.88]
24.5 Cardiac disorders -
cardiac AE
1 586 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.38, 1.41]
24.6 Ear and labyrinth
disorders - hearing loss
2 657 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.41, 3.05]
24.7 Eye disorder - lens
abnormality
2 657 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.08, 2.00]
24.8 Eye disorder - retinal
abnormality
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.9 GI disorders - abdominal
pain
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.93, 3.05]
24.10 GI disorders -
abdominal pain upper
1 187 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.36, 3.60]
24.11 GI disorders - diarrhoea 2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.86, 3.16]
24.12 GI disorders - dyspepsia 1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.25, 5.72]
24.13 GI disorders - GIT
upset
1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.66, 13.69]
24.14 GI disorders - nausea 2 258 Risk Ratio (M-H, Fixed, 95% CI) 2.59 [0.90, 7.47]
24.15 GI disorders - vomiting 2 258 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.91, 9.55]
24.16 General disorders and
administration site conditions -
asthenia
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.42, 3.42]
24.17 General disorders and
administration site conditions -
influenza-like illness
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.42, 3.42]
24.18 General disorders and
administration site conditions -
pyrexia
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.66, 2.44]
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24.19 Immune system
disorders - allergic
conjunctivitis
1 71 Risk Ratio (M-H, Fixed, 95% CI) 4.41 [0.25, 78.58]
24.20 Infections and
infestations - bronchitis
1 71 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [0.30, 19.35]
24.21 Infections and
infestations - upper respiratory
tract infection
1 187 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.37, 2.42]
24.22 Infections and
infestations - urinary tract
infection
1 71 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [0.30, 19.35]
24.23 Investigations - ALT
increased
1 187 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.59, 4.90]
24.24 Investigations - elevated
ALT (>2 UNL)
1 586 Risk Ratio (M-H, Fixed, 95% CI) 4.90 [0.24, 101.60]
24.25 Investigations - AST
increased
1 187 Risk Ratio (M-H, Fixed, 95% CI) 2.21 [0.59, 8.29]
24.26 Investigations - blood
creatinine increased
1 187 Risk Ratio (M-H, Fixed, 95% CI) 3.79 [0.83, 17.38]
24.27 Investigations - isolated
serum creatinine increase above
upper limit of normal
2 657 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [1.88, 3.51]
24.28 Investigations - platelet
count increased
1 187 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.08, 1.91]
24.29 Musculoskeletal and
connective tissue disorders -
arthralgia
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.55, 3.13]
24.30 Musculoskeletal and
connective tissue disorders -
back pain
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.73, 2.34]
24.31 Musculoskeletal and
connective tissue disorders -
osteoporosis
1 187 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [0.47, 11.91]
24.32 Nervous system
disorders - headache
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.68, 3.05]
24.33 Nervous system
disorders - vertigo
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.32, 3.93]
24.34 Renal and urinary
disorders - proteinuria
1 187 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.50, 2.66]
24.35 Respiratory, thoracic
and mediastinal disorders -
cough
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.67, 4.81]
24.36 Respiratory, thoracic
and mediastinal disorders -
influenza
2 258 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.52, 2.13]
24.37 Respiratory, thoracic
and mediastinal disorders -
nasopharyngitis
1 187 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.59, 6.08]
24.38 Respiratory, thoracic
and mediastinal disorders -
oropharyngeal pain
1 187 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [0.59, 13.73]
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24.39 Respiratory, thoracic
and mediastinal disorders -
pharyngitis
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 2.00]
24.40 Respiratory, thoracic
and mediastinal disorders -
pharyngolaryngeal pain
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.37, 2.08]
24.41 Respiratory, thoracic
and mediastinal disorders -
rhinitis
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.58, 2.83]
24.42 Skin and subcutaneous
tissue disorders - Rash
1 60 Risk Ratio (M-H, Fixed, 95% CI) 2.67 [0.78, 9.09]
25 Any drug-related AE (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
26 Drug-related AEs 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
26.1 Blood and lymphatic
system disorder - neutropenia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.2 Injury, poisoning and
procedural complications -
infusion site haemorrhage
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.3 Injury, poisoning and
procedural complications -
infusion site pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.4 Injury, poisoning and
procedural complications -
infusion site swelling
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.5 Injury, poisoning and
procedural complications -
injection site pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.6 Injury, poisoning and
procedural complications -
injection site reaction
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.7 Investigations - blood
creatinine increased
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.8 Investigations - ALT
increased
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.9 Investigations - AST
increased
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.10 GI disorders -
abdominal pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.11 GI disorders -
abdominal pain upper
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.12 GI disorders - diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.13 GI disorders - nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.14 GI disorders - vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.15 Immune system
disorders - hypersensitivity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.16 Immune system
disorders - urticaria
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.17 Musculoskeletal and
connective tissue disorders -
arthropathy
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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26.18 Renal and urinary
disorders - proteinuria
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.19 Skin and subcutaneous
tissue disorders - alopecia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.20 Skin and subcutaneous
tissue disorders - rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.21 Injury, poisoning and
procedural complications -
pulmonary toxicity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.22 Eye disorders -
Ophthalmological toxicity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.23 Ear and labyrinth
disorders - Audiological toxicity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Satisfaction with treatment
(very satisfied or satisfied)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
27.1 Week 4 - participants
previously treated with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.2 Week 24 - participants
previously treated with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.3 End of study (1 year) -
participants previously treated
with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.4 Week 4 - DFO-naive
participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.5 Week 24 - DFO-naive
participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.6 End of study (1 year) -
DFO-naive participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Convenience (good or very
good)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
28.1 Week 4 - participants
previously treated with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.2 Week 24 - participants
previously treated with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.3 End of study (1 year) -
participants previously treated
with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.4 Week 4 - DFO-naive
participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.5 Week 24 - DFO-naive
participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28.6 End of study (1 year) -
DFO-naive participants
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
29 Willingness to continue
treatment
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
29.1 Participants treated
previously with DFO
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
29.2 DFO-naive participants 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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30 Time lost from normal
activities due to treatment
(hours/month): participants
treated previously with DFO
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
30.1 week 4 - patients treated
previously with DFO
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.2 week 24 - patients treated
previously with DFO
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.3 end of study (1 year) -
patients treated previously with
DFO
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.4 week 4 - DFO-naive
patients
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.5 week 24 - DFO-naive
patients
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30.6 end of study (1 year) -
DFO-naive patients
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
31 Adherence (% of planned dose) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
32 Discontinuations 8 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.60, 1.50]
32.1 Deferasirox 10 mg/kg/
day
1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 3.64]
32.2 Deferasirox 20 mg/kg/
day
2 174 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.10, 9.96]
32.3 Deferasirox 25 mg/kg/
day
1 120 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.61]
32.4 Deferasirox 40 mg/kg/
day
2 211 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.51, 2.05]
32.5 Deferasirox - variable
dosage
2 646 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.67, 2.85]
32.6 Deferasirox dosing
unknown
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
33 Dose adjustments and dose
interruptions
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
34 Dose interruptions (interrupted
at least once)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
35 Dose reduction (at least once) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
36 Dose adjustments (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
37 Dose interruptions due to an
AE (# participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
38 Haemoglobin (g/dL): mean
change from baseline and at
end of study
2 180 Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.82, -0.21]
38.1 At 8 months (change
from baseline)
1 138 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.81, -0.11]
38.2 At 1 year (at end of
study)
1 42 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.33, -0.07]
39 Transfusion index
(mL/kg/year): mean at end of
study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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40 Transferrin saturation (%):
mean at end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
41 Platelet count (x10³/mm³):
mean at end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
42 Absolute neutrophilic count
(/mm³): mean at end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 3 146 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 at 1 year 2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 at 2 years 1 18 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Incidence of thyroid disease at
end of study
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 ALT (U/L): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 AST (U/L): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Urea (mg/dL): mean change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Creatinine (mg/dL): mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Neutrophil (count per mm³):
mean change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Serum ferritin (ng/mL): mean
change from baseline and at
end of study
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 All participants 2 83 Mean Difference (IV, Fixed, 95% CI) 229.99 [-403.14,
863.11]
8.2 Ferritin > 4000 1 11 Mean Difference (IV, Fixed, 95% CI) 1129.0 [-2226.18,
4484.18]
8.3 Ferritin 2000 - 4000 1 16 Mean Difference (IV, Fixed, 95% CI) -151.0 [-743.80,
441.80]
8.4 Ferritin < 2000 1 11 Mean Difference (IV, Fixed, 95% CI) 388.0 [-255.71,
1031.71]
9 LIC (mg/g) evaluated by MRI
(R2*): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Myocardial T2* (ms): mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11 Any AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12 AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12.1 GI disorders - diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 GI disorders - nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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12.3 GI disorders - pain
abdomen
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.4 GI disorders - vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.5 Musculoskeletal and
connective tissue disorders -
arthralgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.6 Skin and subcutaneous
tissue disorders - rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.7 Blood and lymphatic
system disorder -
agranulocytosis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.8 Blood and lymphatic
system disorder - neutropenia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.9 Investigations - AST
levels > 2x UNL
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.10 Investigations - ALT
levels > 2x UNL
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.11 Investigations - serum
creatinine 50% increase from
baseline
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.12 Renal and urinary
disorders - renal failure
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Discontinuations (#
participants affected)
3 179 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 2.99]
14 Discontinuation due to an AE
(# participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 Transferrin saturation (%):
mean at end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16 Haemoglobin (g/dL): mean at
end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17 Transfusion index
(mL/kg/year): mean at end of
study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18 ALP (U/L): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 6. Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Neutrophil (µg/L): mean at end
of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 ALT (g/dL): mean at end of
study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 AST (g/dL): mean at end of
study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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5 Serum ferritin: mean at end of
study (ng/mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Discontinuations 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Haemoglobin (g/dL): mean at
end of study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 ALP (g/dL): mean at end of
study
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 7. Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serum ferritin (ng/mL): mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 LIC (mg/g) evaluated by MRI
(R2*): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Myocardial T2* (ms): mean
change from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Serious AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Serious drug-related AE (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Cholecystitis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Serious non-related drug AE 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Appendicitis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Blood and lymphatic
system disorder -
agranulocytosis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Blood and lymphatic
system disorder - neutropenia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Drug-related AEs (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Drug-related AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 Blood and lymphatic
system disorders -
agranulocytosis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Blood and lymphatic
system disorders - neutropenia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 GI disorders - GI
problems
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Investigations - ALT
increase ( ≥ 3 folds)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
112Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10.5 Investigations - serum
creatinine ( ≥ 33%) above
baseline in 2 consecutive
occasions
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 Musculoskeletal and
connective tissue disorders -
arthralgia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.7 Skin and subcutaneous
tissue disorders - skin rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Non-related drug AEs (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Non-related drug AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12.1 Infections and
infestations - infections
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 GI disorders 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Skin and subcutaneous
tissue disorders
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Mild elevation of hepatic
transaminases at start of therapy
(# participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14 Initial gastrointestinal
manifestations (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 Quality of life (%) (measured
by SF-36): mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16 Adherence: actual dose/total
prescribed dose
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17 Discontinuations 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
18 Serious AE resulting in study
discontinuation or interruption
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 8. Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at any time point 1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 Deferasirox 5 mg/kg/day:
at 12 months
1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Deferasirox 10 mg/kg/
day: at 12 months
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serum ferritin (ng/mL): mean
change from baseline
1 154 Mean Difference (IV, Fixed, 95% CI) -306.74 [-398.23,
-215.24]
2.1 Deferasirox 5 mg/kg/day 1 78 Mean Difference (IV, Fixed, 95% CI) -259.1 [-377.35,
-140.85]
2.2 Deferasirox 10 mg/kg/day 1 76 Mean Difference (IV, Fixed, 95% CI) -377.79 [-522.21,
-233.37]
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3 LIC (mg Fe/g dw) evaluated by
MRI R2: least squares mean
change from baseline
1 159 Mean Difference (IV, Fixed, 95% CI) -3.27 [-4.44, -2.09]
3.1 Deferasirox 5 mg/kg/day 1 78 Mean Difference (IV, Fixed, 95% CI) -2.33 [-4.00, -0.66]
3.2 Deferasirox 10 mg/kg/day 1 81 Mean Difference (IV, Fixed, 95% CI) -4.18 [-5.83, -2.53]
4 LIC (mg Fe/g dw) evaluated by
MRI R2: mean change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Non-transfusion-
dependent β-thalassemia 5 mg/
kg/day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Non-transfusion-
dependent β-thalassemia 10
mg/kg/day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 α-thalassemia 5 mg/kg/
day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 α-thalassemia 10 mg/kg/
day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 HbE/β-thalassemia 5 mg/
kg/day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 HbE/β-thalassemia 10
mg/kg/day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 < 18 years 5 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 < 18 years 10 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 ≥18 years 5 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 ≥18 years 10 mg/kg/day 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 LIC: decrease of ≥ 3 mg Fe/g
dw (# participants affected)
1 166 Risk Ratio (M-H, Fixed, 95% CI) 4.16 [1.90, 9.11]
5.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.98, 9.50]
5.2 Deferasirox 10 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 5.26 [1.76, 15.71]
6 LIC: ≥ 30% reduction Fe/g dw
(# participants affected)
1 166 Risk Ratio (M-H, Fixed, 95% CI) 14.17 [2.88, 69.74]
6.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 15.02 [0.93, 242.87]
6.2 Deferasirox 10 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 13.75 [1.97, 95.97]
7 LIC: shift to lower iron burden
range (# participants affected)
1 166 Risk Ratio (M-H, Fixed, 95% CI) 3.35 [1.62, 6.91]
7.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [1.10, 10.45]
7.2 Deferasirox 10 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 3.31 [1.28, 8.55]
8 LIC: achieve LIC < 5 mg Fe/g
dw (# participants affected)
1 166 Risk Ratio (M-H, Fixed, 95% CI) 5.35 [1.30, 21.99]
8.1 deferasirox 5mg/kg/d 1 83 Risk Ratio (M-H, Fixed, 95% CI) 4.07 [0.54, 30.96]
8.2 deferasirox 10mg/kg/d 1 83 Risk Ratio (M-H, Fixed, 95% CI) 6.62 [0.91, 48.05]
9 Drug-related serious AEs (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Drug-related serious AEs (#
participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 GI disorders - abdominal
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Infections and
infestations - cellulitis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10.3 Skin and subcutaneous
tissue disorders - pruritus
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.4 Skin and subcutaneous
tissue disorders - rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.5 General disorders -
pyrexia
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.6 Hepatobiliary disorders -
hepatotoxicity
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Any AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12 Mild AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
13 Moderate AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14 Severe AE (# participants
affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15.1 Ear and labyrinth
disorders - neurosensory
deafness
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Investigations - abnormal
platelet count (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Investigations - abnormal
neutrophils count (post-
baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 Investigations - abnormal
ALT (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.5 Investigations - abnormal
AST (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.6 Investigations - abnormal
serum creatinine (post-
baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.7 Investigations - abnormal
creatinine clearance (post-
baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.8 Investigations - urinary
protein/creatinine ratio (post-
baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.9 Investigations - abnormal
(low) systolic blood pressure
(post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.10 Investigations -
abnormal (high) systolic blood
pressure (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.11 Investigations -
abnormal (low) diastolic blood
pressure (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.12 Investigations -
abnormal (high) diastolic blood
pressure (post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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15.13 Investigations -
abnormal (low) pulse rate
(post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.14 Investigations -
abnormal (high) pulse rate
(post-baseline)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.15 Renal and urinary
disorders - proteinuria
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Drug-related AEs 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
16.1 GI disorders - abdominal
pain
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 GI disorders - abdominal
pain upper
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 GI disorders - diarrhoea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 GI disorders - nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.5 Nervous system disorders
- headache
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.6 Skin and subcutaneous
tissue disorders - skin rash
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Adherence (# participants
taking the planned study dose)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
18 Discontinuations 1 166 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.50, 3.52]
18.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.33, 4.25]
18.2 Deferasirox 10 mg/kg/
day
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.33, 7.08]
19 Discontinuing study due to AE
(# participants affected)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
20 Dose increase 1 166 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.63, 1.19]
20.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.57, 1.38]
20.2 Deferasirox 10 mg/kg/
day
1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.54, 1.33]
21 Dose interruption (at least
once)
1 166 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.88, 1.39]
21.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.43]
21.2 Deferasirox 10 mg/kg/
day
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.87, 1.62]
22 Dose reduction 1 166 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.70, 3.06]
22.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.54, 4.30]
22.2 Deferasirox 10 mg/kg/
day
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.49, 4.00]
23 Dose reduction due to AE 1 166 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.69, 3.38]
23.1 Deferasirox 5 mg/kg/day 1 83 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [0.63, 6.63]
23.2 Deferasirox 10 mg/kg/
day
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.39, 3.39]
24 Haemoglobin (g/L): mean
change from baseline
1 144 Mean Difference (IV, Fixed, 95% CI) 1.54 [-0.82, 3.90]
24.1 Deferasirox 5 mg/kg/day 1 71 Mean Difference (IV, Fixed, 95% CI) 1.00 [-2.31, 4.31]
24.2 Deferasirox 10 mg/kg/
day
1 73 Mean Difference (IV, Fixed, 95% CI) 2.10 [-1.27, 5.47]
25 Transferrin saturation (%):
mean change from baseline
1 141 Mean Difference (IV, Fixed, 95% CI) -7.10 [-11.71, -2.50]
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25.1 Deferasirox 5 mg/kg/day 1 70 Mean Difference (IV, Fixed, 95% CI) -7.16 [-12.95, -1.37]
25.2 Deferasirox 10 mg/kg/
day
1 71 Mean Difference (IV, Fixed, 95% CI) -7.01 [-14.59, 0.57]
Analysis 1.1. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 1
Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 1 Transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 1 Mortality at any time point
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Galanello 1999 0/18 0/6 Not estimable
Nisbet-Brown 2001 0/18 0/5 Not estimable
Total (95% CI) 36 11 Not estimable
Total events: 0 (Deferasirox), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2 AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 1 Transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 2 AEs
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Eye disorders - retinal infarct
Nisbet-Brown 2001 1/18 0/5 0.95 [ 0.04, 20.33 ]
2 GI disorders - abdominal pain
Nisbet-Brown 2001 1/18 0/5 0.95 [ 0.04, 20.33 ]
3 GI disorders - diarrhoea
Nisbet-Brown 2001 4/18 0/5 2.84 [ 0.18, 45.53 ]
4 GI disorders - nausea
Nisbet-Brown 2001 4/18 0/5 2.84 [ 0.18, 45.53 ]
5 Investigations - extended QT interval, hypocalcaemia, hypoparathyroidism
Nisbet-Brown 2001 1/18 0/5 0.95 [ 0.04, 20.33 ]
6 Skin and subcutaneous tissue disorders - rash
Nisbet-Brown 2001 4/18 0/5 2.84 [ 0.18, 45.53 ]
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3
Discontinuations due to serious AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 1 Transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 3 Discontinuations due to serious AEs
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nisbet-Brown 2001 8/18 1/6 2.67 [ 0.41, 17.17 ]
0.01 0.1 1 10 100
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Analysis 2.1. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 1
Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 1 Mortality at any time point
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 8 months
Molavi 2013 0/69 0/69 Not estimable
Subtotal (95% CI) 69 69 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 At 48 weeks (deferasirox 10 mg/kg/day)
Piga 2002 0/24 0/11 Not estimable
Subtotal (95% CI) 24 11 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 At 48 weeks (deferasirox 20 mg/kg/day )
Piga 2002 0/24 0/12 Not estimable
Subtotal (95% CI) 24 12 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 At 1 year
Cappellini 2005b 1/296 3/290 74.7 % 0.33 [ 0.03, 3.12 ]
Elalfy 2015a 0/30 0/55 Not estimable
Hassan 2016 0/30 0/30 Not estimable
Peng 2013 0/12 0/12 Not estimable
Pennell 2014 1/96 1/91 25.3 % 0.95 [ 0.06, 14.93 ]
Subtotal (95% CI) 464 478 100.0 % 0.48 [ 0.09, 2.63 ]
Total events: 2 (Deferasirox), 4 (Deferoxamine)
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
5 At 2 years
Chirico 2013 0/13 0/6 Not estimable
Subtotal (95% CI) 13 6 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 594 576 100.0 % 0.48 [ 0.09, 2.63 ]
Total events: 2 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 2
LVEF (%): least squares mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 2 LVEF (%): least squares mean change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pennell 2014 91 -0.5 (4.48) 81 0 (4.41) -0.50 [ -1.83, 0.83 ]
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Analysis 2.3. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 3
LVEF (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 3 LVEF (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Improvement from abnormal LVEF to normal range
Pennell 2014 6/11 5/10 1.09 [ 0.48, 2.48 ]
2 Decrease from normal LVEF to below LLN
Pennell 2014 7/80 9/71 0.69 [ 0.27, 1.76 ]
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Analysis 2.4. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 4
Incidence of thyroid disease at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 4 Incidence of thyroid disease at end of study
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chirico 2013 2/6 5/13 0.87 [ 0.23, 3.26 ]
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Analysis 2.5. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 5
ALT (# participants affected): improvement from abnormal to normal range.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 5 ALT (# participants affected): improvement from abnormal to normal range
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 20/63 22/56 0.81 [ 0.50, 1.32 ]
0.01 0.1 1 10 100
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Analysis 2.6. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 6
ALT (U/L) at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 6 ALT (U/L) at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 35 (25.6) 30 54.5 (32.4) -19.50 [ -34.28, -4.72 ]
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Analysis 2.7. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 7
AST (U/L) at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 7 AST (U/L) at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 25.9 (18.9) 30 42.2 (27.8) -16.30 [ -28.33, -4.27 ]
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Analysis 2.8. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 8
Serum creatinine (mg/dL) at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 8 Serum creatinine (mg/dL) at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 0.6 (0.18) 30 0.53 (0.2) 0.07 [ -0.03, 0.17 ]
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Analysis 2.9. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 9
Blood urea (mg/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 9 Blood urea (mg/dL): mean at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 35.2 (6.5) 30 28.1 (5.7) 7.10 [ 4.01, 10.19 ]
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Analysis 2.10. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 10
Serum ferritin (ng/mL): mean change from baseline and at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 10 Serum ferritin (ng/mL): mean change from baseline and at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30mg deferoxamine)
Cappellini 2005b 15 1189 (700) 13 211 (459) 7.3 % 978.00 [ 544.71, 1411.29 ]
Subtotal (95% CI) 15 13 7.3 % 978.00 [ 544.71, 1411.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
2 More than 3 to 7 mg Fe/g dw (10/35)
Cappellini 2005b 73 833 (817) 77 32 (585) 26.4 % 801.00 [ 572.53, 1029.47 ]
Subtotal (95% CI) 73 77 26.4 % 801.00 [ 572.53, 1029.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.87 (P < 0.00001)
3 More than 7 mg Fe/g dw (20/41)
-1000 -500 0 500 1000
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cappellini 2005b 80 -36 (721) 89 -364 (614) 33.4 % 328.00 [ 124.94, 531.06 ]
Subtotal (95% CI) 80 89 33.4 % 328.00 [ 124.94, 531.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
4 More than 14 mg Fe/g dw (30/51)
Cappellini 2005b 115 -926 (1416) 101 -1003 (1428) 9.5 % 77.00 [ -303.18, 457.18 ]
Subtotal (95% CI) 115 101 9.5 % 77.00 [ -303.18, 457.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
5 Any iron overload
Elalfy 2015a 15 1507.33 (982.09) 30 1172.67 (590.34) 4.7 % 334.66 [ -205.37, 874.69 ]
Hassan 2016 30 -1444 (2403.6) 30 -1003 (1669.54) 1.3 % -441.00 [ -1488.23, 606.23 ]
Molavi 2013 69 -591.76 (903.87) 69 -527.6 (835.72) 16.3 % -64.16 [ -354.62, 226.30 ]
Peng 2013 12 4236.25 (7793.31) 12 -2697.25 (3054.45) 0.1 % 6933.50 [ 2197.53, 11669.47 ]
Pennell 2014 91 2797.25 (4948.95) 81 -1830.25 (2143.24) 1.1 % 4627.50 [ 3508.68, 5746.32 ]
Subtotal (95% CI) 217 222 23.4 % 234.25 [ -8.02, 476.52 ]
Heterogeneity: Chi2 = 72.70, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 500 502 100.0 % 454.42 [ 337.13, 571.71 ]
Heterogeneity: Chi2 = 95.60, df = 8 (P<0.00001); I2 =92%
Test for overall effect: Z = 7.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 22.90, df = 4 (P = 0.00), I2 =83%
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Analysis 2.11. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 11
Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)
Cappellini 2005b 15 1189 (700) 13 211 (459) 7.9 % 978.00 [ 544.71, 1411.29 ]
Subtotal (95% CI) 15 13 7.9 % 978.00 [ 544.71, 1411.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
2 More than 3 to 7 mg Fe/g dw (10/35)
Cappellini 2005b 73 833 (817) 77 32 (585) 28.4 % 801.00 [ 572.53, 1029.47 ]
Subtotal (95% CI) 73 77 28.4 % 801.00 [ 572.53, 1029.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.87 (P < 0.00001)
3 More than 7 mg Fe/g dw (20/41)
Cappellini 2005b 80 -36 (721) 89 -364 (614) 35.9 % 328.00 [ 124.94, 531.06 ]
Subtotal (95% CI) 80 89 35.9 % 328.00 [ 124.94, 531.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
4 More than 14 mg Fe/g dw (30/51)
Cappellini 2005b 115 -926 (1416) 101 -1003 (1428) 10.2 % 77.00 [ -303.18, 457.18 ]
Subtotal (95% CI) 115 101 10.2 % 77.00 [ -303.18, 457.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
5 Any iron overload
Molavi 2013 69 -591.76 (903.87) 69 -527.6 (835.72) 17.6 % -64.16 [ -354.62, 226.30 ]
Subtotal (95% CI) 69 69 17.6 % -64.16 [ -354.62, 226.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 352 349 100.0 % 418.94 [ 297.23, 540.65 ]
Heterogeneity: Chi2 = 31.64, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 6.75 (P < 0.00001)
Test for subgroup differences: Chi2 = 31.64, df = 4 (P = 0.00), I2 =87%
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Analysis 2.12. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 12
Liver R2* (Hz): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 12 Liver R2* (Hz): mean change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Peng 2013 12 -299.75 (419.88) 12 -509.25 (576.69) 209.50 [ -194.11, 613.11 ]
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Analysis 2.13. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 13
LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline
Study or subgroup Favours deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 -1.7 (2.54) 30 -1.4 (2.1) 84.0 % -0.30 [ -1.79, 1.19 ]
Pennell 2014 91 -8.9 (11.4) 81 -12.7 (11.4) 16.0 % 3.80 [ 0.39, 7.21 ]
Total (95% CI) 106 111 100.0 % 0.36 [ -1.01, 1.72 ]
Heterogeneity: Chi2 = 4.66, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 14
LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 LIC 3 mg Fe/g dw or less (5/30)
Cappellini 2005b 15 4.8 (3.77) 13 0.5 (1.11) 12.2 % 4.30 [ 2.30, 6.30 ]
Subtotal (95% CI) 15 13 12.2 % 4.30 [ 2.30, 6.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000025)
2 LIC more than 3 mg to 7 mg (10/35) Fe/g dw
Cappellini 2005b 68 3.8 (3.85) 75 0 (2.36) 43.4 % 3.80 [ 2.74, 4.86 ]
Subtotal (95% CI) 68 75 43.4 % 3.80 [ 2.74, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.03 (P < 0.00001)
3 LIC more than 7 mg to 14 mg Fe/g dw (20/41)
Cappellini 2005b 77 -0.4 (4.7) 87 -1.9 (2.93) 32.9 % 1.50 [ 0.28, 2.72 ]
Subtotal (95% CI) 77 87 32.9 % 1.50 [ 0.28, 2.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
4 LIC more than 14 mg Fe/g dw (30/51)
Cappellini 2005b 108 -8.9 (8.07) 98 -6.4 (6.93) 11.6 % -2.50 [ -4.55, -0.45 ]
Subtotal (95% CI) 108 98 11.6 % -2.50 [ -4.55, -0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
Total (95% CI) 268 273 100.0 % 2.37 [ 1.68, 3.07 ]
Heterogeneity: Chi2 = 34.23, df = 3 (P<0.00001); I2 =91%
Test for overall effect: Z = 6.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 34.23, df = 3 (P = 0.00), I2 =91%
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Analysis 2.15. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 15
Responder analysis I (responder: fall in LIC > 10%).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 15 Responder analysis I (responder: fall in LIC > 10%)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Response at 48 weeks (deferasirox 10 mg/kg/day)
Piga 2002 11/24 8/11 0.63 [ 0.36, 1.11 ]
2 Response at 48 weeks (deferasirox 20 mg/kg/day)
Piga 2002 16/22 8/10 0.91 [ 0.61, 1.36 ]
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Analysis 2.16. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 16
Responder analysis II (responder: LIC 1 to < 7 mg Fe/g dw).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 16 Responder analysis II (responder: LIC 1 to < 7 mg Fe/g dw)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Response at 1 year (LIC below 7 mg Fe/g dw)
Cappellini 2005b 34/85 72/87 38.8 % 0.48 [ 0.37, 0.64 ]
Subtotal (95% CI) 85 87 38.8 % 0.48 [ 0.37, 0.64 ]
Total events: 34 (Deferasirox), 72 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 5.14 (P < 0.00001)
2 Response at 1 year (LIC at least 7 mg Fe/g dw)
Cappellini 2005b 112/191 112/190 61.2 % 0.99 [ 0.84, 1.18 ]
Subtotal (95% CI) 191 190 61.2 % 0.99 [ 0.84, 1.18 ]
Total events: 112 (Deferasirox), 112 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 276 277 100.0 % 0.80 [ 0.69, 0.92 ]
Total events: 146 (Deferasirox), 184 (Deferoxamine)
Heterogeneity: Chi2 = 19.17, df = 1 (P = 0.00001); I2 =95%
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Chi2 = 19.01, df = 1 (P = 0.00), I2 =95%
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Analysis 2.17. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 17
Myocardial T2* (ms): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 17 Myocardial T2* (ms): mean change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 2.1 (6.75) 30 2.13 (4.61) -0.03 [ -3.82, 3.76 ]
-4 -2 0 2 4
Favours deferoxamine Favours deferasirox
Analysis 2.18. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 18
Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All participants
Pennell 2014 91 -0.24 (0.7) 81 -0.15 (0.5) -0.09 [ -0.27, 0.09 ]
2 Participants with T2* <10 ms
Pennell 2014 31 -0.4 (0.9) 25 -0.3 (0.7) -0.10 [ -0.52, 0.32 ]
3 Participants with T2*≥10 ms
Pennell 2014 60 -0.2 (0.6) 56 -0.1 (0.4) -0.10 [ -0.28, 0.08 ]
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Analysis 2.19. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 19
Myocardial T2* (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 19 Myocardial T2* (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Normalization
Pennell 2014 16/91 5/81 2.85 [ 1.09, 7.43 ]
2 Improvement (from 6 - < 10 ms to 10 -≤ 20 ms)
Pennell 2014 11/31 5/25 1.77 [ 0.71, 4.44 ]
3 Worsening (from 10-≤ 20 ms to 6 - < 10 ms)
Pennell 2014 4/60 3/56 1.24 [ 0.29, 5.32 ]
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Analysis 2.20. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 20
Iron excretion-intake ratio.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 20 Iron excretion-intake ratio
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)
Cappellini 2005b 15 0.58 (0.328) 13 0.95 (0.101) 12.6 % -0.37 [ -0.54, -0.20 ]
Subtotal (95% CI) 15 13 12.6 % -0.37 [ -0.54, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000034)
2 More than 3 to 7 mg Fe/g dw (10/35)
Cappellini 2005b 68 0.67 (0.365) 75 0.98 (0.217) 38.7 % -0.31 [ -0.41, -0.21 ]
Subtotal (95% CI) 68 75 38.7 % -0.31 [ -0.41, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.09 (P < 0.00001)
3 More than 7 mg Fe/g dw (20/41)
Cappellini 2005b 77 1.02 (0.398) 87 1.13 (0.241) 36.7 % -0.11 [ -0.21, -0.01 ]
Subtotal (95% CI) 77 87 36.7 % -0.11 [ -0.21, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
4 More than 14 mg Fe/g dw (30/51)
Cappellini 2005b 108 1.67 (0.716) 98 1.44 (0.596) 12.0 % 0.23 [ 0.05, 0.41 ]
Subtotal (95% CI) 108 98 12.0 % 0.23 [ 0.05, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Total (95% CI) 268 273 100.0 % -0.18 [ -0.24, -0.12 ]
Heterogeneity: Chi2 = 32.95, df = 3 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 32.95, df = 3 (P = 0.00), I2 =91%
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Analysis 2.21. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 21
Any serious AEs (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 21 Any serious AEs (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cappellini 2005b 2/296 3/290 22.8 % 0.65 [ 0.11, 3.88 ]
Pennell 2014 10/96 10/91 77.2 % 0.95 [ 0.41, 2.17 ]
Total (95% CI) 392 381 100.0 % 0.88 [ 0.42, 1.86 ]
Total events: 12 (Deferasirox), 13 (Deferoxamine)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 22
Serious AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 22 Serious AEs
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cardiac disorders - arrhythmia
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
2 Endocrine disorders - hypogonadism
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
3 GI disorders abdominal abscess
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
4 GI disorders amoebiasis
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
5 GI disorders - appendicitis
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
6 GI disorders - colitis
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
7 GI disorders - diarrhoea
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
8 GI disorders - gastric haemorrhage
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
9 GI disorders - gastroenteritis
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
10 GI disorders - ileus
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
11 GI disorders - upper abdominal pain
Pennell 2014 1/96 1/91 0.95 [ 0.06, 14.93 ]
12 GI disorders - vomiting
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
13 GI disorders - GI infection
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
14 General disorders and administration site conditions - pyrexia
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
15 General disorders and administration site conditions - local swelling
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
16 Hepatobiliary disorders - liver abscess
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
17 Hepatobiliary disorders - cholelithiasis
Pennell 2014 1/96 1/91 0.95 [ 0.06, 14.93 ]
18 Immune system disorders - face oedema
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
19 Infections and infestations - herpes zoster
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
20 Infections and infestations - tooth infection
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
21 Infections and infestations - urinary tract infection
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
22 Injury, poisoning and procedural complications - oesophageal rupture
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
23 Injury, poisoning and procedural complications - haemosiderosis
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
24 Injury, poisoning and procedural complications - iron overload
Pennell 2014 0/96 2/91 0.19 [ 0.01, 3.90 ]
25 Metabolism and nutrition disorders - hyperglycaemia
Pennell 2014 1/96 1/91 0.95 [ 0.06, 14.93 ]
26 Musculoskeletal and connective tissue disorders - back pain
Pennell 2014 1/96 0/91 2.85 [ 0.12, 68.96 ]
27 Musculoskeletal and connective tissue disorders - pain in jaw
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
28 Nervous system disorders - grand mal convulsion
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
29 Nervous system disorders - meningitis
Pennell 2014 0/96 1/91 0.32 [ 0.01, 7.66 ]
30 Respiratory, thoracic and mediastinal disorders - acute tonsilitis
Pennell 2014 1/96 1/91 0.95 [ 0.06, 14.93 ]
0.002 0.1 1 10 500
Favours deferasirox Favours deferoxamine
136Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.23. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 23
Any AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 23 Any AE (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 65/96 69/91 71.4 % 0.89 [ 0.75, 1.07 ]
Piga 2002 47/48 21/23 28.6 % 1.07 [ 0.94, 1.22 ]
Total (95% CI) 144 114 100.0 % 0.94 [ 0.83, 1.08 ]
Total events: 112 (Deferasirox), 90 (Deferoxamine)
Heterogeneity: Chi2 = 3.90, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 2.24. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 24
AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 24 AEs
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blood and lymphatic system disorder - agranulocytosis
Cappellini 2005b 0/296 0/290 Not estimable
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 344 313 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Blood and lymphatic system disorder - leukopenia
Molavi 2013 3/69 0/69 100.0 % 7.00 [ 0.37, 133.02 ]
Subtotal (95% CI) 69 69 100.0 % 7.00 [ 0.37, 133.02 ]
Total events: 3 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
3 Blood and lymphatic system disorder - neutropenia
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 48 23 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Blood and lymphatic system disorder - thrombocytopenia
Molavi 2013 4/69 1/69 100.0 % 4.00 [ 0.46, 34.88 ]
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 117 92 100.0 % 4.00 [ 0.46, 34.88 ]
Total events: 4 (Deferasirox), 1 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
5 Cardiac disorders - cardiac AE
Cappellini 2005b 15/296 20/290 100.0 % 0.73 [ 0.38, 1.41 ]
Subtotal (95% CI) 296 290 100.0 % 0.73 [ 0.38, 1.41 ]
Total events: 15 (Deferasirox), 20 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
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Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Ear and labyrinth disorders - hearing loss
Cappellini 2005b 8/296 7/290 100.0 % 1.12 [ 0.41, 3.05 ]
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 344 313 100.0 % 1.12 [ 0.41, 3.05 ]
Total events: 8 (Deferasirox), 7 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
7 Eye disorder - lens abnormality
Cappellini 2005b 2/296 5/290 100.0 % 0.39 [ 0.08, 2.00 ]
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 344 313 100.0 % 0.39 [ 0.08, 2.00 ]
Total events: 2 (Deferasirox), 5 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
8 Eye disorder - retinal abnormality
Piga 2002 0/48 0/23 Not estimable
Subtotal (95% CI) 48 23 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 GI disorders - abdominal pain
Pennell 2014 7/96 2/91 16.0 % 3.32 [ 0.71, 15.55 ]
Piga 2002 23/48 8/23 84.0 % 1.38 [ 0.73, 2.59 ]
Subtotal (95% CI) 144 114 100.0 % 1.69 [ 0.93, 3.05 ]
Total events: 30 (Deferasirox), 10 (Deferoxamine)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 1.73 (P = 0.083)
10 GI disorders - abdominal pain upper
Pennell 2014 6/96 5/91 100.0 % 1.14 [ 0.36, 3.60 ]
Subtotal (95% CI) 96 91 100.0 % 1.14 [ 0.36, 3.60 ]
Total events: 6 (Deferasirox), 5 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
11 GI disorders - diarrhoea
Pennell 2014 12/96 4/91 33.6 % 2.84 [ 0.95, 8.50 ]
Piga 2002 13/48 6/23 66.4 % 1.04 [ 0.45, 2.38 ]
Subtotal (95% CI) 144 114 100.0 % 1.65 [ 0.86, 3.16 ]
Total events: 25 (Deferasirox), 10 (Deferoxamine)
Heterogeneity: Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 1.50 (P = 0.13)
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Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
12 GI disorders - dyspepsia
Piga 2002 5/48 2/23 100.0 % 1.20 [ 0.25, 5.72 ]
Subtotal (95% CI) 48 23 100.0 % 1.20 [ 0.25, 5.72 ]
Total events: 5 (Deferasirox), 2 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
13 GI disorders - GIT upset
Hassan 2016 6/30 2/30 100.0 % 3.00 [ 0.66, 13.69 ]
Subtotal (95% CI) 30 30 100.0 % 3.00 [ 0.66, 13.69 ]
Total events: 6 (Deferasirox), 2 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
14 GI disorders - nausea
Pennell 2014 6/96 2/91 43.2 % 2.84 [ 0.59, 13.73 ]
Piga 2002 10/48 2/23 56.8 % 2.40 [ 0.57, 10.06 ]
Subtotal (95% CI) 144 114 100.0 % 2.59 [ 0.90, 7.47 ]
Total events: 16 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
15 GI disorders - vomiting
Pennell 2014 6/96 1/91 27.5 % 5.69 [ 0.70, 46.33 ]
Piga 2002 8/48 2/23 72.5 % 1.92 [ 0.44, 8.32 ]
Subtotal (95% CI) 144 114 100.0 % 2.95 [ 0.91, 9.55 ]
Total events: 14 (Deferasirox), 3 (Deferoxamine)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
16 General disorders and administration site conditions - asthenia
Piga 2002 10/48 4/23 100.0 % 1.20 [ 0.42, 3.42 ]
Subtotal (95% CI) 48 23 100.0 % 1.20 [ 0.42, 3.42 ]
Total events: 10 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
17 General disorders and administration site conditions - influenza-like illness
Piga 2002 10/48 4/23 100.0 % 1.20 [ 0.42, 3.42 ]
Subtotal (95% CI) 48 23 100.0 % 1.20 [ 0.42, 3.42 ]
Total events: 10 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
18 General disorders and administration site conditions - pyrexia
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Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 6/96 5/91 38.8 % 1.14 [ 0.36, 3.60 ]
Piga 2002 17/48 6/23 61.2 % 1.36 [ 0.62, 2.98 ]
Subtotal (95% CI) 144 114 100.0 % 1.27 [ 0.66, 2.44 ]
Total events: 23 (Deferasirox), 11 (Deferoxamine)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
19 Immune system disorders - allergic conjunctivitis
Piga 2002 4/48 0/23 100.0 % 4.41 [ 0.25, 78.58 ]
Subtotal (95% CI) 48 23 100.0 % 4.41 [ 0.25, 78.58 ]
Total events: 4 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
20 Infections and infestations - bronchitis
Piga 2002 5/48 1/23 100.0 % 2.40 [ 0.30, 19.35 ]
Subtotal (95% CI) 48 23 100.0 % 2.40 [ 0.30, 19.35 ]
Total events: 5 (Deferasirox), 1 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
21 Infections and infestations - upper respiratory tract infection
Pennell 2014 8/96 8/91 100.0 % 0.95 [ 0.37, 2.42 ]
Subtotal (95% CI) 96 91 100.0 % 0.95 [ 0.37, 2.42 ]
Total events: 8 (Deferasirox), 8 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
22 Infections and infestations - urinary tract infection
Piga 2002 5/48 1/23 100.0 % 2.40 [ 0.30, 19.35 ]
Subtotal (95% CI) 48 23 100.0 % 2.40 [ 0.30, 19.35 ]
Total events: 5 (Deferasirox), 1 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
23 Investigations - ALT increased
Pennell 2014 9/96 5/91 100.0 % 1.71 [ 0.59, 4.90 ]
Subtotal (95% CI) 96 91 100.0 % 1.71 [ 0.59, 4.90 ]
Total events: 9 (Deferasirox), 5 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
24 Investigations - elevated ALT (>2 UNL)
Cappellini 2005b 2/296 0/290 100.0 % 4.90 [ 0.24, 101.60 ]
Subtotal (95% CI) 296 290 100.0 % 4.90 [ 0.24, 101.60 ]
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Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 2 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
25 Investigations - AST increased
Pennell 2014 7/96 3/91 100.0 % 2.21 [ 0.59, 8.29 ]
Subtotal (95% CI) 96 91 100.0 % 2.21 [ 0.59, 8.29 ]
Total events: 7 (Deferasirox), 3 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
26 Investigations - blood creatinine increased
Pennell 2014 8/96 2/91 100.0 % 3.79 [ 0.83, 17.38 ]
Subtotal (95% CI) 96 91 100.0 % 3.79 [ 0.83, 17.38 ]
Total events: 8 (Deferasirox), 2 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
27 Investigations - isolated serum creatinine increase above upper limit of normal
Cappellini 2005b 112/296 41/290 93.9 % 2.68 [ 1.95, 3.68 ]
Piga 2002 4/48 2/23 6.1 % 0.96 [ 0.19, 4.86 ]
Subtotal (95% CI) 344 313 100.0 % 2.57 [ 1.88, 3.51 ]
Total events: 116 (Deferasirox), 43 (Deferoxamine)
Heterogeneity: Chi2 = 1.48, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 5.94 (P < 0.00001)
28 Investigations - platelet count increased
Pennell 2014 2/96 5/91 100.0 % 0.38 [ 0.08, 1.91 ]
Subtotal (95% CI) 96 91 100.0 % 0.38 [ 0.08, 1.91 ]
Total events: 2 (Deferasirox), 5 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
29 Musculoskeletal and connective tissue disorders - arthralgia
Pennell 2014 7/96 4/91 50.3 % 1.66 [ 0.50, 5.48 ]
Piga 2002 6/48 3/23 49.7 % 0.96 [ 0.26, 3.49 ]
Subtotal (95% CI) 144 114 100.0 % 1.31 [ 0.55, 3.13 ]
Total events: 13 (Deferasirox), 7 (Deferoxamine)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
30 Musculoskeletal and connective tissue disorders - back pain
Pennell 2014 8/96 4/91 27.5 % 1.90 [ 0.59, 6.08 ]
Piga 2002 18/48 8/23 72.5 % 1.08 [ 0.55, 2.10 ]
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Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 144 114 100.0 % 1.30 [ 0.73, 2.34 ]
Total events: 26 (Deferasirox), 12 (Deferoxamine)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
31 Musculoskeletal and connective tissue disorders - osteoporosis
Pennell 2014 5/96 2/91 100.0 % 2.37 [ 0.47, 11.91 ]
Subtotal (95% CI) 96 91 100.0 % 2.37 [ 0.47, 11.91 ]
Total events: 5 (Deferasirox), 2 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
32 Nervous system disorders - headache
Pennell 2014 5/96 5/91 48.7 % 0.95 [ 0.28, 3.17 ]
Piga 2002 16/48 4/23 51.3 % 1.92 [ 0.72, 5.09 ]
Subtotal (95% CI) 144 114 100.0 % 1.44 [ 0.68, 3.05 ]
Total events: 21 (Deferasirox), 9 (Deferoxamine)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.33)
33 Nervous system disorders - vertigo
Piga 2002 7/48 3/23 100.0 % 1.12 [ 0.32, 3.93 ]
Subtotal (95% CI) 48 23 100.0 % 1.12 [ 0.32, 3.93 ]
Total events: 7 (Deferasirox), 3 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
34 Renal and urinary disorders - proteinuria
Pennell 2014 11/96 9/91 100.0 % 1.16 [ 0.50, 2.66 ]
Subtotal (95% CI) 96 91 100.0 % 1.16 [ 0.50, 2.66 ]
Total events: 11 (Deferasirox), 9 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
35 Respiratory, thoracic and mediastinal disorders - cough
Piga 2002 15/48 4/23 100.0 % 1.80 [ 0.67, 4.81 ]
Subtotal (95% CI) 48 23 100.0 % 1.80 [ 0.67, 4.81 ]
Total events: 15 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
36 Respiratory, thoracic and mediastinal disorders - influenza
Pennell 2014 10/96 6/91 47.7 % 1.58 [ 0.60, 4.17 ]
Piga 2002 6/48 5/23 52.3 % 0.58 [ 0.20, 1.69 ]
Subtotal (95% CI) 144 114 100.0 % 1.05 [ 0.52, 2.13 ]
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 16 (Deferasirox), 11 (Deferoxamine)
Heterogeneity: Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.15 (P = 0.88)
37 Respiratory, thoracic and mediastinal disorders - nasopharyngitis
Pennell 2014 8/96 4/91 100.0 % 1.90 [ 0.59, 6.08 ]
Subtotal (95% CI) 96 91 100.0 % 1.90 [ 0.59, 6.08 ]
Total events: 8 (Deferasirox), 4 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
38 Respiratory, thoracic and mediastinal disorders - oropharyngeal pain
Pennell 2014 6/96 2/91 100.0 % 2.84 [ 0.59, 13.73 ]
Subtotal (95% CI) 96 91 100.0 % 2.84 [ 0.59, 13.73 ]
Total events: 6 (Deferasirox), 2 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
39 Respiratory, thoracic and mediastinal disorders - pharyngitis
Piga 2002 17/48 8/23 100.0 % 1.02 [ 0.52, 2.00 ]
Subtotal (95% CI) 48 23 100.0 % 1.02 [ 0.52, 2.00 ]
Total events: 17 (Deferasirox), 8 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
40 Respiratory, thoracic and mediastinal disorders - pharyngolaryngeal pain
Piga 2002 11/48 6/23 100.0 % 0.88 [ 0.37, 2.08 ]
Subtotal (95% CI) 48 23 100.0 % 0.88 [ 0.37, 2.08 ]
Total events: 11 (Deferasirox), 6 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
41 Respiratory, thoracic and mediastinal disorders - rhinitis
Piga 2002 16/48 6/23 100.0 % 1.28 [ 0.58, 2.83 ]
Subtotal (95% CI) 48 23 100.0 % 1.28 [ 0.58, 2.83 ]
Total events: 16 (Deferasirox), 6 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
42 Skin and subcutaneous tissue disorders - Rash
Hassan 2016 8/30 3/30 100.0 % 2.67 [ 0.78, 9.09 ]
Subtotal (95% CI) 30 30 100.0 % 2.67 [ 0.78, 9.09 ]
Total events: 8 (Deferasirox), 3 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 2.25. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 25
Any drug-related AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 25 Any drug-related AE (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 34/96 28/91 1.15 [ 0.76, 1.73 ]
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Analysis 2.26. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 26
Drug-related AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 26 Drug-related AEs
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blood and lymphatic system disorder - neutropenia
Hassan 2016 0/30 0/30 Not estimable
2 Injury, poisoning and procedural complications - infusion site haemorrhage
Pennell 2014 0/96 2/91 0.19 [ 0.01, 3.90 ]
3 Injury, poisoning and procedural complications - infusion site pain
Pennell 2014 0/96 3/91 0.14 [ 0.01, 2.59 ]
4 Injury, poisoning and procedural complications - infusion site swelling
Pennell 2014 0/96 3/91 0.14 [ 0.01, 2.59 ]
5 Injury, poisoning and procedural complications - injection site pain
Pennell 2014 0/96 2/91 0.19 [ 0.01, 3.90 ]
6 Injury, poisoning and procedural complications - injection site reaction
Pennell 2014 0/96 2/91 0.19 [ 0.01, 3.90 ]
7 Investigations - blood creatinine increased
Pennell 2014 8/96 2/91 3.79 [ 0.83, 17.38 ]
8 Investigations - ALT increased
Pennell 2014 6/96 1/91 5.69 [ 0.70, 46.33 ]
9 Investigations - AST increased
Pennell 2014 6/96 1/91 5.69 [ 0.70, 46.33 ]
10 GI disorders - abdominal pain
Pennell 2014 3/96 0/91 6.64 [ 0.35, 126.78 ]
11 GI disorders - abdominal pain upper
Pennell 2014 4/96 1/91 3.79 [ 0.43, 33.29 ]
12 GI disorders - diarrhoea
Pennell 2014 6/96 1/91 5.69 [ 0.70, 46.33 ]
13 GI disorders - nausea
Pennell 2014 3/96 0/91 6.64 [ 0.35, 126.78 ]
14 GI disorders - vomiting
Pennell 2014 3/96 0/91 6.64 [ 0.35, 126.78 ]
15 Immune system disorders - hypersensitivity
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 0/96 2/91 0.19 [ 0.01, 3.90 ]
16 Immune system disorders - urticaria
Pennell 2014 1/96 2/91 0.47 [ 0.04, 5.14 ]
17 Musculoskeletal and connective tissue disorders - arthropathy
Hassan 2016 0/30 0/30 Not estimable
18 Renal and urinary disorders - proteinuria
Pennell 2014 7/96 3/91 2.21 [ 0.59, 8.29 ]
19 Skin and subcutaneous tissue disorders - alopecia
Pennell 2014 2/96 0/91 4.74 [ 0.23, 97.46 ]
20 Skin and subcutaneous tissue disorders - rash
Pennell 2014 3/96 0/30 2.24 [ 0.12, 42.13 ]
21 Injury, poisoning and procedural complications - pulmonary toxicity
Hassan 2016 0/30 0/30 Not estimable
22 Eye disorders - Ophthalmological toxicity
Hassan 2016 0/30 0/30 Not estimable
23 Ear and labyrinth disorders - Audiological toxicity
Hassan 2016 0/30 0/30 Not estimable
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Analysis 2.27. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 27
Satisfaction with treatment (very satisfied or satisfied).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 27 Satisfaction with treatment (very satisfied or satisfied)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Week 4 - participants previously treated with DFO
Cappellini 2005b 266/289 142/281 1.82 [ 1.61, 2.05 ]
2 Week 24 - participants previously treated with DFO
Cappellini 2005b 259/283 124/277 2.04 [ 1.79, 2.34 ]
3 End of study (1 year) - participants previously treated with DFO
Cappellini 2005b 246/289 109/282 2.20 [ 1.89, 2.57 ]
4 Week 4 - DFO-naive participants
Cappellini 2005b 4/7 4/8 1.14 [ 0.44, 2.94 ]
5 Week 24 - DFO-naive participants
Cappellini 2005b 7/7 3/8 2.41 [ 1.04, 5.57 ]
6 End of study (1 year) - DFO-naive participants
Cappellini 2005b 7/7 4/8 1.88 [ 0.95, 3.69 ]
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Analysis 2.28. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 28
Convenience (good or very good).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 28 Convenience (good or very good)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Week 4 - participants previously treated with DFO
Cappellini 2005b 276/289 60/281 4.47 [ 3.57, 5.61 ]
2 Week 24 - participants previously treated with DFO
Cappellini 2005b 265/283 49/277 5.29 [ 4.10, 6.84 ]
3 End of study (1 year) - participants previously treated with DFO
Cappellini 2005b 268/289 32/282 8.17 [ 5.89, 11.34 ]
4 Week 4 - DFO-naive participants
Cappellini 2005b 5/7 2/8 2.86 [ 0.79, 10.36 ]
5 Week 24 - DFO-naive participants
Cappellini 2005b 7/7 0/8 16.88 [ 1.13, 251.01 ]
6 End of study (1 year) - DFO-naive participants
Cappellini 2005b 7/7 1/8 5.63 [ 1.29, 24.51 ]
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Analysis 2.29. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 29
Willingness to continue treatment.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 29 Willingness to continue treatment
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants treated previously with DFO
Cappellini 2005b 246/289 38/282 6.32 [ 4.68, 8.52 ]
2 DFO-naive participants
Cappellini 2005b 7/7 4/8 1.88 [ 0.95, 3.69 ]
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Analysis 2.30. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 30
Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 week 4 - patients treated previously with DFO
Cappellini 2005b 287 1.9 (8.4) 277 11.1 (23) -9.20 [ -12.08, -6.32 ]
2 week 24 - patients treated previously with DFO
Cappellini 2005b 287 1.5 (6) 277 11.7 (28.5) -10.20 [ -13.63, -6.77 ]
3 end of study (1 year) - patients treated previously with DFO
Cappellini 2005b 287 2.8 (16.8) 277 11.2 (21.8) -8.40 [ -11.62, -5.18 ]
4 week 4 - DFO-naive patients
Cappellini 2005b 7 1.3 (3.3) 8 3.1 (5.9) -1.80 [ -6.56, 2.96 ]
5 week 24 - DFO-naive patients
Cappellini 2005b 7 0 (0) 8 7 (12.6) Not estimable
6 end of study (1 year) - DFO-naive patients
Cappellini 2005b 7 0.6 (1.5) 8 6 (6) -5.40 [ -9.70, -1.10 ]
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Analysis 2.31. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 31
Adherence (% of planned dose).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 31 Adherence (% of planned dose)
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pennell 2014 96 99 (3.5) 91 100.4 (10.9) -1.40 [ -3.75, 0.95 ]
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Analysis 2.32. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 32
Discontinuations.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 32 Discontinuations
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 10 mg/kg/day
Piga 2002 0/24 1/11 5.9 % 0.16 [ 0.01, 3.64 ]
Subtotal (95% CI) 24 11 5.9 % 0.16 [ 0.01, 3.64 ]
Total events: 0 (Deferasirox), 1 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
2 Deferasirox 20 mg/kg/day
Molavi 2013 0/69 0/69 Not estimable
Piga 2002 2/24 1/12 3.9 % 1.00 [ 0.10, 9.96 ]
Subtotal (95% CI) 93 81 3.9 % 1.00 [ 0.10, 9.96 ]
Total events: 2 (Deferasirox), 1 (Deferoxamine)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.0 (P = 1.0)
3 Deferasirox 25 mg/kg/day
Elalfy 2015a 0/60 5/60 16.0 % 0.09 [ 0.01, 1.61 ]
Subtotal (95% CI) 60 60 16.0 % 0.09 [ 0.01, 1.61 ]
Total events: 0 (Deferasirox), 5 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
4 Deferasirox 40 mg/kg/day
Peng 2013 0/12 0/12 Not estimable
Pennell 2014 14/96 13/91 38.9 % 1.02 [ 0.51, 2.05 ]
Subtotal (95% CI) 108 103 38.9 % 1.02 [ 0.51, 2.05 ]
Total events: 14 (Deferasirox), 13 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
5 Deferasirox - variable dosage
Cappellini 2005b 17/296 12/290 35.3 % 1.39 [ 0.67, 2.85 ]
Hassan 2016 0/30 0/30 Not estimable
Subtotal (95% CI) 326 320 35.3 % 1.39 [ 0.67, 2.85 ]
Total events: 17 (Deferasirox), 12 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
6 Deferasirox dosing unknown
Chirico 2013 0/12 0/13 Not estimable
Subtotal (95% CI) 12 13 Not estimable
Total events: 0 (Deferasirox), 0 (Deferoxamine)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 623 588 100.0 % 0.95 [ 0.60, 1.50 ]
Total events: 33 (Deferasirox), 32 (Deferoxamine)
Heterogeneity: Chi2 = 4.92, df = 4 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 4.76, df = 4 (P = 0.31), I2 =16%
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Analysis 2.33. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 33
Dose adjustments and dose interruptions.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 33 Dose adjustments and dose interruptions
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cappellini 2005b 109/296 96/290 1.11 [ 0.89, 1.39 ]
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Analysis 2.34. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 34
Dose interruptions (interrupted at least once).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 34 Dose interruptions (interrupted at least once)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 18/96 16/91 1.07 [ 0.58, 1.96 ]
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Analysis 2.35. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 35
Dose reduction (at least once).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 35 Dose reduction (at least once)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pennell 2014 15/96 18/91 0.79 [ 0.42, 1.47 ]
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Analysis 2.36. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 36
Dose adjustments (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 36 Dose adjustments (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Piga 2002 27/48 4/23 3.23 [ 1.28, 8.16 ]
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Analysis 2.37. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 37
Dose interruptions due to an AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 37 Dose interruptions due to an AE (# participants affected)
Study or subgroup Deferasirox Deferoxamine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Piga 2002 16/48 5/23 1.53 [ 0.64, 3.67 ]
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Analysis 2.38. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 38
Haemoglobin (g/dL): mean change from baseline and at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 38 Haemoglobin (g/dL): mean change from baseline and at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 8 months (change from baseline)
Molavi 2013 69 -0.71 (1.24) 69 -0.25 (0.83) 76.3 % -0.46 [ -0.81, -0.11 ]
Subtotal (95% CI) 69 69 76.3 % -0.46 [ -0.81, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
2 At 1 year (at end of study)
Elalfy 2015a 15 7.8 (1) 27 8.5 (1) 23.7 % -0.70 [ -1.33, -0.07 ]
Subtotal (95% CI) 15 27 23.7 % -0.70 [ -1.33, -0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Total (95% CI) 84 96 100.0 % -0.52 [ -0.82, -0.21 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00098)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
-1 -0.5 0 0.5 1
Favours deferoxamine Favours deferasirox
156Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.39. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 39
Transfusion index (mL/kg/year): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 39 Transfusion index (mL/kg/year): mean at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 219.6 (55.6) 27 203.5 (61.3) 16.10 [ -20.32, 52.52 ]
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Analysis 2.40. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 40
Transferrin saturation (%): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 40 Transferrin saturation (%): mean at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 61.1 (9.9) 27 62.1 (5.5) -1.00 [ -6.42, 4.42 ]
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Analysis 2.41. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 41
Platelet count (x10³/mm³): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 41 Platelet count (x10 /mm ): mean at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 345 (52) 30 337 (44) 8.00 [ -16.38, 32.38 ]
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Analysis 2.42. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 42
Absolute neutrophilic count (/mm³): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine
Outcome: 42 Absolute neutrophilic count (/mm ): mean at end of study
Study or subgroup Deferasirox Deferoxamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hassan 2016 30 1980 (605) 30 2098 (554) -118.00 [ -411.55, 175.55 ]
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Analysis 3.1. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 1
Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 1 Mortality at any time point
Study or subgroup Deferasirox Deferiprone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 at 1 year
Elalfy 2015a 0/30 0/60 Not estimable
Sanjeeva 2015 0/19 0/19 Not estimable
Subtotal (95% CI) 49 79 Not estimable
Total events: 0 (Deferasirox), 0 (Deferiprone)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 at 2 years
Chirico 2013 0/6 0/12 Not estimable
Subtotal (95% CI) 6 12 Not estimable
Total events: 0 (Deferasirox), 0 (Deferiprone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 55 91 Not estimable
Total events: 0 (Deferasirox), 0 (Deferiprone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.2. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 2
Incidence of thyroid disease at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 2 Incidence of thyroid disease at end of study
Study or subgroup Deferasirox Deferiprone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chirico 2013 2/6 3/12 1.33 [ 0.30, 5.96 ]
0.01 0.1 1 10 100
Favours deferasirox Favours deferiprone
Analysis 3.3. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 3
ALT (U/L): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 3 ALT (U/L): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 31.79 (89.6297) 19 11.8 (49.3612) 19.99 [ -26.02, 66.00 ]
-100 -50 0 50 100
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Analysis 3.4. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 4
AST (U/L): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 4 AST (U/L): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 20.89 (77.5118) 19 18.79 (41.2789) 2.10 [ -37.39, 41.59 ]
-100 -50 0 50 100
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Analysis 3.5. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 5
Urea (mg/dL): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 5 Urea (mg/dL): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 0.8 (10.4896) 19 -5.16 (13.7041) 5.96 [ -1.80, 13.72 ]
-20 -10 0 10 20
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Analysis 3.6. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 6
Creatinine (mg/dL): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 6 Creatinine (mg/dL): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 -0.04 (0.2739) 19 0.02 (0.267) -0.06 [ -0.23, 0.11 ]
-1 -0.5 0 0.5 1
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Analysis 3.7. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 7
Neutrophil (count per mm³): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 7 Neutrophil (count per mm ): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 53 (2556.7145) 19 753 (2171.4133) -700.00 [ -2208.28, 808.28 ]
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Analysis 3.8. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 8
Serum ferritin (ng/mL): mean change from baseline and at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 8 Serum ferritin (ng/mL): mean change from baseline and at end of study
Study or subgroup Deferasirox Deferiprone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 All participants
Elalfy 2015a 15 1507.33 (982.09) 30 1340.67 (1277.26) 87.9 % 166.66 [ -508.55, 841.87 ]
Sanjeeva 2015 19 -1675 (2576.12) 19 -2366 (3127.21) 12.1 % 691.00 [ -1130.81, 2512.81 ]
Subtotal (95% CI) 34 49 100.0 % 229.99 [ -403.14, 863.11 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Ferritin > 4000
Sanjeeva 2015 5 -3827 (2853.8778) 6 -4956 (2794.4978) 100.0 % 1129.00 [ -2226.18, 4484.18 ]
Subtotal (95% CI) 5 6 100.0 % 1129.00 [ -2226.18, 4484.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 Ferritin 2000 - 4000
Sanjeeva 2015 7 -1556 (606.45) 9 -1405 (591.9941) 100.0 % -151.00 [ -743.80, 441.80 ]
Subtotal (95% CI) 7 9 100.0 % -151.00 [ -743.80, 441.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
4 Ferritin < 2000
Sanjeeva 2015 7 -258 (550.1409) 4 -646 (508.4463) 100.0 % 388.00 [ -255.71, 1031.71 ]
Subtotal (95% CI) 7 4 100.0 % 388.00 [ -255.71, 1031.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 3.9. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 9 LIC
(mg/g) evaluated by MRI (R2*): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 -1.7 (2.54) 30 -0.9 (4.09) -0.80 [ -2.75, 1.15 ]
-4 -2 0 2 4
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Analysis 3.10. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 10
Myocardial T2* (ms): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 10 Myocardial T2* (ms): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 2.1 (6.75) 30 2.6 (4.19) -0.50 [ -4.23, 3.23 ]
-10 -5 0 5 10
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Analysis 3.11. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 11
Any AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 11 Any AE (# participants affected)
Study or subgroup Deferasirox Deferiprone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sanjeeva 2015 7/19 15/22 0.54 [ 0.28, 1.04 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 3.12. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 12
AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 12 AEs
Study or subgroup Deferasirox Deferiprone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GI disorders - diarrhoea
Sanjeeva 2015 0/19 0/22 Not estimable
2 GI disorders - nausea
Sanjeeva 2015 6/19 6/22 1.16 [ 0.45, 3.00 ]
3 GI disorders - pain abdomen
Sanjeeva 2015 0/19 1/22 0.38 [ 0.02, 8.89 ]
4 GI disorders - vomiting
Sanjeeva 2015 6/19 6/22 1.16 [ 0.45, 3.00 ]
5 Musculoskeletal and connective tissue disorders - arthralgia
Sanjeeva 2015 1/19 9/22 0.13 [ 0.02, 0.93 ]
6 Skin and subcutaneous tissue disorders - rash
0.001 0.01 0.1 1 10 100 1000
Favours deferasirox Favours deferiprone
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(. . . Continued)
Study or subgroup Deferasirox Deferiprone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sanjeeva 2015 0/19 0/22 Not estimable
7 Blood and lymphatic system disorder - agranulocytosis
Sanjeeva 2015 0/19 0/19 Not estimable
8 Blood and lymphatic system disorder - neutropenia
Sanjeeva 2015 0/19 1/19 0.33 [ 0.01, 7.70 ]
9 Investigations - AST levels > 2x UNL
Sanjeeva 2015 4/19 4/19 1.00 [ 0.29, 3.43 ]
10 Investigations - ALT levels > 2x UNL
Sanjeeva 2015 4/19 3/19 1.33 [ 0.34, 5.17 ]
11 Investigations - serum creatinine 50% increase from baseline
Sanjeeva 2015 1/19 0/19 3.00 [ 0.13, 69.31 ]
12 Renal and urinary disorders - renal failure
Sanjeeva 2015 0/19 0/19 Not estimable
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Analysis 3.13. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 13
Discontinuations (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 13 Discontinuations (# participants affected)
Study or subgroup Deferasirox Deferiprone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chirico 2013 0/6 0/12 Not estimable
Elalfy 2015a 0/60 0/60 Not estimable
Sanjeeva 2015 0/19 3/22 100.0 % 0.16 [ 0.01, 2.99 ]
Total (95% CI) 85 94 100.0 % 0.16 [ 0.01, 2.99 ]
Total events: 0 (Deferasirox), 3 (Deferiprone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 14
Discontinuation due to an AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 14 Discontinuation due to an AE (# participants affected)
Study or subgroup Deferasirox Deferiprone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sanjeeva 2015 0/19 3/22 0.16 [ 0.01, 2.99 ]
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Analysis 3.15. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 15
Transferrin saturation (%): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 15 Transferrin saturation (%): mean at end of study
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 61.1 (9.9) 30 68.5 (8.6) -7.40 [ -13.28, -1.52 ]
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Analysis 3.16. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 16
Haemoglobin (g/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 16 Haemoglobin (g/dL): mean at end of study
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 7.8 (1) 30 8.2 (1.22) -0.40 [ -1.07, 0.27 ]
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Analysis 3.17. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 17
Transfusion index (mL/kg/year): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 17 Transfusion index (mL/kg/year): mean at end of study
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015a 15 219.6 (55.6) 30 218.9 (59.4) 0.70 [ -34.56, 35.96 ]
-100 -50 0 50 100
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Analysis 3.18. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 18
ALP (U/L): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone
Outcome: 18 ALP (U/L): mean change from baseline
Study or subgroup Deferasirox Deferiprone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sanjeeva 2015 19 -8 (97.329) 19 -8 (89.2832) 0.0 [ -59.39, 59.39 ]
-100 -50 0 50 100
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Analysis 6.1. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 1 Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 1 Mortality at any time point
Study or subgroup Deferasirox + DFO DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 at 12 months
Molavi 2014 0/46 0/48 Not estimable
0.01 0.1 1 10 100
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Analysis 6.2. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 2 Neutrophil (µg/L): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 2 Neutrophil ( g/L): mean at end of study
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 54.65 (8.94) 48 55.96 (8.94) -1.31 [ -4.93, 2.31 ]
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Analysis 6.3. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 3 ALT (g/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 3 ALT (g/dL): mean at end of study
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 61.6 (29.75) 48 54.58 (20.01) 7.02 [ -3.27, 17.31 ]
-10 -5 0 5 10
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Analysis 6.4. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 4 AST (g/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 4 AST (g/dL): mean at end of study
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 59.19 (21.02) 48 51.81 (18.63) 7.38 [ -0.66, 15.42 ]
-10 -5 0 5 10
Favours deferasirox + DFO Favours DFO
171Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.5. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 5 Serum ferritin: mean at end of study (ng/mL).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 5 Serum ferritin: mean at end of study (ng/mL)
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 3529.04 (1540.36) 48 3441.2 (1910) 87.84 [ -612.23, 787.91 ]
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Analysis 6.6. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 6 Discontinuations.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 6 Discontinuations
Study or subgroup Deferasirox + DFO DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Molavi 2014 0/46 0/48 Not estimable
0.01 0.1 1 10 100
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Analysis 6.7. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 7 Haemoglobin (g/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 7 Haemoglobin (g/dL): mean at end of study
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 9.1 (0.91) 48 9.46 (0.77) -0.36 [ -0.70, -0.02 ]
-0.5 -0.25 0 0.25 0.5
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Analysis 6.8. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs
deferoxamine, Outcome 8 ALP (g/dL): mean at end of study.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine
Outcome: 8 ALP (g/dL): mean at end of study
Study or subgroup Deferasirox + DFO DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Molavi 2014 46 431.78 (135.98) 48 334 (117.73) 97.78 [ 46.27, 149.29 ]
-200 -100 0 100 200
Favours deferasirox + DFO Favours DFO
173Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.1. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 1 Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 1 Mortality at any time point
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 at 12 months
Elalfy 2015b 0/48 0/48 Not estimable
0.01 0.1 1 10 100
Deferasirox + deferiprone Deferiprone + DFO
Analysis 7.2. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 2 Serum ferritin (ng/mL): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 2 Serum ferritin (ng/mL): mean change from baseline
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015b 48 -1069.21 (2110.52) 48 -753.31 (1486.96) -315.90 [ -1046.26, 414.46 ]
-1000 -500 0 500 1000
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Analysis 7.3. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015b 48 -2.35 (4.64) 48 -1.73 (3.41) -0.62 [ -2.25, 1.01 ]
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Analysis 7.4. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 4 Myocardial T2* (ms): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 4 Myocardial T2* (ms): mean change from baseline
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015b 48 3.16 (6.24) 48 1.48 (3.13) 1.68 [ -0.29, 3.65 ]
-2 -1 0 1 2
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Analysis 7.5. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 5 Serious AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 5 Serious AE (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 1/48 1/48 1.00 [ 0.06, 15.53 ]
0.01 0.1 1 10 100
Deferasirox + deferiprone Deferiprone + DFO
Analysis 7.6. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 6 Serious drug-related AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 6 Serious drug-related AE (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cholecystitis
Elalfy 2015b 1/48 0/48 3.00 [ 0.13, 71.85 ]
0.01 0.1 1 10 100
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Analysis 7.7. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 7 Serious non-related drug AE.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 7 Serious non-related drug AE
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Appendicitis
Elalfy 2015b 0/48 1/48 0.33 [ 0.01, 7.98 ]
0.01 0.1 1 10 100
Deferasirox + deferiprone Deferiprone + DFO
Analysis 7.8. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 8 AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 8 AEs
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blood and lymphatic system disorder - agranulocytosis
Elalfy 2015b 0/48 0/48 Not estimable
2 Blood and lymphatic system disorder - neutropenia
Elalfy 2015b 5/48 3/48 1.67 [ 0.42, 6.59 ]
0.01 0.1 1 10 100
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Analysis 7.9. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 9 Drug-related AEs (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 9 Drug-related AEs (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 28/48 26/48 1.08 [ 0.76, 1.53 ]
0.5 0.7 1 1.5 2
Deferasirox + deferiprone Deferiprone + DFO
Analysis 7.10. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 10 Drug-related AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 10 Drug-related AEs
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Blood and lymphatic system disorders - agranulocytosis
Elalfy 2015b 0/48 0/48 Not estimable
2 Blood and lymphatic system disorders - neutropenia
Elalfy 2015b 5/48 3/48 1.67 [ 0.42, 6.59 ]
3 GI disorders - GI problems
Elalfy 2015b 6/48 10/48 0.60 [ 0.24, 1.52 ]
4 Investigations - ALT increase (≥ 3 folds)
Elalfy 2015b 4/48 3/48 1.33 [ 0.32, 5.64 ]
5 Investigations - serum creatinine (≥ 33%) above baseline in 2 consecutive occasions
0.01 0.1 1 10 100
Deferasirox + deferiprone Deferiprone + DFO
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(. . . Continued)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 3/48 1/48 3.00 [ 0.32, 27.83 ]
6 Musculoskeletal and connective tissue disorders - arthralgia
Elalfy 2015b 8/48 9/48 0.89 [ 0.37, 2.11 ]
7 Skin and subcutaneous tissue disorders - skin rash
Elalfy 2015b 2/48 0/48 5.00 [ 0.25, 101.48 ]
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Analysis 7.11. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 11 Non-related drug AEs (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 11 Non-related drug AEs (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 17/48 18/48 0.94 [ 0.56, 1.60 ]
0.5 0.7 1 1.5 2
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Analysis 7.12. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 12 Non-related drug AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 12 Non-related drug AEs
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infections and infestations - infections
Elalfy 2015b 12/48 11/48 1.09 [ 0.53, 2.23 ]
2 GI disorders
Elalfy 2015b 3/48 3/48 1.00 [ 0.21, 4.71 ]
3 Skin and subcutaneous tissue disorders
Elalfy 2015b 2/48 4/48 0.50 [ 0.10, 2.60 ]
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Analysis 7.13. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 13 Mild elevation of hepatic transaminases at start of therapy (# participants
affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 13 Mild elevation of hepatic transaminases at start of therapy (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 5/48 3/48 1.67 [ 0.42, 6.59 ]
0.2 0.5 1 2 5
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Analysis 7.14. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 14 Initial gastrointestinal manifestations (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 14 Initial gastrointestinal manifestations (# participants affected)
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 8/48 11/48 0.73 [ 0.32, 1.65 ]
0.5 0.7 1 1.5 2
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Analysis 7.15. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 15 Quality of life (%) (measured by SF-36): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 15 Quality of life (%) (measured by SF-36): mean change from baseline
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015b 48 5.62 (16.17) 48 4.91 (12.67) 0.71 [ -5.10, 6.52 ]
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Analysis 7.16. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 16 Adherence: actual dose/total prescribed dose.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 16 Adherence: actual dose/total prescribed dose
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elalfy 2015b 48 0.95 (0.22) 48 0.8 (0.22) 0.15 [ 0.06, 0.24 ]
-0.2 -0.1 0 0.1 0.2
Deferiprone + DFO Deferasirox + deferiprone
Analysis 7.17. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 17 Discontinuations.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 17 Discontinuations
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 0/48 0/48 Not estimable
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Analysis 7.18. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone +
deferoxamine, Outcome 18 Serious AE resulting in study discontinuation or interruption.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine
Outcome: 18 Serious AE resulting in study discontinuation or interruption
Study or subgroup
Deferasirox
+
deferiprone Deferiprone + DFO Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elalfy 2015b 0/48 0/48 Not estimable
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Analysis 8.1. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 1
Mortality at any time point.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 1 Mortality at any time point
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day: at 12 months
Taher 2012 0/48 0/25 Not estimable
Subtotal (95% CI) 48 25 Not estimable
Total events: 0 (Deferasirox), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Deferasirox 10 mg/kg/day: at 12 months
Taher 2012 0/49 0/26 Not estimable
Subtotal (95% CI) 49 26 Not estimable
Total events: 0 (Deferasirox), 0 (Placebo)
Heterogeneity: not applicable
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: not applicable
Total (95% CI) 97 51 Not estimable
Total events: 0 (Deferasirox), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 8.2. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2
Serum ferritin (ng/mL): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 2 Serum ferritin (ng/mL): mean change from baseline
Study or subgroup Deferasirox Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 51 -130.47 (260.555) 27 128.63 (249.689) 59.9 % -259.10 [ -377.35, -140.85 ]
Subtotal (95% CI) 51 27 59.9 % -259.10 [ -377.35, -140.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.29 (P = 0.000018)
2 Deferasirox 10 mg/kg/day
Taher 2012 50 -249.16 (389.356) 26 128.63 (249.689) 40.1 % -377.79 [ -522.21, -233.37 ]
Subtotal (95% CI) 50 26 40.1 % -377.79 [ -522.21, -233.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.13 (P < 0.00001)
Total (95% CI) 101 53 100.0 % -306.74 [ -398.23, -215.24 ]
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 6.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.55, df = 1 (P = 0.21), I2 =36%
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Analysis 8.3. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3
LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline
Study or subgroup Deferasirox Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 51 -1.95 (3.57) 27 0.38 (3.6) 49.3 % -2.33 [ -4.00, -0.66 ]
Subtotal (95% CI) 51 27 49.3 % -2.33 [ -4.00, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
2 Deferasirox 10 mg/kg/day
Taher 2012 54 -3.8 (3.53) 27 0.38 (3.6) 50.7 % -4.18 [ -5.83, -2.53 ]
Subtotal (95% CI) 54 27 50.7 % -4.18 [ -5.83, -2.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.96 (P < 0.00001)
Total (95% CI) 105 54 100.0 % -3.27 [ -4.44, -2.09 ]
Heterogeneity: Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 5.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.38, df = 1 (P = 0.12), I2 =58%
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Analysis 8.4. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 4
LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline
Study or subgroup Deferasirox Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Non-transfusion-dependent -thalassemia 5 mg/kg/day
Taher 2012 28 -1.2 (3.2) 16 0.7 (2.8) -1.90 [ -3.71, -0.09 ]
2 Non-transfusion-dependent -thalassemia 10 mg/kg/day
Taher 2012 29 -4.5 (3.6) 16 0.7 (2.8) -5.20 [ -7.10, -3.30 ]
3 -thalassemia 5 mg/kg/day
Taher 2012 5 -4.7 (2.5) 3 -0.9 (4) -3.80 [ -8.83, 1.23 ]
4 -thalassemia 10 mg/kg/day
Taher 2012 9 -2.5 (4.1) 4 -0.9 (4) -1.60 [ -6.35, 3.15 ]
5 HbE/ -thalassemia 5 mg/kg/day
Taher 2012 18 -2.1 (2.6) 8 -0.2 (4.5) -1.90 [ -5.24, 1.44 ]
6 HbE/ -thalassemia 10 mg/kg/day
Taher 2012 16 -3.2 (5) 7 -0.2 (4.5) -3.00 [ -7.14, 1.14 ]
7 < 18 years 5 mg/kg/day
Taher 2012 6 -1.6 (2) 4 -0.2 (1.3) -1.40 [ -3.45, 0.65 ]
8 < 18 years 10 mg/kg/day
Taher 2012 7 -4.3 (3.2) 4 -0.2 (1.3) -4.10 [ -6.79, -1.41 ]
9≥18 years 5 mg/kg/day
Taher 2012 45 -1.9 (3.2) 23 0.3 (3.8) -2.20 [ -4.01, -0.39 ]
10≥18 years 10 mg/kg/day
Taher 2012 47 -3.7 (4.3) 23 0.3 (3.8) -4.00 [ -5.98, -2.02 ]
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Analysis 8.5. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 5
LIC: decrease of ≥ 3 mg Fe/g dw (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 5 LIC: decrease of≥ 3 mg Fe/g dw (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 18/55 3/28 50.0 % 3.05 [ 0.98, 9.50 ]
Subtotal (95% CI) 55 28 50.0 % 3.05 [ 0.98, 9.50 ]
Total events: 18 (Deferasirox), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 Deferasirox 10 mg/kg/day
Taher 2012 31/55 3/28 50.0 % 5.26 [ 1.76, 15.71 ]
Subtotal (95% CI) 55 28 50.0 % 5.26 [ 1.76, 15.71 ]
Total events: 31 (Deferasirox), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0029)
Total (95% CI) 110 56 100.0 % 4.16 [ 1.90, 9.11 ]
Total events: 49 (Deferasirox), 6 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 8.6. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 6
LIC: ≥ 30% reduction Fe/g dw (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 6 LIC: ≥ 30% reduction Fe/g dw (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 14/55 0/28 33.2 % 15.02 [ 0.93, 242.87 ]
Subtotal (95% CI) 55 28 33.2 % 15.02 [ 0.93, 242.87 ]
Total events: 14 (Deferasirox), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Deferasirox 10 mg/kg/day
Taher 2012 27/55 1/28 66.8 % 13.75 [ 1.97, 95.97 ]
Subtotal (95% CI) 55 28 66.8 % 13.75 [ 1.97, 95.97 ]
Total events: 27 (Deferasirox), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
Total (95% CI) 110 56 100.0 % 14.17 [ 2.88, 69.74 ]
Total events: 41 (Deferasirox), 1 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 8.7. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 7
LIC: shift to lower iron burden range (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 7 LIC: shift to lower iron burden range (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 20/55 3/28 42.9 % 3.39 [ 1.10, 10.45 ]
Subtotal (95% CI) 55 28 42.9 % 3.39 [ 1.10, 10.45 ]
Total events: 20 (Deferasirox), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
2 Deferasirox 10 mg/kg/day
Taher 2012 26/55 4/28 57.1 % 3.31 [ 1.28, 8.55 ]
Subtotal (95% CI) 55 28 57.1 % 3.31 [ 1.28, 8.55 ]
Total events: 26 (Deferasirox), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
Total (95% CI) 110 56 100.0 % 3.35 [ 1.62, 6.91 ]
Total events: 46 (Deferasirox), 7 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 8.8. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 8
LIC: achieve LIC < 5 mg Fe/g dw (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 8 LIC: achieve LIC < 5 mg Fe/g dw (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 deferasirox 5mg/kg/d
Taher 2012 8/55 1/28 50.0 % 4.07 [ 0.54, 30.96 ]
Subtotal (95% CI) 55 28 50.0 % 4.07 [ 0.54, 30.96 ]
Total events: 8 (Deferasirox), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
2 deferasirox 10mg/kg/d
Taher 2012 13/55 1/28 50.0 % 6.62 [ 0.91, 48.05 ]
Subtotal (95% CI) 55 28 50.0 % 6.62 [ 0.91, 48.05 ]
Total events: 13 (Deferasirox), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
Total (95% CI) 110 56 100.0 % 5.35 [ 1.30, 21.99 ]
Total events: 21 (Deferasirox), 2 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 8.9. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 9
Drug-related serious AEs (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 9 Drug-related serious AEs (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 4/110 0/56 4.62 [ 0.25, 84.35 ]
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Analysis 8.10. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 10
Drug-related serious AEs (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 10 Drug-related serious AEs (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GI disorders - abdominal pain
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
2 Infections and infestations - cellulitis
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
3 Skin and subcutaneous tissue disorders - pruritus
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
4 Skin and subcutaneous tissue disorders - rash
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
5 General disorders - pyrexia
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
6 Hepatobiliary disorders - hepatotoxicity
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
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Analysis 8.11. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 11
Any AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 11 Any AE (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 85/110 45/56 0.96 [ 0.82, 1.13 ]
0.5 0.7 1 1.5 2
Favours deferasirox Favours placebo
Analysis 8.12. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 12
Mild AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 12 Mild AE (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 44/110 24/56 0.93 [ 0.64, 1.36 ]
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Analysis 8.13. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 13
Moderate AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 13 Moderate AE (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 24/110 12/56 1.02 [ 0.55, 1.88 ]
0.01 0.1 1 10 100
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Analysis 8.14. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 14
Severe AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 14 Severe AE (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 17/110 9/56 0.96 [ 0.46, 2.02 ]
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Analysis 8.15. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 15
AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 15 AEs
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ear and labyrinth disorders - neurosensory deafness
Taher 2012 0/110 1/56 0.17 [ 0.01, 4.14 ]
2 Investigations - abnormal platelet count (post-baseline)
Taher 2012 6/110 6/56 0.51 [ 0.17, 1.51 ]
3 Investigations - abnormal neutrophils count (post-baseline)
Taher 2012 5/110 3/56 0.85 [ 0.21, 3.42 ]
4 Investigations - abnormal ALT (post-baseline)
Taher 2012 0/110 1/56 0.17 [ 0.01, 4.14 ]
5 Investigations - abnormal AST (post-baseline)
Taher 2012 1/110 1/56 0.51 [ 0.03, 7.99 ]
6 Investigations - abnormal serum creatinine (post-baseline)
Taher 2012 3/110 0/56 3.59 [ 0.19, 68.40 ]
7 Investigations - abnormal creatinine clearance (post-baseline)
Taher 2012 2/110 0/56 2.57 [ 0.13, 52.59 ]
8 Investigations - urinary protein/creatinine ratio (post-baseline)
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
9 Investigations - abnormal (low) systolic blood pressure (post-baseline)
Taher 2012 9/110 9/56 0.51 [ 0.21, 1.21 ]
10 Investigations - abnormal (high) systolic blood pressure (post-baseline)
Taher 2012 0/110 1/56 0.17 [ 0.01, 4.14 ]
11 Investigations - abnormal (low) diastolic blood pressure (post-baseline)
Taher 2012 14/110 8/56 0.89 [ 0.40, 2.00 ]
12 Investigations - abnormal (high) diastolic blood pressure (post-baseline)
Taher 2012 0/110 0/56 Not estimable
13 Investigations - abnormal (low) pulse rate (post-baseline)
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
14 Investigations - abnormal (high) pulse rate (post-baseline)
Taher 2012 1/110 2/56 0.25 [ 0.02, 2.75 ]
15 Renal and urinary disorders - proteinuria
Taher 2012 1/110 0/56 1.54 [ 0.06, 37.22 ]
0.005 0.1 1 10 200
Favours deferasirox Favours placebo
194Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.16. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 16
Drug-related AEs.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 16 Drug-related AEs
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GI disorders - abdominal pain
Taher 2012 2/110 1/56 1.02 [ 0.09, 10.99 ]
2 GI disorders - abdominal pain upper
Taher 2012 3/110 0/56 3.59 [ 0.19, 68.40 ]
3 GI disorders - diarrhoea
Taher 2012 5/110 1/56 2.55 [ 0.30, 21.27 ]
4 GI disorders - nausea
Taher 2012 7/110 4/56 0.89 [ 0.27, 2.92 ]
5 Nervous system disorders - headache
Taher 2012 3/110 2/56 0.76 [ 0.13, 4.44 ]
6 Skin and subcutaneous tissue disorders - skin rash
Taher 2012 7/110 1/56 3.56 [ 0.45, 28.25 ]
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Analysis 8.17. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 17
Adherence (# participants taking the planned study dose).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 17 Adherence (# participants taking the planned study dose)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 104/110 54/56 0.98 [ 0.92, 1.05 ]
0.5 0.7 1 1.5 2
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Analysis 8.18. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 18
Discontinuations.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 18 Discontinuations
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 7/55 3/28 60.0 % 1.19 [ 0.33, 4.25 ]
Subtotal (95% CI) 55 28 60.0 % 1.19 [ 0.33, 4.25 ]
Total events: 7 (Deferasirox), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
2 Deferasirox 10 mg/kg/day
Taher 2012 6/55 2/28 40.0 % 1.53 [ 0.33, 7.08 ]
Subtotal (95% CI) 55 28 40.0 % 1.53 [ 0.33, 7.08 ]
Total events: 6 (Deferasirox), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 110 56 100.0 % 1.32 [ 0.50, 3.52 ]
0.01 0.1 1 10 100
Favours deferasirox Favours placebo
(Continued . . . )
196Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 13 (Deferasirox), 5 (Placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 8.19. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 19
Discontinuing study due to AE (# participants affected).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 19 Discontinuing study due to AE (# participants affected)
Study or subgroup Deferasirox Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Taher 2012 6/110 2/56 1.53 [ 0.32, 7.32 ]
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Analysis 8.20. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 20
Dose increase.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 20 Dose increase
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 26/55 15/28 50.0 % 0.88 [ 0.57, 1.38 ]
Subtotal (95% CI) 55 28 50.0 % 0.88 [ 0.57, 1.38 ]
Total events: 26 (Deferasirox), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Deferasirox 10 mg/kg/day
Taher 2012 25/55 15/28 50.0 % 0.85 [ 0.54, 1.33 ]
Subtotal (95% CI) 55 28 50.0 % 0.85 [ 0.54, 1.33 ]
Total events: 25 (Deferasirox), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 110 56 100.0 % 0.87 [ 0.63, 1.19 ]
Total events: 51 (Deferasirox), 30 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
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Analysis 8.21. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 21
Dose interruption (at least once).
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 21 Dose interruption (at least once)
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 36/55 18/28 50.0 % 1.02 [ 0.73, 1.43 ]
Subtotal (95% CI) 55 28 50.0 % 1.02 [ 0.73, 1.43 ]
Total events: 36 (Deferasirox), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.92)
2 Deferasirox 10 mg/kg/day
Taher 2012 42/55 18/28 50.0 % 1.19 [ 0.87, 1.62 ]
Subtotal (95% CI) 55 28 50.0 % 1.19 [ 0.87, 1.62 ]
Total events: 42 (Deferasirox), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 110 56 100.0 % 1.10 [ 0.88, 1.39 ]
Total events: 78 (Deferasirox), 36 (Placebo)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 8.22. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 22
Dose reduction.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 22 Dose reduction
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 12/55 4/28 50.0 % 1.53 [ 0.54, 4.30 ]
Subtotal (95% CI) 55 28 50.0 % 1.53 [ 0.54, 4.30 ]
Total events: 12 (Deferasirox), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 Deferasirox 10 mg/kg/day
Taher 2012 11/55 4/28 50.0 % 1.40 [ 0.49, 4.00 ]
Subtotal (95% CI) 55 28 50.0 % 1.40 [ 0.49, 4.00 ]
Total events: 11 (Deferasirox), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 110 56 100.0 % 1.46 [ 0.70, 3.06 ]
Total events: 23 (Deferasirox), 8 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 8.23. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 23
Dose reduction due to AE.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 23 Dose reduction due to AE
Study or subgroup Deferasirox Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 12/55 3/28 42.9 % 2.04 [ 0.63, 6.63 ]
Subtotal (95% CI) 55 28 42.9 % 2.04 [ 0.63, 6.63 ]
Total events: 12 (Deferasirox), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Deferasirox 10 mg/kg/day
Taher 2012 9/55 4/28 57.1 % 1.15 [ 0.39, 3.39 ]
Subtotal (95% CI) 55 28 57.1 % 1.15 [ 0.39, 3.39 ]
Total events: 9 (Deferasirox), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 110 56 100.0 % 1.53 [ 0.69, 3.38 ]
Total events: 21 (Deferasirox), 7 (Placebo)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 8.24. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 24
Haemoglobin (g/L): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 24 Haemoglobin (g/L): mean change from baseline
Study or subgroup Deferasirox Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 47 -1.8 (5.45) 24 -2.8 (7.31) 50.8 % 1.00 [ -2.31, 4.31 ]
Subtotal (95% CI) 47 24 50.8 % 1.00 [ -2.31, 4.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 Deferasirox 10 mg/kg/day
Taher 2012 48 -0.7 (6.27) 25 -2.8 (7.31) 49.2 % 2.10 [ -1.27, 5.47 ]
Subtotal (95% CI) 48 25 49.2 % 2.10 [ -1.27, 5.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 95 49 100.0 % 1.54 [ -0.82, 3.90 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 8.25. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 25
Transferrin saturation (%): mean change from baseline.
Review: Deferasirox for managing iron overload in people with thalassaemia
Comparison: 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo
Outcome: 25 Transferrin saturation (%): mean change from baseline
Study or subgroup Deferasirox Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Deferasirox 5 mg/kg/day
Taher 2012 47 -3.79 (14.234) 23 3.37 (10.083) 63.1 % -7.16 [ -12.95, -1.37 ]
Subtotal (95% CI) 47 23 63.1 % -7.16 [ -12.95, -1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.015)
2 Deferasirox 10 mg/kg/day
Taher 2012 47 -3.64 (22.443) 24 3.37 (10.083) 36.9 % -7.01 [ -14.59, 0.57 ]
Subtotal (95% CI) 47 24 36.9 % -7.01 [ -14.59, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 94 47 100.0 % -7.10 [ -11.71, -2.50 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Search strategies August 2015
MEDLINE (via OvidSP)
#1 deferasirox*.mp.
#2 (ICL670* or ICL 670*).mp.
#3 (CGP72670* or CGP 72670*).mp.
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(Continued)
#4 exjade*.mp.
#5 desirox*.mp.
#6 jadenu*.mp.
#7 2-hydroxyphenyl.mp.
#8 triazol-1-yl.mp.
#9 benzoic acid.mp.
#10 7 and 8 and 9
#11 1 or 2 or 3 or 4 or 5 or 6 or 10
#12 (2010* or 2011* or 2012* or 2013* or 2014* or 2015*).ed,ep,dc. or (“2010” or “2011” or “2012” or
“2013” or “2014” or “2015”).yr
#13 11 and 12
#14 randomized controlled trial.pt.
#15 controlled clinical trial.pt.
#16 randomi#ed.ab.
#17 placebo.ab.
#18 drug therapy.fs.
#19 randomly.ab.
#20 trial.ab.
#21 groups.ab.
#22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
#23 exp animals/ not humans.sh.
#24 22 not 23
#25 13 and 24
Notes
date searched: August 06, 2015
Time-span: 2010-2015
204Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
MEDLINE Daily Update (via OvidSP)
#1 deferasirox*.mp.
#2 (ICL670* or ICL 670*).mp.
#3 (CGP72670* or CGP 72670*).mp.
#4 exjade*.mp.
#5 desirox*.mp.
#6 jadenu*.mp.
#7 2-hydroxyphenyl.mp.
#8 triazol-1-yl.mp.
#9 benzoic acid.mp.
#10 7 and 8 and 9
#11 1 or 2 or 3 or 4 or 5 or 6 or 10
Notes
date searched: August 06, 2015
MEDLINE In-Process and Other Non-Indexed Citations (via OvidSP)
#1 deferasirox*.mp.
#2 (ICL670* or ICL 670*).mp.
#3 (CGP72670* or CGP 72670*).mp.
#4 exjade*.mp.
#5 desirox*.mp.
#6 jadenu*.mp.
#7 2-hydroxyphenyl.mp.
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(Continued)
#8 triazol-1-yl.mp.
#9 benzoic acid.mp.
#10 7 and 8 and 9
#11 1 or 2 or 3 or 4 or 5 or 6 or 10
Notes
date searched: August 06, 2015
Embase (via OvidSP)
#1 deferasirox/
#2 DEFERASIROX*.mp.
#3 (ICL670* or ICL 670*).mp.
#4 (CGP72670* or CGP 72670*).mp.
#5 desirox*.mp.
#6 exjade*.mp.
#7 jadenu*.mp.
#8 2-HYDROXYPHENYL.mp.
#9 TRIAZOL-1-YL.mp.
#10 BENZOIC ACID.mp.
#11 8 and 9 and 10
#12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 11
#13 limit 12 to yr=“2010 -Current”
#14 (RANDOM* or PLACEBO* or DOUBLE-BLIND*).mp.
#15 13 and 14
#16 limit 15 to medline
#17 15 not 16
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(Continued)
Notes
date searched: August 06, 2015
Time-span: 2010-2015
PubMed -subset “supplied by publisher”
#1 Search deferasirox*[tw]
#2 Search (ICL670*[tw] OR ICL 670*[tw])
#3 Search (CGP72670*[tw] OR CGP 72670*[tw])
#4 Search exjade*[tw]
#5 Search desirox*[tw]
#6 Search jadenu*[tw]
#7 Search 2-hydroxyphenyl[tw]
#8 Search triazol-1-yl[tw]
#9 Search benzoic acid[tw]
#10 Search (#7 AND #8 AND #9)
#11 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10)
#12 Search (# 11 AND publisher[sb])
Notes
date searched: August 06, 2015
Cochrane Library (via Wiley: www.thecochranelibrary.com)
#1 deferasirox*
#2 ICL670* or (ICL next 670*)
#3 CGP72670* or (CGP next 72670*)
#4 exjade*
#5 desirox*
#6 jadenu*
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(Continued)
#7 2 next hydroxyphenyl
#8 triazol next 1 next yl
#9 benzoic next acid
#10 (#7 and #8 and #9)
#11 (#1 or #2 or #3 or #4 or #5 or #6 or #10)
#12 #11 Publication Year from 2010 to 2015 (Word variations have been searched)
Notes
date searched: August 06, 2015
Time-span: 2010-2015
Biosis Previews (via Thomson Reuters)
#1 ts=deferasirox*
#2 ts=(ICL670* or “ICL 670*”)
#3 ts=(CGP72670* or “CGP 72670*”)
#4 ts=exjade*
#5 ts=desirox*
#6 ts=jadenu*
#7 ts=“2-hydroxyphenyl”
#8 ts=“triazol-1-yl”
#9 ts=“benzoic acid”
#10 #7 AND #8 AND #9
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10
#12 ts=(rando* or placebo or trial or “single-blind*” or “double-blind*” or groups)
#13 #11 AND #12
Notes
date searched: August 06, 2015
Time-span: 2010-2015
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(Continued)
Web of Science Core Collection (via Web of Science, Thomson Reuters)
#1 ts=deferasirox*
#2 ts=(ICL670* or “ICL 670*”)
#3 ts=(CGP72670* or “CGP 72670*”)
#4 ts=exjade*
#5 ts=desirox*
#6 ts=jadenu*
#7 ts=“2-hydroxyphenyl”
#8 ts=“triazol-1-yl”
#9 ts=“benzoic acid”
#10 #7 AND #8 AND #9
#11 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10
#12 ts=(rando* or placebo or trial or “single-blind*” or “double-blind*” or groups)
#13 #11 AND #12
Notes
date searched: August 06, 2015
Time-span: 2010-2015
Appendix 2. Search strategies June 2010
MEDLINE and Medline In-Process (via Ovid)
#1 deferasirox*.mp
#2 (ICL670* or ICL 670*).mp
#3 (CGP72670* or CGP 72670*).mp
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(Continued)
#4 exjade*.mp
#5 2-hydroxyphenyl.mp
#6 triazol-1-yl.mp
#7 benzoic acid.mp
#8 and/5-7
#9 or/1-4,8
#10 remove duplicates from 9
Notes
.mp = title, original title, abstract, name of substance word, subject heading word,
unique identifier
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
searched Medline 1950 to June Week 3 2010, Medline in Process and Other
Non-Indexed Citations to June 25, 2010
date searched: June 28, 2010
EMBASE (via Ovid)
#1 deferasirox*.mp
#2 (ICL670* or ICL 670*).mp
#3 (CGP72670* or CGP 72670*).mp
#4 exjade*.mp
#5 2-hydroxyphenyl.mp
#6 triazol-1-yl.mp
#7 benzoic acid.mp
#8 and/5-7
#9 or/1-4,8
#10 remove duplicates from 9
210Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Notes
.mp = title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
searched 1980 to 2010 Week 24
date searched: June 24, 2010
BIOSIS Previews (via Ovid)
#1 deferasirox*.mp
#2 (ICL670* or ICL 670*).mp
#3 (CGP72670* or CGP 72670*).mp
#4 exjade*.mp
#5 2-hydroxyphenyl.mp
#6 triazol-1-yl.mp
#7 benzoic acid.mp
#8 and/5-7
#9 or/1-4,8
#10 remove duplicates from 9
Notes
.mp = abstract, biosystematic codes, original language book title (non-english),
book title (english), chemicals & biochemicals, concept codes, diseases, geopolit-
ical locations, gene name, major concepts, miscellaneous descriptors, methods &
equipment, organisms, parts, structures & systems of organisms, sequence data,
super taxa, title, time, taxa notes
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
searched 1969 to 2010 Week 29
date searched: June 28, 2010
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(Continued)
Cochrane Library (via Wiley Interscience)
#1 deferasirox*
#2 ICL670* or ICL next 670*
#3 CGP72670* or CGP next 72670*
#4 exjade*
#5 2-hydroxyphenyl
#6 triazol-1-yl
#7 benzoic acid
#8 (#5 AND #6 AND #7)
#9 (#1 OR #2 OR #3 OR #4 OR #8)
Notes
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
Issues searched: Cochrane Database of Systematic Reviews 2010, Issue 6; other
Cochrane Library Databases 2010 Issue 2
date searched: June 29, 2010
Web of Science (via Thomson Reuters)
#1 ts=deferasirox*
#2 ts=(ICL670* or “ICL 670*”)
#3 ts=(CGP72670* or “CGP 72670*”)
#4 ts=exjade*
#5 ts=“2-hydroxyphenyl”
#6 ts=“triazol-1-yl”
#7 ts=“benzoic acid”
#8 #5 AND #6 AND #7
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(Continued)
#9 #1 OR #2 OR #3 OR #4 OR #8
Notes
ts = topic
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
searched 1945 to June 26, 2010
date searched: June 30, 2010
Derwent Drug File and XTOXLINE (via DIMDI)
#1 deferasirox* (text field)
#2 ICL670* or ICL 670* (text field)
#3 CGP72670* or CGP 72670* (text field)
#4 exjade* (text field)
#5 2-hydroxyphenyl (text field)
#6 triazol-1-yl (text field)
#7 benzoic acid (text field)
#8 #5 and #6 and #7
#9 #1 or #2 or #3 or #4 or #8
NOTES
The chemical substance name “4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-
yl) benzoic acid” was searched by splitting it up in searchable terms (2-hydrox-
yphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #
8)
searched Derwent Drug File January 1, 1983 - June 23, 2010, XTOXLINE
January 1,1965 - June 29, 2010
date searched: July 1, 2010
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WH A T ’ S N E W
Date Event Description
20 July 2017 New search has been performed Inclusion criteria adapted to people with thalassaemia in-
termedia
The search strategy was expanded and 12 new stud-
ies (1103 participants) were included (Chirico 2013;
Elalfy 2015a; Elalfy 2015b;Habibian 2014;Hassan 2016;
Kakkar 2014; Molavi 2013; Molavi 2014; Peng 2013;
Pennell 2014; Sanjeeva 2015; Taher 2012;.
Five additional comparisonswere included for peoplewith
thalassemia major:
• deferasirox versus deferiprone;
• deferasirox versus deferasirox + deferiprone;
• deferasirox + deferiprone versus deferiprone;
• deferasirox + deferoxamine versus deferoxamine;
• deferasirox + deferiprone versus deferiprone +
deferoxamine.
One comparisonwas included for people with thalassemia
intermedia:
• deferasirox versus placebo.
20 July 2017 New citation required but conclusions have not changed The inclusion of new trials did not significantly alter the
conclusions of the review
H I S T O R Y
Date Event Description
22 July 2016 Amended Contact details updated.
22 May 2012 Amended Contact details updated.
12 August 2009 Amended Contact details updated.
10 January 2008 New citation required and major changes Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
Joerg Meerpohl: conception, design and coordination of the review. Data collection and data management as well as analysis and
interpretation of the data. Writing of the review and approval of the final version.
Claudia Bollig: coordination of the review update. Conduct of the search in August 2015. Data collection and data management as
well as analysis and interpretation of the data (update). Writing of the review and approval of the final version (update).
Lisa Schell: data collection and data management (update). Analysis and interpretation of data (update). Approval of final version
(update).
Gerta Rücker: statistical advice and methodological support. General advice on the review and approval of the final version.
Roman Allert: data collection (update). Approval of final version.
Edith Motschall: advice on search strategy and conduct of search in June 2010. Approval of final version.
Charlotte Niemeyer: interpretation of the data and clinical expertise. General advice on the review and approval of the final version.
Dirk Bassler: data collection and data management for the previous version. Analysis and interpretation of data. Involvement in writing
the review and approval of the final version.
D E C L A R A T I O N S O F I N T E R E S T
Joerg Meerpohl enrolled two adolescents with thalassaemia and one with Diamond-Blackfan anaemia in a post-marketing surveillance
study on deferasirox and participated once in a Novartis advisory board meeting on paediatric iron overload prior to 2010.
For the remaining authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane, Germany.
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Although these outcomes were not defined a priori, we also extracted: Blood urea, platelet count, neutrophilic count, urinary b-2
microglobulin, urinary N-acetyl-beta-glucosaminidase levels, serum copper, serum zinc, growth and development, transfusion index,
haemoglobin, transferrin saturation, ALP levels.
Inclusion criteria adapted to people with non-transfusion dependent thalassaemia.
We defined the number of patients who discontinued treatment as a form of adherence in our ’summary of findings’ table.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Benzoates [administration & dosage; adverse effects; ∗therapeutic use]; Clinical Trials, Phase II as Topic; Clinical
Trials, Phase III as Topic; Deferoxamine [administration & dosage; therapeutic use]; Erythrocyte Transfusion [adverse effects]; Ferritins
[blood]; Iron Chelating Agents [administration & dosage; adverse effects; ∗therapeutic use]; Iron Overload [blood; ∗drug therapy; etiol-
ogy]; Patient Satisfaction; Pyridones [administration & dosage; therapeutic use]; Randomized Controlled Trials as Topic; Thalassemia
[∗complications; mortality; therapy]; Triazoles [administration & dosage; adverse effects; ∗therapeutic use]
MeSH check words
Humans
216Deferasirox for managing iron overload in people with thalassaemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
